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Abstract 
 
 
 
 
The isolation and characterisation of cancer stem cells (CSCs) remain a major 
challenge. The ‘traditional’ (or ‘stochastic’) model of cancer suggests that cancer 
cells progress through clonal evolution and therefore, all cancer cells must be 
destroyed. The alternative model, the ‘hierarchical’ (or CSC) model proposes that a 
subpopulation of cancer cells, referred to as CSCs, initiates and sustains the 
continuous expansion of cancer growth. Studies have shown that CSCs are similar to 
normal stem cells as they are able to self-renew and to differentiate into a non-CSC 
progeny. However, their proliferation pathways are deregulated, they can form 
metastasis, trigger recurrences after chemotherapy and are tumourigenic. In the CSC 
model, the CSCs essentially need to be targeted and eradicated.  
Although it is recognised that CSCs do exist, there is still a large gap in defining their 
molecular and functional characteristics. In this study, we have explored different 
approaches to isolate colorectal CSCs. 
In the first approach, CSCs were isolated using a putative CSC marker, CD133. 
Cancer cell suspensions were obtained from patient tumour specimens. Several 
conditions were used to isolate CD133+ cells by immunoaffinity. Technical 
difficulties were encountered throughout the procedure that prevented the isolation of 
CSCs using the CD133 antibody. In the second approach, we determined whether 
CSCs could be isolated using chemotherapeutic drugs since it has been shown that 
CSCs are resistant to such treatments.  Cancer cells resistant to a short-term exposure 
with the chemotherapy drug oxaliplatin were isolated from two colorectal cancer cell 
lines. Data from in vivo tumourigenicity, expression of putative CSC markers and 
quiescence indicated that the intrinsically resistant cells did not exhibit CSC 
properties when compared with the untreated population. In the third approach, CSCs 
were isolated based on the aldehyde dehydrogenase 1 (ALDH1) activity. A high 
ALDH1 activity has been shown to be a marker of stem cells/CSCs. 
Immunohistochemistry revealed that ALDH1hi cells expressed more putative CSC 
markers CD44, CD166, ABCG2 and Lgr-5 than ALDH1lo cells. However, both 
populations were similarly clonogenic in vitro, they were equally invasive, as 
resistant to chemotherapeutic regimens and their cell cycle status was similar.  
In conclusion, the approaches taken to isolate CSCs from cancer tissue samples or 
cell lines generated limited success. The data suggest that more refined techniques are 
required to isolate CSCs. On the other hand, they highlight the techniques that should 
be avoided in future studies. The results also question several concepts of the CSC 
theory, such as the intrinsic resistance of CSCs, and therefore emphasize on the need 
of gathering more evidence to validate the CSC model. 
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1.1 Colorectal cancer  
 
 
Colorectal cancer is the second most frequent cause of cancer death in the developed 
countries  and more than 500,000 deaths a year are attributable to colorectal cancer 
across the world .  
Early diagnosis has been successfully developed for colorectal cancer. Colorectal 
cancer first develops slowly as a benign adenoma, and only after a number of years 
does the adenoma transform to malignant adenocarcinoma. This sequence provides a 
good opportunity to detect and remove benign polyps before the disease develops 
further. Moreover, treatments at an early stage of the neoplasm are often successful 
and survival rates are high (5 year survival is 83% when disease is detected at Dukes’ 
stage A) [1]. 
However, recurrent disease or resistant metastases still kill more than one third of the 
patients affected. Despite decades of effort, the 5 year survival for stage IV is still 
only about 10% [2]. There is obviously an urgent need for novel and improved 
treatment. 
 
1.1.1 Aetiology and epidemiology  
 
Several parameters are thought to be involved in colorectal cancer genesis. 
Age is a determinant factor since most of the patients with colorectal carcinoma are 
diagnosed after age 50 years [3]. Low physical activity [4-6] and a high fat diet [7, 8]  
have been shown to increase the incidence of colorectal cancer. Sex distribution is 
more or less balanced, even though in Western countries rectal cancer affects slightly 
more men, whereas colon cancer is more prevalent in women [9]. 
The genesis of colorectal cancer is also influenced by environmental factors as 
suggested by its spread in economically developed countries. Higher incidence rates 
have been found in North America and Western Europe, whilst the lowest rates are in 
Sub-Saharan Africa [10]. This geographic shift directly correlates colorectal cancer 
incidence with the modern lifestyle. 
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Genetic predisposition is another parameter involved in colorectal cancer. All of the 
patients with familial adenomatous polyposis (FAP) develop cancer by the age of 50 
[11]. FAP is an autosomal inherited condition, in which Adenomatosis polyposis coli 
(APC) gene is mutated on the long arm of chromosome 5, suggesting that mutation of 
APC gene is an early event in colorectal carcinogenesis. Gardner’s syndrome (a 
variant of FAP) is also associated with high predisposition to large number of polyps. 
Other familial syndromes, for example the hereditary non-polyposis colorectal cancer 
syndromes (HNPCC), predispose to adenomatous polyps with high malignancy 
potential [12]. 
 
1.1.2 Colorectal cancer staging 
 
Dukes was the first to establish a system of international terminology for colorectal 
cancer [13]. It was introduced more than 60 years ago and divided the malignancies 
into three stages (A to C). It was later modified by the addition of a fourth stage and 
other subsets. In the first stage, A, tumour growth is contiguous with the bowel wall 
but does not penetrate it. At stage B, the tumour invades the surrounding muscularis 
and advential layers, and then reaches the lymph nodes (stage C). Eventually, the 
tumour forms metastases (stage D). 
This first classification was not the most correct due to the large variations in survival 
rates among individuals at each stage (Table 1). However it has been, and still is, 
widely used because of its simplicity for pathologists. 
 
Dukes’ stage 5 year survival 
A 80 % 
B 48-62 % 
C 22-33 % 
D 10 % 
 
Table 1. Five year survival rates for patients 
       with different stages of colorectal carcinoma [14]. 
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More recently, the Tumour-Node-Metastasis (TNM) system was developed by the 
American Joint Commission on Cancer in 1987 to classify all tumours using the same 
criteria [15]. It is more specific, but also more complex, and presents variants for each 
type of cancer. Four stages I (curable) to IV (metastasis/inoperable) are defined 
according to the combination of the sub stages T, N and M. T describes the size of the 
original tumour and its spread in the nearby tissues with 0 to 4 sub stages of invasion. 
N represents the involvement of lymph nodes (0 to 3 sub stages) and M the presence 
or not of metastasis (0 or 1). This classification also encompasses other parameters 
such as grade of cells (= refers to the amount of differentiation of the cells), invasion 
to veins, and clinical conditions (chemotherapy, resection). 
 
 
1.1.3 Current treatments 
 
Surgery has always been the treatment of choice for colorectal cancer. Surgical 
techniques are more or less invasive (local excision, resection or even colostomy) 
depending on the stage of the cancer, and their efficiency has been proven. However, 
they do not completely prevent recurrences and 10-15% of the patients undergoing 
surgery will develop local recurrences [16]. Usually, radiotherapy as well as 
chemotherapy are used as adjuvant therapy at the time of surgery, in order to remove 
any residual cancer cells. 
Radiotherapy is restricted to rectal carcinomas. The difficulties in the accuracy of 
dosimetry and targeting render colon radiotherapy impossible since radiosensitive 
organs such as liver and kidneys surround the colon.  
Historically, chemotherapy against colorectal cancer first started with the 
administration of 5-fluorouracil (5-FU) as an adjuvant therapeutic agent against 
metastatic disease. Progressively, new generations of agents have appeared, with the 
introduction of irinotecan and oxaliplatin as part of standard chemotherapy, and even 
more recently bevacizumab, cetuximab and panitumumab. The use of these 
chemotherapeutic agents is relatively successful and nowadays patients suffering 
from metastatic colorectal cancer have an increased overall survival of nearly 2 years 
[17].  
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1.1.4 New strategies for cancer treatment 
 
Despite more than 50 years of intense research, the war on cancer is not over yet. 
Early detection is still the best way to prevent cancer death. In terms of prognosis, 
huge efforts on screening programs have allowed the prolongation of life, however 
we still do not know yet how to eradicate cancer completely. New strategies are now 
being developed in order to alleviate the limitations of the current treatments 
discussed above. Immunotherapy for instance, is an expanding field with the 
emergence of tools such as the anti-cancer vaccine TroVax [18].  
Cell therapy is also another promising field of cancer research. Cell therapy aims at 
replacing cells that have been lost through physical, chemical or ischaemic injury, or 
as a result of degenerative diseases. The field covered by cell therapy is vast, and has 
already proven itself for a large range of diseases: spinal cord injury [19] and 
cartilage joint injury repair [20], multiple sclerosis [21], Parkinson’s disease [22], 
and, to a certain extent, cancer [23] .   
Besides the exploration of new treatments, cancer research seems to undergo a shift. 
After all, if during the previous decades research has only helped in the limited 
understanding of certain mechanisms regarding the molecular behaviour of cancer, 
then an essential question still remains : what is cancer ? The traditional explanation 
for the origin, development and progression of cancer may be incomplete as the 
current therapeutic strategies do not lead to complete remission. An alternative model 
has been proposed and is based on the similarities between stem cells and a 
subpopulation of cancer cells that have the ability to initiate tumours. This model has 
fast become a popular view into defining the putative mechanisms of cancer 
development.  
The cancer stem cell (CSC) theory will be presented after a brief account of stem 
cells and their biology. 
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1.2 Stem cells and intestinal stem cells 
 
Stem cells are defined as undifferentiated cells, possessing an unlimited capacity of  
self-renewal, and the ability to generate differentiated cells [24].  
Embryonic stem (ES) cells are chronologically the first source of stem cells, but also 
the most controversial due to ethical issues concerning their harvesting, which 
involves the destruction of an embryo [25]. The whole organism and all of its 
components are derived from them and they possess the unique capacity to give rise 
to any cell type. Adult stem cells (ASCs) have been said to be the remnants of the 
primitive embryonic stage. They reside in most of the organs at a low percentage 
throughout life, and their high proliferation capacity allows the organism to 
compensate for the loss of cells in tissues due to wear and tear (especially in blood, 
intestine and skin lining), or accidental loss due to injuries or degenerative diseases 
[26]. The range of cell types that ASCs can produce is limited. Important sources of 
ASC have been detected in the bone marrow and peripheral blood, liver, skin and gut, 
brain and skeletal muscle [27]. Besides ES and ASCs, stem cells have also been 
discovered in foetus, placenta, amniotic fluid and umbilical cord tissues [28-30].  
All stem cells are defined by two undeniable hallmarks : self-renewal and the ability 
to differentiate.  
 
1.2.1 Self-renewal and differentiation 
 
Self-renewal is generally recognised as the cell’s capacity to generate two daughter 
cells, of which at least one remains identical to the mother cell. According to the 
prevailing stem cell model, self-renewal is a property of the undifferentiated cells. A 
cell committed to a differentiation pathway progressively loses its self-renewal 
capacity as it acquires a higher level of differentiation. However, this rule is not 
universal. Cells such as T and B immune cells maintain their renewal capability. They 
both possess a high clonogenic potential, although they are terminally differentiated 
into lymphoid cells [31]. Nevertheless, self-renewal remains essential to define stem 
cells, as it allows them to preserve a constant pool in tissues.  
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Stem cell homeostasis is maintained by a balance between self-renewal and 
differentiation. According to the current model, homeostasis is tightly regulated by 
symmetric or asymmetric division [32]. When stem cells undergo division, the fate of 
the two daughter cells may be similar or different. In the first case (symmetrical 
division), the two daughter cells both retain the stem cell features (Figure 1A) or are 
committed to a differentiation pathway (Figure 1B). In the latter case (asymmetric 
division) one cell retains the potential for self-renewal whereas the other becomes a 
progenitor cell committed to differentiation (Figure 1C). Its progeny consists 
essentially of transit-amplifying cells, a rapid cycling population of committed 
precursors capable of producing large numbers of terminally differentiated progeny. 
This differentiated progeny eventually undergoes terminal division arrest [33]. 
 
 
 
Figure 1. Symmetric (A,B) versus asymmetric (C) division. Stem cells can divide 
symmetrically, i.e. generate similar daughter cells, two stem cells (A) (self-renewal) or two 
differentiated cells (B). They can also divide asymmetrically (C) and manage in a single 
division both self-renewal and differentiation. SC : stem cell. PC :  progenitor/differentiated 
cell. (Adapted from Lessard et al. (2004) [34]). 
 
Theoretically, homeostasis and regeneration can be accounted for by symmetrical 
division alone [35]. Symmetric division is the only process through which stem cells 
can expand their number. Symmetric division is, for instance, responsible for the 
germline expansion of Caenorhaditis elegans [36], and is involved in the larval 
development  and the adult germline stem cells of Drosophila [37, 38] as well as in  
mammalian stem cells during  the embryonic and foetal stages [39].  
Asymmetric division is a very attractive model, as it helps to understand how the 
stem cell pool can remain constant throughout life. In a single division, the necessary 
maintenance and renewal of differentiated tissues are ensured and, at the same time, 
stem cells preserve their numbers and phenotype. When stem cell proliferation is 
PC 
B. C. 
SC 
A. 
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required especially after injury, stem cells can potentially switch to symmetric 
division, since asymmetric division cannot sustain a stem cell expansion on its own 
[35]. This double and powerful tool renders stem cells perfectly flexible and able to 
dynamically prevent their depletion.  
 
 
Intrinsic mechanisms of asymmetric division 
 
In many organisms there is strong evidence that stem cells are capable of 
asymmetrical division in order to provide cells with different properties during 
proliferation. 
It has been shown in models such as the Caenorhabditis elegans germ lines, that the 
positioning of the mitotic spindle is an important factor that determines the process of 
asymmetric division [40]. Asymmetric division in that case divides the zygote into a 
smaller blastomere (mesoderm and endoderm precursor) and a larger blastomere 
(ectoderm precursor) [41].  
Asymmetric division can also generate cell type diversity when the cell fate 
determinants are asymmetrically localized and unequally distributed to the daughter 
cells [42]. For instance, in the developing mammalian nervous system, Notch-1, a cell 
fate determinant associated with modulation of the stem cell self-renewal, is basally 
polarised in the dividing cells, and therefore unequally inherited during horizontal 
division. Through this process, one single division contributes to the production of 
two distinct cell types [43].  
 
The mechanisms described above (cell polarization and mitotic spindle position) can 
be considered as intrinsic mechanisms [35]. But there also exist extrinsic 
mechanisms, and stem cell homeostasis cannot be fully understood without 
considering the importance of the cells neighbouring the stem cells. 
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Extrinsic mechanisms of asymmetric division 
 
Maintaining a stem cell state in vitro is one of the main challenges in stem cell 
biology. In vivo, this state is regulated by the microenvironment and neighbouring 
cells. The site where stem cells reside has been defined as their “niche”, and is 
essential for the maintenance of a life-long stem cell reservoir [44]. Although little is 
known about the regulation of the microenvironement, it is now established that the 
stem cell environment is made of various types of differentiated cells. Secreted 
molecules like cytokines, and direct cell-cell interactions allow the stem cell 
characteristics to be maintained and protected [44]. One of the best-known models 
illustrating the influence of the microenvironment on stem cells is the Drosophila 
germarium. It has been demonstrated that the germ line stem cells are maintained by 
cell to cell interactions within their niche. If a division involves a loss of  this contact 
then the daughter cell becomes a cytoblast (transit-amplifying cell) and differentiates 
to produce the cyst [45]. In vertebrates, haematopoietic stem cells (HSCs) are a good 
illustration of this phenomenon. In the bone marrow, HSC are surrounded by 
macrophages, adipocytes and fibroblasts, and are in direct contact with the osteoblasts 
located along the inner surface of the trabecular bone. This environment is adequate 
to maintain their stem cell state throughout life. However, migration of HSCs out of 
this zone and loss of interaction with the osteoblasts induces their differentiation 
towards myeloid and lymphoid progenitors [45]. 
The niche therefore seems to have a major role in regulating the balance between 
symmetric and asymmetric divisions. A better understanding of the niche and of 
relations between stem cells and their neighbours could be of primary importance in 
developing therapeutic solutions. 
 
More studies are needed to assess the modes of division used by mammalian stem 
cells in vivo. It is difficult to study adult stem cells because they are not  abundant and 
biologically quiescent. If the regulation of stem cell homeostasis may be controlled 
by both asymmetric and symmetric divisions, the process through which stem cells 
can switch from one to the other needs to be further elucidated. 
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1.2.2 Stem cell plasticity 
 
Any stem cell possesses the capacity to differentiate into terminally differentiated cell 
types. However, stem cells are more or less plastic, according to the variety of cell 
types they can generate. An arbitrary hierarchy of stem cells has been established as a 
function of their degree of plasticity. 
 
Totipotent cells 
Totipotent cells are able to produce a whole organism and even the adjacent tissues 
necessary for their development. This class of stem cells corresponds to the zygote 
(and by extension to the daughter cells of the first two divisions), which not only 
forms the embryo but also the different adjacent tissues such as the chorion and the 
placenta [46]. 
 
Pluripotent cells 
Pluripotent cells are able to give rise to a variety of mature progeny. ES cells are 
pluripotent cells isolated by immunosurgery from the inner cell mass (ICM) of the 
blastocyst stage of an embryo at about 5 days after fertilization [47].  
After isolation, ES cells are cultured as cell lines capable of continuous growth in 
culture (almost immortal cell lines), under certain in vitro conditions. Human ES cell 
lines all express high levels of active telomerase, a key enzyme that ensures 
chromosome stability despite great numbers of cell divisions [48]. They express the 
transcription factor Oct-4, which allows them to maintain a self-renewal capacity and 
pluripotency [49]. However, under certain conditions, differentiation can be induced 
and ES cells may generate a broad range of cell types from ectodermal, mesodermal, 
and endodermal tissues [50]. 
The first cell line derived from a human embryo was achieved in 1998 [51]. To date, 
about 50 well-characterised human ES cell lines have been reported worldwide. 
ES cells possess the highest degree of plasticity among the stem cells that have been 
studied up to now. Unlike the ASCs, which are derived from an adult organism, no 
clinical trials on human ES cells have been conducted to date. This delay may be 
explained by two major hurdles. First, the ethical issues raised by the research on the 
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embryo and the debate over the use and destruction of embryos for clinical purposes 
[25]. On the technical front, the tumourigenic potential of the ES cells hinders further 
clinical applications. It is really important to emphasise that ES cells and cancer cells 
have many common characteristics, including unlimited proliferation [52] and high 
expression of telomerase [48]. Moreover, ES cells have been shown to generate 
teratomas when injected in immunocompromised mice [50]. To avoid the formation 
of teratomas, one possibility would be to transplant fully differentiated ES cells 
and/or use the appropriate growth factors to induce cells into the desired committed 
lineage [53].  
 
Multipotent to unipotent cells 
Multipotent cells have a more restricted lineage differentiating capacity than ES cells 
and are usually referred as ASCs. They can produce a large range of differentiated 
cells but are restricted to a particular tissue. HSCs for instance are multipotent, since 
they are the source of all blood cell types [54]. ASCs such as spermatogenic stem 
cells can produce only one cell type (spermatozoid) and are therefore unipotent. 
Although less plastic than ES cells, ASCs can self-renew and differentiate. They 
remain in a quiescent state within their niche until they receive a stimulus to 
differentiate [45].  
ASCs present several advantages in comparison to ES. Firstly, they are not associated 
with ethical issues and possess the advantage of being easily available. HSCs can be 
harvested by simple blood collection or bone marrow aspiration. Importantly, large 
amounts are available at the same time which tends to shorten the in vitro period 
preceding the transplantation in a clinical assay. Using ASCs also avoids heterograft 
complications, as autologous transplantation is possible. Moreover, the issue of 
tumourigenicity seems to be more relevant with ES rather than ASCs [55]. 
Recent discoveries have also reinforced the advantage of using ASCs over ES cells. 
The plasticity of bone marrow stem cells (BMSCs) is more extensive than initially 
thought, and HSCs have been reported to give rise to cell types of endo-, meso- and 
ectodermal origin, including myocytes, neurons, liver and pancreatic cells [56-60]. 
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1.2.3 Intestinal stem cells 
 
Intestinal crypts and villi are covered with epithelial cells renewing on average every 
5 days in mice [61]. Intestinal crypts house the stem cells responsible for the high 
turnover of the epithelium. Stem cells reside at the base of the crypts, and produce 
transit-amplifying cells, able to divide at a very high frequency (12-16 hours [62]). In 
48 hours, these multipotent cells undergo up to 5 rounds of divisions. Their progeny 
migrate upwards, and once they reach the villi, they start differentiating into Goblet 
cells (in the colon), Paneth cells (in the small intestine), entero-endocrine or 
absorptive epithelial cells. All of the cells migrate from the crypts towards the villi, 
except the Paneth cells which move down to the base of the crypt to support 
maintenance of the stem cell niche. Goblet cells are their counterpart in the colon but 
remain on the sides of the crypts. As indicated from the proliferative index from 
Figure 2, there is an inverse relationship between proliferation and differentiation of 
cells along the length of the crypts. 
 
 
 
 
 
 
Figure 2. Stem cells, transit-amplifying and differentiated cells in the small intestine (A) and 
colon crypts (B). Along the length of the crypt, there is an inverse relationship between 
proliferation and differentiation. Source : [63]. 
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The lack of specific stem cell markers renders the identification of intestinal stem 
cells tedious. Stem cells within the proximal small intestine have been detected at 
position +4 at close vicinity to the crypt, immediately above the Paneth cells [64]. 
These self-renewing and pluripotent cells have recently been shown to express Bmi1 
protein [65]. The ablation of Bmi1 expressing cells led to the disruption of crypts, 
thus indicating the implication of these cells in crypt maintenance, and the possible 
role of Bmi1 as an intestinal stem cell marker. 
 
Recent reports have now detected another putative intestinal stem cell. The cell 
surface marker Lgr-5 (leucine-rich-repeat containing G-protein-coupled receptor 5), a 
Wnt pathway target gene, is specifically expressed in the crypt base columnar cells, 
disposed in between the Paneth cells. Using in vivo lineage tracing, Barker et al. 
(2007) have proposed that Lgr-5 expressing cells are the stem cells of the small 
intestine and colon [66]. More recently, studies on Lgr-5+ cells have proved that these 
basal columnar cells are also those from which colorectal tumours preferentially 
originate [67].  In knock-in mouse models, deletion of the apc gene (leading to the 
activation of the Wnt proliferation pathway) in the Lgr-5+ columnar cells initiates 
their transformation. While remaining in the bottom of the crypts, the transformed 
columnar cells generate a macroscopic adenoma in less than 5 weeks. In other knock-
in mouse models, the same deletion in transit-amplifying cells only generated rare 
adenomas, even after 30 weeks, suggesting that columnar cells, i.e. stem cells, and 
not transit-amplifying cells, are preferentially the cells in which mutated APC leads to 
cancer. 
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1.3 The CSC theory and the origin and development of 
cancer 
 
 
1.3.1 The traditional view of cancer 
 
 
 
Clonality of cancer 
It is generally accepted that most, if not all tumours are clonally derived, i.e. they 
initially are derived from the proliferation of one abnormal cell. Evidence in favour of 
this concept is mainly supported from studies that investigated the distribution of 
genetically distinct types of X-linked isoenzymes with, in particular, the study of 
glucose-6-phosphate dehydrogenase (G6PD). 30% of African women are 
heterozygous [68] at this allele where, typically, the same member of the X 
chromosome pair is functional in all malignant cells. This phenomenon has been 
studied specifically in blood cancers as a tool to prove the clonality of neoplasms 
[69]. Additionally, many cancer cells possess the same abnormal karyotype and blood 
cancer cells have been shown to secrete a homogenous panel of cytokines, which 
suggests a common ancestry of all the cancer cells [69, 70].  
 
Cancer progression is a multi-step process 
The initial step towards carcinogenesis (termed ‘initiation’) is the process by which a 
cell undergoes irreversible genetic changes. Initiators (or carcinogens) are able to 
interact with deoxyribonucleic acids (DNA) directly or after their activation via drug 
metabolizing enzymes [71, 72]. The mutations they cause are irreversible and any 
daughter cells produced from the division of the mutated cell will also carry the 
mutation, thus creating a pre-neoplastic clone of cells. Once a particular cell has been 
affected by an initiator it is susceptible to promotion (see below) until its death. 
In the second step towards carcinogenesis (termed ‘promotion’), continuous, 
epigenetic and reversible changes alter the ‘initiated’ cells, which then go on to 
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expand and take over the population of normal cells through clonal selection. At this 
stage, the cancer phenotype is expressed. The advanced steps towards carcinogenesis 
(termed ‘progression’) include further phenotypic changes, as well as the passage 
from a benign to a malignant tumour. 
Colorectal cancer is one of the best models illustrating the subsequent events 
occurring in carcinogenesis. Due to the availability of tissue from each of the stages 
displayed in Figure 3, DNA alterations contributing to the different steps of 
development have been analysed and chronologically defined as follows :  
 
 
 
Figure 3. The adenoma-carcinoma sequence in sporadic colorectal cancer and in HNPCC.          
Adapted from Fearon and Volgestein (1990) [73] . 
 
 
 
 
The apc gene, which is mutated in more than 70% of colorectal cancers, has been 
called the ‘gatekeeper’ gene as it seems to be the rate-limiting step in colorectal 
carcinogenesis [73] . This gene is a key member of the Wnt pathway, which is a 
cascade of signalling events involving a series of intracellular molecules. Its role is 
essential in development as deregulation of this signalling pathway results in 
carcinogenesis. In patients with FAP familial cancers (i.e. with a genetic 
predisposition), where apc is mutated in the germline cells and therefore transmitted 
to progeny [74], cancer appears earlier than in patients with sporadic cancers, in 
whom mutations affect random somatic cells, and therefore forms tumours over a 
longer period of time. 
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Nature of the genetic alterations 
Genetic alterations responsible for carcinogenesis result in the aberrant regulation of 
growth control. 
Essentially, alterations involve the hyperactivation of proliferation pathways such as 
the notch [75], sonic hedgehog (shh) [76], and Wnt pathways as previously 
mentioned in colorectal cancer initiation [77] (Figure 4). Other alterations can affect 
the expression of oncogenes such as c-myc, or result in the down regulation of 
tumour suppressor genes such as p53 [78].  
 
 
 
 
 
 
 
Figure 4. Schematic diagram of the signalling pathways involved in cancer biology. In a 
number of carcinomas, cancer cells are affected in their proliferation pathways. Mutations in 
Wnt, Shh and Notch 1 pathways can lead to carcinogenesis [79]. 
 
    PROLIFERATION      
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The proliferation pathways are predominantly active at the embryonic stage and are 
also functional in stem cells, as they seem to regulate their development and maintain 
their self-renewal capacity [80-83]. Any change in the tight regulation of stem cell 
self-renewal can easily lead to tumourigenesis. 
 
The heterogenic nature of cancer cells/tumourigenicity 
 
Heterogeneity of cells in the tissues is observed at the morphological and functional 
levels. They display differential expression of secreted factors and cell surface 
markers. All tissues are comprised of architecturally distinct layers each with a 
functional role, as illustrated by Figure 2 in the intestinal epithelium.  
Similarly to normal tissues, solid cancers are also comprised of heterogeneous 
populations of cells. Most tumours usually reproduce the patterns of differentiation 
seen in the primary tissues from which they are derived, even though their processes 
of differentiation may follow alternative pathways (cf. ability for invasion).  
At the functional level, one important criterion of heterogeneity is the capacity to 
regenerate a tumour. Large numbers of cancer cells are required in order to produce 
tumours in xenotransplanted immunodeficient mice [84],  which suggests that, 
amongst the population of injected cancer cells, only a small fraction of them 
possesses  tumour-initiating potential. 
 To explain cancer cell heterogeneity, the traditional (stochastic) model of cancer 
suggests that the behaviour of tumour cells is variable, unpredictable, reversible - 
depending on various factors, be they intrinsic or extrinsic [85]. Heterogeneity of 
cancer cells is based on a stochastic model. A stochastic model is a non deterministic 
model, whereby, besides its predictable process, its development includes a random 
element. The stochastic model of cancer follows that any cancer cell can 
hypothetically acquire a function such as tumourigenicity, provided it is influenced by 
a combination of factors (signalling pathways, microenvironment, intracellular levels 
of transcription factors, genetic or epigenetic alterations, etc.). Unpredictability 
therefore makes the separation between tumourigenic and non-tumourigenic cells 
very difficult to achieve. 
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1.3.2 The CSC model as an alternative to the traditional model 
 
 
The idea that cancer cells possess the same properties as stem cells has been 
suggested many years ago, and is well established now. For instance, ES cells 
resemble cancer cells in surprising ways. They possess intrinsic cancer cell-like 
properties and they develop teratomas when transplanted at an undifferentiated stage. 
Histologically, similarities between developing foetal cells and teratocarcinoma cells 
have been recognised more than 150 years ago [86].  
 
 
The CSC view of cancer as a multi-step process 
The relationship between the turnover rate of a tissue and the risk of developing 
tumour is difficult to establish. How can multiple alterations alter tissues with short 
life span cells, such as the bowel epithelial cells that are regenerated on average every 
5 days ? The role that CSCs may play in this setting is providing new insights into the 
mechanisms of cancer progression. In colorectal cancer for instance, the multiple 
alterations which are required for a normal epithelium to degenerate into carcinoma 
have been described extensively (cf. Figure 3) [87]. The idea that multi-step genetic 
mutations leading to cell malignancy can occur in cells with a long life span fits 
appropriately with the concept of CSCs [88]. It is argued that in many tissues the only 
cells present for a sufficiently long duration to accrue the requisite number of 
molecular abnormalities leading malignancy are stem cells.  
 
The CSC explanation of cancer origin and heterogeneity 
Use of the CSC model to explain the origin of cancer differs from the traditional 
view. CSCs have acquired mutations leading to uncontrolled growth and retain (or 
regain) their capacity for self-renewal and pluripotency. Like stem cells in normal 
tissues, CSCs lose some of their characteristics upon differentiation, through 
epigenetic changes, hence resulting in the heterogeneous cell population found within 
tumours [89]. Therefore, in the CSC model, heterogeneity is synonymous to intrinsic 
biological differences that occur through epigenetic changes. Epigenetic changes 
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involve all the mechanisms responsible for the modification of the gene activation 
status other than changes (e.g. mutations) in the underlying DNA sequence. 
 
The nature of the original cell has not been stated by the CSC model, as explained by 
Dick (2008) [90]. Stem cells may be preferentially the target of cancer initiation, but 
it is not excluded that tumours may also stem from differentiated cells that have 
regained the capacity to divide, self-renew and organize tissue-specific differentiation 
through genetic alterations. It is nevertheless intrinsic to the CSC theory that the 
originating cell is/becomes capable of self-renewal, differentiation and extensive 
proliferation. 
 
 
CSC and tumourigenicity  
Previous studies on clonogenic assays have shown that it is only a minority of cancer 
cells that can proliferate and form new tumours in transplanted mouse models. The 
CSC model posits that these cells are the CSCs. Non-CSCs in comparison only have a 
limited proliferation potential. Since CSCs possess the ability for self-renewal and 
proliferate extensively, it may explain the associated heterogeneity of cells found 
within a tumour mass regarding to tumourigenicity. In the traditional evolution 
model, differences between tumourigenic and non tumourigenic cells are the result of 
unstable, genetic or epigenetic changes. The potential for each cell to form a tumour 
depends on a stochastic probability [90]. In the CSC model, this potential is restricted 
to a specific population, with stem cell properties. The tumourigenic potential is lost 
upon differentiation and is the result of  epigenetic changes [85] (Figure 5). 
Therefore, even though the term CSC has been used extensively, a CSC is 
intrinsically defined as a rare cell amongst other cells within the bulk of a tumour that 
is able to reconstitute a tumour when injected into an immuno-compromised mouse.  
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Figure 5. Heterogeneity and tumourigenicity in cancer. The hierarchical (=CSC) and 
traditional (=stochastic) models of cancer have different hypotheses with regard to the 
functional heterogeneity of cancer cells. Initiating a tumour in the CSC model is considered 
to be the exclusive property of cells capable of self-renewal and differentiation. Cells are 
therefore not biologically equivalent, and have different functions according to their position 
in the hierarchy. CSCs can self-renew and also generate non-tumourigenic cells. In the 
traditional (stochastic) view of cancer, tumour cells are biologically equivalent, but intrinsic 
and extrinsic factors also influence their behaviour, and the tumourigenic properties can be 
randomly acquired by any cell in the bulk. Adapted from Dick (2008) [90]. 
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Such cells were first identified in leukaemic patients in 1997 by Bonnet and Dick 
[91]. They showed that as few as 100 of these rare CD34+/CD38- cancer cells were 
able to initiate leukaemia in non-obese diabetic severe combined immunodeficiency 
(NOD/SCID) mice and that these self-renewing cells were able to proliferate and 
differentiate into leukemic blasts. 
It took several years before CSCs or tumour-initiating cells were identified in solid 
tumours. Al-Hajj  et al. (2003) [92] succeeded in identifying CSCs in breast cancer, 
followed by Singh et al. [93], who isolated CSCs from brain tumours [94]. 
Subsequently, CSCs were discovered in prostate [95], liver [96], skin [97], and colon 
[98-100] cancer. 
 
Clinical implications 
The identification of CSCs brings about important therapeutic implications in terms 
of selective drug targets and recurrence/metastasis prevention essentially.  
If tumours truly follow a CSC model of development, therapy should aim at targeting 
the CSCs and not the cells that form the main mass of the tumour [101]. Similarly to 
normal stem cells, CSCs are predicted to possess enhanced mechanisms of resistance 
due to  high levels of transporters [102-104], of anti-apoptotic proteins (bcl-2 family 
members [105]), slow cell cycling [106], and enhanced DNA damage repair [107]. 
These features explain how CSCs may escape the conventional chemotherapeutic 
treatments, and thus be responsible for recurrence and metastases. 
Current treatments are characterised by ineffectiveness and serious adverse effects. 
The investigation of markers that may distinguish CSCs from the rest of the tumour 
and normal stem cells should give way to targeted therapies that may limit the 
damage caused to healthy tissues, while being more efficient.  
The successful eradication of tumours will therefore require the successful isolation 
of CSCs, the identification of specific markers such as cell surface markers, and the 
understanding of the molecular mechanisms involved in the surviving, self-renewal 
and differentiation pathways of CSCs. A comparison with the rest of the tumour cells 
and cells from healthy tissues will be required. 
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1.4 The biology of CSCs 
 
1.4.1 CSCs versus normal stem cells – proliferation pathways 
 
Regardless of the origin of CSCs, they share several properties with normal stem 
cells.  
The CSC model predicts that, as in any organ, cells within a tumour bulk are 
hierarchically organised, and derived from a rare population of CSCs, or their direct 
progeny (Figure 6) [91]. In order to ensure the continued expansion of malignant 
cells, CSCs can self-renew, i.e. maintain their pool, and in the meantime differentiate 
into progenitor and transit-amplifying cancer cells.  
 
 
 
Adult normal stem cell Malignant cancer stem cell
Progenitor cell
Self-renewal
Progenitor cell
Mature normal cell
No proliferation
‘benign’ cancer cell
No tumour-initiating ability
Self-renewal
mutations
Proliferation
 
    
Figure 6. In the CSC hierarchical model, the origin of cancer is restricted to CSCs. Like their 
stem cell counterpart, CSCs can self-renew and/or differentiate into progenitor cells which 
possess a high rate of division. Mature cells are not able to proliferate anymore. The question 
marks denote that the cellular origin of cancer is not yet defined. (adapted from Sagar et al. 
(2007) [108]). 
 
? 
    ? 
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Transit-amplifying cells are cells that are capable of extensive proliferation and 
differentiation but which progressively lose the tumourigenic potential upon 
differentiation [83]. 
The mechanisms of CSC self-renewal are suspected to be similar to those regulating 
stem cells in normal organs. Asymmetric division has been suggested to play an 
important role in maintaining the CSC pool, and producing a hierarchically organised 
tumour bulk [35]. Disruptions affecting the mechanisms regulating the asymmetric 
and symmetric modes of division have been shown to lead to tumourigenesis in 
Drosophila melanogaster. This observation has led to the idea that cancer may 
originate from stem cells [35, 109, 110].  The essential difference between normal 
stem cells and CSCs is that proliferation is no longer controlled in CSCs [111]. The 
ratio of CSCs/cancer cells is retained, but the total number of cells is constantly 
increasing, whereas, in normal stem cells, proliferation occurs only on demand.  
The hypothesis is that CSCs have undergone a series of mutations in their 
proliferation pathways such as Notch [75], shh [112], Wnt [113], which disrupt the 
proliferation balance in CSCs [83]. 
 
 
1.4.2 Other attributes of CSCs  
 
 
CSCs are thought to be more invasive and form metastases more frequently than non-
CSCs. In breast cancer for instance, the invasive property has been identified in a 
subpopulation of CSCs expressing the CD44+/CD24- CSC phenotype [114]. 
 
CSCs are also suspected to be more resistant to chemotherapy than the other cancer 
cells [115] although the link between CSCs and chemoresistance is still not well 
defined. In the conventional model of drug resistance, mutations occur randomly in 
one or several cells, according to a stochastic model here again, and confer on them a 
selective advantage during chemotherapy. The CSC hypothesis assumes that in most 
cases, resistance is driven through a rare population of CSCs, mainly as a 
consequence of their resting stem cell phenotype, high levels of transporters 
(Multidrug resistance 1 (MDR1), Adenosine triphosphate-binding cassette G1 
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(ABCG1) [102-104], of anti-apoptotic proteins (bcl-2 family members [105]), slow 
cell cycling [106], or enhanced DNA damage repair [107], thus providing them with 
innate resistance. Conversely to CSCs, differentiated tumour cells lose their intrinsic 
resistance upon differentiation, although they can always acquire resistance through 
the processes of gene amplification or chromosomal rearrangements [116].  
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1.5 Isolation of CSCs 
 
Controversy still exists as to the true nature of CSCs. Their isolation has still not been 
conclusively derived and their use as a clinical tool is still undefined. To date, the 
isolation of putative CSCs has been based on intrinsic and stable properties that are 
believed to be unique to these cells.  
 
1.5.1 Current strategies to isolate CSCs 
Side population 
Hoechst-dye is a tool primarily used in a strategy to enrich a subpopulation of HSCs. 
The cells that are able to expel the dye represent a distinct subset of cells identifiable 
by flow cytometry, and have been called “side-population” (SP) cells. This ability to 
exclude the dye relies essentially on the overexpression of transporters  of the ABC 
family [117]. SP cells were identified in murine HSC by Goodell et al. [118] and their 
potential to repopulate lethally irradiated mice was 1000 fold higher in comparison to 
the whole bone marrow cells. Although there is controversy on the SP content in 
CSCs [119], SP cells have been identified among the human gastrointestinal, liver, 
nasopharyngeal and lung cancer cells [103, 104, 120, 121]. In several occasions, the 
SP cells have proven to be enriched with cancer-initiating cells [104] and to have 
stem-cell like properties such as increased invasiveness, high levels of telomerase 
activity [122], increased expression of drug resistance associated genes and evidence 
for self-renewal [103]. A critical limitation to the use of SP is that the Hoechst dye is 
cytotoxic depending on the dose used and the type of cells being treated. 
Cell markers  
Several studies to date have reported the existence of CSC specific markers, as shown 
in Table 2. Based on their similarities with normal stem cells, CSCs were isolated 
with corresponding stem cell surface markers. CD133, initially referred to as AC133, 
was chosen as the most relevant candidate marker since it                                                                                                                                                                                                                                             
is an important hallmark of ‘stemness’ state in primitive cells from the neural, 
epithelial, endothelial and  haematopoietic tissues [123-125]. CD133 has also been 
reported to be present on CSCs from different haematopoietic and solid tumours such 
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as leukaemia, brain [93], colon [98, 99], liver [96] and prostate cancer [95]. CD133 
thus appears to be the most likely candidate for a universal ‘stemness’ marker in 
cancer. Subsequently, other markers for the identification of CSCs have also been 
identified, importantly  the marker CD44 in breast cancer [92]. CD44 in combination 
with CD24- and Epithelium specific antigen (ESA)+ allows the purification of breast 
tumour-initiating cells. CD44 is also expressed in pancreatic [111], breast [92], 
prostate [95] and colorectal CSCs [100]. In colorectal cancer, the proposed 
combination of markers CD44+/CD166+/ESAhi is expressed by a highly tumourigenic 
population. Other markers used to isolate CSCs are ABCB5 and CD90. They are 
involved in CSC isolation, in melanoma [126]  and liver cancer [127], respectively.  
 
 
Table 2. Summary of the most common markers used for CSC isolation 
Cancer type CSC markers Reference(s) 
Leukemia CD34+/CD38− [91] 
Breast ESA+/CD44+/CD24−/low [92] 
Brain CD133+ [93] [128] 
CD44+ [129] 
CD44+/α2β1hi/CD133+ [95] Prostate 
CD44+/CD24− [130] 
CD133+ [98] [99] 
CD44+/ESA+/CD166+ [100, 131] Colorectal 
CD44+ [132] 
CD133+ [102, 133] 
Pancreatic 
ESA+/CD44+/CD24+ [134] 
Head&neck CD44+ [135] 
CD133+ [136] [96] [137] 
CD90+ [127] Liver 
EpCAM+ [138] 
Retinoblastoma CD133+ [139] 
Lung CD133+ [122, 140] 
Kidney CD133+ [141] 
CD133+ [142] 
Ovary 
CD44+/MyD88+ [143] 
Melanoma CD90+ [126] 
Larynx CD133+ [144] 
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In most cases, these markers have not yet shown any functional activity. Some of 
them have been correlated with clinicopathological parameters. Essentially, CD133 
and CD166 are associated with low patient survival in colorectal cancer [145-147], 
whilst the function of CD44 in this setting is still contradictory [148-151]. CD133 and 
CD24 may correlate with invasiveness and differentiation [152], whilst CD44 has 
also been reported to be involved in invasion and migration [151, 153, 154]. 
 
Sphere formation 
The isolation of CSCs from the rest of a cancer cell population can be performed by 
reproducing a neurosphere assay set up by Reynolds and Weiss [155, 156]. This assay 
was used to isolate neural stem cells and relies on the unique ability of stem cells to 
form spheres. Expanding cells within these spheres seems to favour self-renewal 
rather than differentiation, thus enhancing the number of stem cells. Such a method 
has been adapted to purify putative CSC populations in brain cancer [157-161] as 
well as in breast [162], colorectal [163], pancreatic [164], ovarian [165], and prostate 
cancer [166], in order to isolate cells with a self-renewing capacity. 
 
 
Aldehyde dehydrogenase  (ALDH) 
Another strategy to isolate stem cells and CSCs is based on the targeting of cells with 
high Aldehyde dehydrogenase (ALDH) activity, in particular ALDH1. This enzyme 
mediates the oxidation of intracellular aldehydes to carboxylic acids in the cytosol 
and is involved in retinoid metabolism [167]. It has been shown in mice HSCs that 
retinoids are responsible for the terminal differentiation of late progenitors and the 
self-renewal of early precursor cells [168, 169]. ALDH1 activity is hence implicated 
in maintaining a stem cell phenotype, and is said to be upregulated in HSC and 
neuronal stem cells. ALDH1 has been used successfully to isolate HSC, neural and 
breast stem cell populations [170-172]. Different groups have also isolated ALDH1+ 
populations from leukaemia [173], breast [172, 174], colorectal [100], liver [175] and 
lung [176] cancers. 
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1.5.2 Current knowledge on existence of CSCs in solid tumours 
 
Brain tumours 
 
Brain tumourigenic stem cells (BTSCs) have been detected in primary brain tumours, 
including glioblastoma multiform (GBM), medulloblastoma, ganglioglioma and 
pilocytic astrocytoma [93, 128, 160, 161, 177, 178]. They have also been identified in 
several brain cancer cell lines [157, 179-181]. 
 
Using the neurosphere assay, CSCs are grown to clonal density on uncoated plastic in 
serum free medium supplemented with epidermal growth factor (EGF) and basic 
fibroblast growth factor (bFGF) [155, 156]. Cells that are responsive to these growth 
factors form floating spheres, and are thereafter considered as CSCs if they can 
maintain this sphere forming property after several passages to give rise to a large 
number of differentiated progeny [182]. 
Neurospheres grown from primary brain tumours and brain cancer cell lines express 
CSC-like properties including higher levels of stem cell markers CD133 and nestin, 
which is a cytoskeletal protein associated with neural stem cells [157, 160, 183].  
Neurospheres originating from glioma have been shown to differentiate into neurons 
and astrocytes [184], or when derived from oligoastrocytoma, they have been shown 
to express glial fibrillary acidic protein (GFAP) and myelin basic protein, which 
suggests their capacity for multilineage differentiation [161]. Neurospheres 
themselves possess an enhanced sphere forming potential in vitro and an increased 
cancer-initiating capability in vivo compared to the initial population with only 1000-
5000 cells from neurospheres necessary to reinitiate a tumour [157, 159-161, 183].   
 
 
Besides neurosphere formation, brain CSCs have been targeted by virtue of the stem 
cell surface marker CD133. This marker is expressed at higher levels in the 
neurospheres isolated from brain tumours rather than in the primary tumour tissues 
[157, 160, 183]. Uchida et al. first showed that CD133+ cells isolated from paediatric 
brain tumours presented stem cell characteristics in vitro with high capacity for 
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sphere formation and a certain potential for engraftment in neonatal rat brain [124]. 
Later on, Singh et al. (2003) succeeded in isolating a CD133+ population from 
medulloblastomas and GBM. As few as 100 CD133+ cells could re-initiate a tumour 
in NOD/SCID mice even after several passages, whilst this was not achieved with  
CD133- cells even when 1000 times more cells were used [93, 94]. In addition to this, 
CD133+ cells could generate clusters, they self-renewed and differentiated to 
recapitulate the original phenotype of the tumour they were derived from. 
A few studies confirmed the stem cell-like phenotype of CD133+ glioma cells in vitro 
[185]  and in vivo [107]. In this latter study, Bao et al. (2006) showed that 10,000 
isolated CD133+ cells were able to reinitiate a tumour in immunocompromised mouse 
brains, while 2×106 CD133- cells could not form tumours in 3 out of 5 animals [107]. 
In vitro studies on CD133+ cells also include resistance assays to chemotherapeutic 
agents. In cell lines derived from primary cultures of glioblastomas, CD133+ cells 
were significantly more resistant than CD133- cells when exposed to a panel of  four 
agents including paclitaxel, carboplatin, temozolomide and etoposide. These CD133+ 
expressed higher levels of the drug resistance gene BCRP1 [105]. 
The use of CD133 as a universal BTSC surface marker has however recently been re-
assessed due to conflicting data. Studies reported that CD133- cells were able to form 
neurospheres and were also tumourigenic in nude rats [186, 187]. Moreover, these 
cells were capable of generating CD133+ cells after their re-implantation in rat brains 
[187]. It thus appears that CD133 may not be as essential in brain tumour initiation as 
originally expected. Its role might be more critical for tumour progression rather than 
initiation. 
 
Breast cancer 
 
In primary breast tumours, the combination of the two markers CD44+/CD24- enabled 
Al Hajj et al. (2003) to isolate breast tumour-initiating cells. Additionally, these 
isolated cells that expressed ESA had a reinforced tumourigenic potential in 
NOD/SCID mice [92]. ESA has previously been used to identify a breast stem cell 
population defined as MUC-/ESA+ [188]. As few as 200 cells presenting the 
CD44+/CD24-/ESA+ phenotype generated a tumour in all of the mice tested when 
injected into mammary fat pad of NOD/SCID mice. Furthermore, only the cells with 
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CD44+/CD24- expression progressed into the other phenotypes CD44+/CD24+, CD44-
/CD24+ and CD44-/CD24- after injection in the mice. This indicates that if 
CD44+/CD24- phenotype can differentiate and reconstitute all the phenotypes present 
within the tumour bulk, it might be the most primitive phenotype among them. 
Similarly, in breast cancer cell lines SUM149 and SUM159, the cells with 
CD44+/CD24-/ESA+ phenotype showed higher tumourigenicity when as few as 100 
cells were injected into NOD/SCID mice. This confirms that CD44+/CD24-/ESA+ 
might be the phenotype of breast CSCs in cell lines as well as in fresh tumour 
samples [189]. Additionally, in two clinical studies where patients received 
neoadjuvant chemotherapy, there was a marked increase in the expression levels of 
CD44+/CD24− compared to untreated patients. This supports the hypothesis that 
CSCs may be more resistant to chemotherapy than the rest of the cancer cells [190, 
191]. 
Further work on breast cancer involved in vitro studies with assays primarily set up to 
culture breast stem cells as non-adherent “mammospheres” [192]. Like the 
neurosphere assay, mammary tissue can generate mammospheres with large 
populations of stem and progenitor cells capable of differentiating into the three types 
of mammary epithelia [192]. Interestingly, when such cultures were performed on 
breast tumours, mammospheres were obtained, and 95% of the cells showed 
CD44+/CD24- phenotype and were highly tumourigenic in vivo [162]. Moreover, 
CD44+/CD24- cells in breast cancer cell lines were associated with invasive 
properties, as confirmed by their efficiency of invading matrigel and by their gene 
expression profiling [114]. Resistance to radiation [193] and to chemotherapy [194] 
were suggested to be the selected advantages of this population according to 
preliminary studies on breast cancer cell lines. 
 
In parallel to the CD44+/CD24-/ESA+ phenotype, the enzymatic assay that targets 
cells with high ALDH1 activity has been confirmed as an alternative tool to isolate 
breast CSCs. In breast cancer primary cultures, an isolated ALDH1+ cell population 
representing 5% of the total population possessed the potential to form 
mammospheres whereas ALDH1- cells could not [172]. ALDH1+ cells were also 
highly tumourigenic in vivo and able to regenerate tumour diversity with only 500 
cells injected. However, the overlap with CD44+/CD24- population was less than 
1.2%, which emphasizes the fact that isolating CSCs by a single cell surface marker 
 44 
may not comprise the whole stem cell population. Cells combining CD44+/CD24- and 
ALDH1+ phenotypes were more tumourigenic with an encouraging number of just 12 
cells being able to initiate the tumour, versus 1500 CD44+/CD24- cells. In breast 
cancer cell lines, a combination of  the markers ALDH1+ and CD44+ also reinforced 
the tumourigenic and metastatic potential of these cells [195]. Indeed, a multi-step 
evolution of cancer predicts that several different markers may be co-expressed in 
CSCs. It is therefore to be expected that, in order to refine CSC isolation, a greater 
number of markers is required. 
 
Recently, the role of ALDH1 was elucidated in a study involving an analysis of 33 
breast cancer cell lines. An ALDH1+ population with obvious stem cell properties 
was detected in 23 of these cell lines. These putative CSCs proved to be an important 
mediator of invasion in vitro and in vivo. ALDH1+ cells developed metastases in 
several distant sites, while ALDH1- developed metastasis only once and it was 
limited to the lymph nodes [174]. 
 
 
 
Colorectal cancer 
 
CD133 was the first marker used to isolate a population of colorectal cancer cells 
with high tumourigenic potential [98, 99]. O’Brien et al. (2007) reported that on 
average 1 in 262 CD133+ colorectal cancer cells was able to initiate cancer [99]. The 
CD133+ population, as compared to the total tumour cell population, would represent 
a 200-fold enrichment in CSCs. Ricci-Vitiani et al. (2007) also confirmed the high 
tumourigenic potential of CD133+ colorectal cancer cells when compared to  CD133- 
cells [98]. The CD133+ population isolated directly from primary colorectal 
specimens [98] possessed an exclusive sphere formation capability compared to the 
CD133- fraction, and could retain the ability to initiate tumours for more than one 
year when cultivated under serum free conditions.  
Cells isolated directly from colorectal specimens have been propagated in serum free 
conditions [163]. The resulting spheres expressed the stem cell marker CD133 and 
were tumourigenic in NOD/SCID mice, whereas cells grown in the presence of serum 
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were not. Moreover, upon deprivation of growth factors, the spheres differentiated 
and lost both CD133 expression and their tumourigenic potential. 
 
In addition to CD133, a combination of the markers CD44+/ESAhi with CD166+ have 
been proposed to also identify a colorectal tumour-initiating population of cells [100, 
131]. It has been shown recently that CD44+ cells were tumourigenic in vivo [132]. In 
all the cases, these populations have been claimed to have an exclusive tumourigenic 
property when compared to their negative counterpart. 
Amongst the populations used to isolate colorectal CSCs, it is unknown whether they 
differ in maturity.  Little is known yet as of the nature of CSCs and their progeny. In 
an effort to classify colorectal CSCs, Todaro et al. (2008) recently proposed a 
hierarchy model where CD133+ cells are seen as the stem cells, and where another 
important stem cell marker Musashi-1 (Msi-1) is likely to be the marker of progenitor 
cells [163]. In this study, it was also shown that amongst a CD133+/Msi-1+ enriched 
population, CD44+ cells are those which possessed the highest metastatic potential. 
In addition to cell surface markers, studies on the role of ALDH1 in colorectal CSCs 
have characterised its role when combined with the ESA+/CD44+ phenotype. The 
potential of the ESA+/CD44+/ALDH1+ cells to enhance tumourigenicity in vivo in 
comparison to their counterpart ESA+/CD44+/ALDH1- [100, 132] has not been clearly 
defined yet. 
 
 
 
Pancreas 
 
The existence of tumour-initiating cells has been reported among most organs, in 
particular liver, pancreas, prostate and ovary.  
In primary pancreatic cancer cells, a population rich in tumour-initiating cells was 
discriminated using the same guidelines as for breast CSCs [134]. This subpopulation 
comprised 0.2 to 0.8% of the original tumour population. As few as 100 cells isolated 
from this phenotype were able to regenerate a tumour comprising a heterogeneous 
population of cells with the phenotype present in the original tumour 
(ESA+/CD44+/CD24+,  ESA+/CD44-/CD24+, ESA+/CD44-/CD24- etc.). In parallel, 
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work has also been carried out using primary tumours and pancreatic cancer cell lines 
to isolate CD133+ cells [102, 133]. In fresh primary tumour samples, only 1-3% of 
the isolated cells were CD133+. Injecting just 500 of these cells into NOD-SCID mice 
was sufficient to reinitiate a tumour [133]. Only 14% of the isolated CD133+ cells 
stained for CD44+/CD24+/ESA+. This suggests that, similar to colorectal cancer, 
different sets of markers can discriminate different populations of cells bearing 
tumour-initiating potential.  
Using PANC-1 pancreatic cancer cell line, a colony forming assay was established 
that allowed the detection of cells able to form adherent spheres over several 
generations in serum free medium [164]. The cells isolated from the spheres were 
capable of excluding Hoechst dye, and when cultured in medium containing serum,   
two types of cells were generated - one with and one without the Hoechst dye 
exclusion capability [164]. 5×105 PANC-1 cells that were dissociated from spheres 
were injected into nude mice to form a visible tumour nodule after 4 weeks. This was 
in contrast with using 20 times more cells (107) from the original population to form 
tumours. The SP that was isolated from PANC-1 [196, 197] showed a high resistance 
to the anti-tumour agent gemcitabin [196]. The CSC nature of this population 
however was not defined.  
 
 
Liver 
 
In the liver, early investigations have been carried out using the marker CD133 to 
isolate putative CSCs. Highly tumourigenic CD133+ cells were discovered in vivo 
from fresh primary tumour samples [137] and from several hepatocellular carcinoma 
(HCC) cancer cell lines [96, 136, 137]. In PCL8024 HCC cell lines, ALDH1 used in 
combination with CD133 [175] seemed to target an even more tumourigenic 
population, since significantly fewer CD133+/ALDH1+ cells (500) were needed for 
tumour formation in comparison to CD133+/ALDH1- cells (10 000)  and CD133-
/ALDH1- cells (300,000). The marker CD90 (also known as Thy-1) has also been 
associated with tumourigenicity. CD90+ cells were more tumourigenic than their 
counterpart in HCC cell lines, which was also validated from primary HCC [127]. In 
primary tumours, CD90+ cells were 200 times more tumourigenic than the rest of the 
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population. The same paper also reported that the CD44 marker is necessary for 
tumour engraftment and tumour metastasis, which has been confirmed in other 
cancers [163]. The marker EpCAM (epithelial cell adhesion molecule, =ESA 
(epithelial specific antigen) also discriminates a highly tumourigenic and metastatic 
liver CSC population, with an interesting highlight on the role of the Wnt/β-catenin 
pathway in the survival of   EpCAM+ cells [138].  
In another attempt to isolate liver CSCs, an SP in the HCC cell line Huh7 promoted 
tumours in NOD/SCID xenograft experiments with as few as 103 SP cells, whereas 
106 cells of the non-SP population were necessary to obtain the same result [104]. 
Prostate and ovarian cancers have been also investigated. Mainly, the phenotypes 
CD44+, CD133+, α2β1hi as well as androgen receptor (AR)- are expressed by cells 
presenting increased clonogenic, metastatic and tumour-initiating potential [95, 129, 
198]. The combination of CD44+/CD24- [130], as described previously in breast 
cancer, may also discriminate a prostate CSC population. In ovarian cancer, the main 
markers to isolate a CSC-like populations were reported to be CD133+ [142] and 
CD44+/MyD88+ [143]. In several prostate and ovarian cancer cell lines, sphere 
formation assays have been established [165, 166], and the resulting spheroids were 
able to expand exponentially after several passages and to establish tumours in mouse 
engraftment experiments. 
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1.6 Traditional or hierarchical model for cancer ? 
 
In order to fully characterise and establish the role of CSCs, their successful isolation 
must be achieved. Currently putative CSCs are isolated based on the techniques 
described above, i.e. surface marker targeting, sphere formation, ALDH assay, and 
chemoresistance selection.  
The efforts invested in CSC isolation during these past few years have reinforced at 
least the evidence for the existence of tumour-initiating cells in nearly all types of 
cancers including colorectal cancer, as reviewed here. The fact that a small population 
of cancer cells express a specific combination of markers to indicate a tumourigenic 
ability, whilst the majority of cancer cells lose these markers upon differentiation, is 
in itself evidence in favour of a hierarchical model of cancer progression [85]. 
To account for this model, it seems that the number of cells with tumourigenic 
properties would be lower relative to the number of the other cancer cells. If the 
majority of cancer cells is capable of tumourigenicity, then the concept of a hierarchy 
becomes less meaningful and it therefore is more likely that a common clonal genetic 
disposition is in effect rather than a specific epigenetic state. In such a case, tumour 
heterogeneity may be explained according to a clonogenic model. Recently, the 
immunodeficient in vivo models used to test cancer cell tumourigenicity have been 
questioned. Indeed, mouse models with improved immunodeficiency have revealed 
more tumourigenic cells than obtained with Nude or NOD/SCID mice [199]. 
Other caveats in the hierarchical model are now being raised, and the debate is 
evolving towards a compromise which accepts that tumours may follow either a 
traditional or a hierarchical model [200], and that clonal evolution can also intervene 
for CSCs [201]. 
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1.7 Aims of the study 
 
The aims of this study were the isolation and the characterisation of putative CSCs 
from colorectal cancer liver metastases. Colorectal cancer has been used as a model 
for this study. After brain and breast cancer, it is one of the first solid tumours in 
which the existence of CSCs has been claimed [98, 99]. Colorectal cancer is directly 
relevant with the CSC theory, as recurrence and metastases are common occurrences 
in patients. Indeed, more than 40% of patients with stage IV disease develop liver 
metastases [202]. If CSCs are proven to be responsible for metastasis, then there will 
certainly be a clinical interest into characterising and targeting these cells. Although 
the ultimate aim of CSC research is the discovery of more specific therapeutic targets, 
the isolation of CSCs remains a major hurdle and the best method to isolate these 
cells has not been defined yet. We therefore compared the efficiency of various 
techniques to isolate CSCs : 
- using CD133 surface marker expression. The efficiency of this marker to 
isolate tumourigenic cells in colorectal cancer has been claimed by two 
different groups [98, 99], however further characterisation  of CD133+ cells is 
needed in order to validate CD133 as a colorectal CSC marker and to explore 
their potential as a therapeutic target. 
- With techniques other than cell surface markers :  
→ using a chemoresistance functional assay. Resistance is considered 
to be a CSC intrinsic characteristic. It is one of the most important parameters 
in a clinical point of view, however little is known yet on the relationship 
between cancer and resistance. Using the resistance properties of CSCs may 
be a means to attain this population in colorectal cancer as it has been shown 
in brain tumour, pancreatic cancer and leukaemia [203-205]. 
→ testing the Aldefluor® assay as a marker for colorectal CSC isolation. 
The high expression of ALDH1 in pre-selected CD44+/ESA+ cell populations 
has been reported in two studies [100, 131]. More work is needed to analyse 
the possibility of ALDH1 as a single marker for colorectal CSC isolation . 
- to characterise whether or not the isolated cells are potential CSCs and, 
- to describe CSC potential therapeutic targets for therapy if CSCs are 
successfully isolated.  
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2 Materials and methods 
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2.1 Source of cells 
 
 
2.1.1 Cancer Cell lines 
 
The colorectal cancer cell line CaCO-2 was obtained from the American Type 
Culture Collection (ATCC, Manassas, Virginia, USA). Colorectal cancer cells CaCO-
2 were grown in Minimal Essential Medium (MEM) (Gibco, UK) supplemented with 
20% fetal bovine serum (FBS) (Biosera, UK) and 1% penicillin-streptomycin (PS) 
(Gibco, UK). All cells were incubated at 37oC in 5% CO2 / 95% air. 
 
 
2.1.2 Tumour dissociation and primary culture from colorectal cancer 
liver metastases 
 
Informed consent and local research ethics committee approval were obtained for the 
use of colorectal liver metastases specimens obtained after operative removal of the 
tumour (Reference Ethical Committee : 07/Q0406/45).  
 
Fresh samples (20) of metastases of colorectal cancer to the liver were collected in a 
sterile tube immediately after surgery and directly processed for cell culture or cell 
separation. All samples were initially rinsed three times in Hanks’ balanced salt 
solution (HBSS) (Gibco, UK) containing 1% PS.  
Tumours used for tumour growth were mechanically sheared using scalpels and 
scissors. 1mm3 pieces of minced tumour tissue were carefully placed on the surface of 
small Petri dishes (35mm2) (Nunc™, Denmark). Explants were allowed to adhere for 
2-3h in a drop of culture medium in Dulbecco's Modified Eagle Medium (DMEM) 
(Gibco, UK) supplemented with 10% FBS and 1% PS. After that, extra medium was 
carefully added as not to dislodge the explants. All cultures were incubated at 37°C 
with 5% CO2 / 95% air. Culture medium was changed twice a week. When the cells 
were confluent (after 4-5 weeks), they were subcultured and grown in T25 flasks. To 
remove fibroblasts from the cultures, 1% of trypsin/ethylenediaminetetraacetic acid 
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(EDTA, T/E) was added to the flasks (0.5mL), and cell detachment was observed 
under light microscopy. Detachment of fibroblasts is quicker than epithelial cells at 
that concentration. Once they rounded up, fibroblasts and T/E were removed from the 
flask with HBSS and replaced with fresh medium. Culturing in DMEM supplemented 
with 2% FBS was another strategy to give a survival advantage to the epithelial cells 
over the fibroblasts. Only one colorectal metastasis primary culture developed as a 
cell line and was called colorectal metastasis 1 (CM1). It was grown in DMEM 
supplemented with 10% FBS and 1% PS.  
 
Samples used for CSC isolation were mechanically dissociated as described above 
and incubated for 1h in 15mg/ml of collagenase I (Sigma, UK) and 133units/ml of 
DNAse I (Sigma, UK). The resulting cell suspension was then sequentially filtered 
through 100µm, 70µm and 40µm strainers to remove debris. To remove red blood 
cells, the tumour cell suspension was incubated on ice for 10min in 30ml of red blood 
cells lysis buffer (10.375mg/ml of NH4Cl , 1.25mg/ml of  KHCO3 and 0.01% of  
(EDTA)), and spun down for 7min at 1800rpm (Heraeus, UK). The resulting pellet 
was resuspended in HBSS and centrifuged for 10min at 800rpm to remove additional 
cell debris and dead cells. The pellet was resuspended in DMEM supplemented with 
10% FBS and cell number and viability were determined by trypan blue exclusion. 
The cell suspension was used for the isolation of CSCs. 
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2.2 Isolation of CD133+ cells 
 
 
Single cell suspensions from 5 colorectal cancer metastases were labelled with anti-
CD133 antibody using commercially available CD133+ MicroBead Kit isolation kit 
(Miltenyi Biotec, Germany) as recommended by the manufacturer. Briefly, 108 
tumour cells were incubated in 350µl MACS buffer (phosphate buffer saline (PBS) 
supplemented with 0.5% bovine serum albumin and 5mM EDTA), 100µl FcR 
blocking agent, 50µl CD133/1 (AC133)-Biotin antibody at 4oC for 10min. Labelled 
cells were then washed twice in MACS buffer and centrifuged at 1800rpm for 3min. 
108 cells were resuspended in 400µl of MACS buffer with 100µl of anti-biotin 
microBeads at 4oC for 15min. Excess of secondary antibody was washed by adding 
10-20 times the labelling volume buffer and resupended in 500µl MACS buffer. 
Magnetic cell separation was performed using either a VarioMACS or a MiniMACS 
separation column (Miltenyi Biotec, Germany). The column was placed in the 
magnetic field of a suitable MACS separator (Miltenyi Biotec, Germany) and washed 
with 3ml of MACS buffer. The cell suspension was then placed into the column. 
Unlabelled cells which passed through were collected and the column was washed 
three times with 3ml of MACS buffer. The column was removed from the magnetic 
field and 5ml of MACS buffer was used to flush out the fraction of magnetically 
labelled CD133+ cells. To ensure an optimal separation and high purity, both labelled 
and unlabelled fractions were processed a second time through new columns. The 
purity of each fraction was then determined by flow cytometry and the cells were 
directly used for further characterisation. 
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2.3 Isolation of chemoresistant putative CSCs 
 
2.3.1 Determination of cell viability by Cell Counting Kit-8 upon 
oxaliplatin exposure 
 
CaCO-2 cancer cells (20000 cells/well) were plated in 96-well plates (Corning Life 
Sciences, USA). 24h later, oxaliplatin was added at various concentrations (0 to 
50µg/ml) to determine its effect on cell growth and survival. The number of surviving 
cells was determined after 24, 48, 72 and 144h with Cell Counting kit-8 reagent 
(CCK-8, Axxora, UK). In this convenient colorimetric assay, the tetrazolium salt 
WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H) is 
cleaved to formazan dye by cellular mitochondrial dehydrogenase. The amount of dye 
generated is directly proportional to the number of living cells and is detectable on a 
spectrophotometer at 450nm. 10µg/ml of the CCK-8 reagent was added to the wells, 
and cells were incubated for 2h at 37oC. Optical density (OD) was directly measured 
using a µQuant microplate spectrophotometer (BioTek, UK). A calibration curve had 
been previously prepared to correlate OD to number of live cells. 
 
2.3.2 Determination of cell viability by trypan blue upon oxaliplatin 
exposure 
 
CaCO-2 cancer cell line (240000 cells/ml)) or CM1 primary culture cells (250000 
cells/ml) were plated in Petri dishes (35mm2) (Nunc™, Denmark). To determine the 
appropriate dose, oxaliplatin was added 24h later at different concentrations (0 to 
10µg/ml) and incubated at 37oC for 48h. Dishes were rinsed three times with PBS and 
medium (DMEM or MEM) supplemented with 10% FBS was added to the cells. The 
number of cells was then counted every 3 to 5 days for CaCO-2, and every 5 to 10 
days for CM1. Cells were harvested using Trypsin (Gibco, UK), and cell viability 
was evaluated by trypan blue exclusion.  
The dose sparing 10% or less of cells was chosen. It was determined to be 5µg/ml for 
both cell lines. 
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2.3.3 Isolation of oxaliplatin-resistant cells 
 
 
CaCO-2 cells were plated in T150 cell culture flasks. At 70% confluency, 5µg/ml of 
oxaliplatin was added to the cells for 48h. After 3 washes in PBS, DMEM 
supplemented with 10% FBS was added to the cells. 
Surviving cells were harvested at day 10 or 11 with trypsin after drug incubation, and 
used directly for characterisation. 
CM1 cells were similarly plated in T150 cell culture flasks, and exposed to 
oxaliplatin in the same way as CaCO-2. However, cells were harvested at day 21-22 
after drug removal. 
 
 
2.4 Isolation of ALDH1hi putative CSCs 
 
 
The Aldefluor® kit (StemCell Technologies, Durham, NC, USA) was used to identify 
a population with a high ALDH enzymatic activity. Reagents from this kit allow the 
oxidation of an ALDH substrate BAAA (BODIPY®-aminoacetaldehyde) into a 
fluorescent product BAA (BODIPY®-aminoacetate) [206], detectable by flow 
cytometry. The staining was processed according to the manufacturer’s protocol. 
Harvested cells were re-suspended in 1ml Aldefluor® assay buffer containing 5µl of 
the ALDH substrate solution, and incubated at 37oC for 1h. As a negative control, an 
aliquot of cells was treated with 15µmol/l diethylaminobenzaldehyde (DEAB), a 
specific ALDH1 inhibitor. After incubation, cells were spun down at 1800 rotations 
per minute for 3min and re-suspended in 400µl of Aldefluor® assay buffer 
supplemented with 1% bovine serum albumin (BSA) (PAA Laboratories GmbH, 
Austria). Cells were immediately sorted into ALDH1hi and ALDH1lo cell fractions 
using fluorescence activated cell sorting (FACS) performed by a FACSdiva (BD 
Biosciences, UK). 
Cell viability was evaluated by trypan blue exclusion after the sorting process. 
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2.5 Flow cytometry staining 
 
 
2.5.1 Cell marker analysis 
 
To analyse cell markers, 105 to 5x105 cells were harvested and stained with the 
appropriate antibodies (details and dilutions in Table 3). Prior to staining with internal 
antibodies, cells were fixed by adding 25µl 1% paraformaldehyde (PFA, Sigma, 
Poole, UK) for 10min after which cells were washed with PBS. Primary antibodies 
for internal staining were diluted in cell permeabilisation agent (FIX & PERM, 
Invitrogen, UK), and primary antibodies for external staining were diluted in PBS 
supplemented with 1% FBS. The cells were incubated with primary antibodies for 
45min at 4oC and then washed with PBS.  Cells were then incubated with a secondary 
antibody conjugated with a fluorescent dye (fluorescein isothiocyanate (FITC) or 
phycoerythrin (PE)) for 30min at 4oC. Cells were washed with PBS and analysed by 
flow cytometry. 
PE- or FITC-conjugated primary antibodies were diluted in PBS supplemented with 
1% FBS. Cells were incubated for 30min at 4oC with these antibodies, washed with 
PBS and analysed by flow cytometry.  
 
 
 
2.5.2 Cell cycle analysis 
 
105 to 106 cells were fixed overnight at 4oC in 70% ice cold ethanol. Cells were then 
washed twice in 2ml PBS and 400µg/ml of propidium iodide (PI) solution (Sigma, 
UK) was added for 1h on ice in the dark. 100µl of PBS was then added to each tube 
prior to flow analysis. 
Incorporation of PI is proportional to the quantity of DNA content, and thus provides 
information on the cell cycle stage of the cells. During G0 or G1 phases, cells possess 
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a normal diploid chromosomal (DNA content (2n)) whereas cells in G2 and just prior 
to mitosis (M) contain exactly twice this amount (4n). As DNA is synthesised during 
S-phase, cells are found with a DNA content ranging between 2n and 4n. Histogram 
plot (Figure 7) shows the following profile : 
 
 
 
 
 
 
 
 
 
 
2.5.3 ALDH1 activity measurement  
 
Cells were labelled in the same way as previously mentioned in paragraph 2.4.  
 
 
 
 
 
2.5.4 Flow cytometry analysis 
 
Cells were analysed using a FACSCalibur Flow Cytometer (BD Biosciences, UK) 
and CellQuest Pro software (BD Biosciences, UK). 
 
S/G2 /M 
G0/G1
Figure 7.  Dot plot representing CaCO-2 cell distribution in the cell cycle 
after PI incorporation. 
 
Apoptotic cells 
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2.6 Immunocytochemistry 
 
 
2.6.1 Cell marker analysis  
 
 
ALDH1hi and ALDH1lo sorted populations were plated on to sterile glass slides 
(Sigma, Poole, UK) and left overnight in a 37°C incubator to allow them to adhere. 
They were fixed in 2% PFA for 10min. In the case of intracellular markers such as : 
Oct-4, Lgr-5, ABCG-2, alkaline phosphatase (AP), sucrase isomaltase (SI) and Msi-1, 
cells were permeabilised with 0.1% Triton-X 100 (Sigma, Poole, UK) for 10min. Post 
permeabilisation or for extracellular markers such as CD24, CD44, CD133 and 
CD166, non-specific binding was blocked using 5% FBS and 3% BSA for 45min at 
room temperature. The primary antibodies were added immediately afterwards, 
incubated for 1h at room temperature and then washed three times with the blocking 
solution for 5min. Fluorescein isothiocyanate (FITC) or phycoerythrin (PE) 
conjugated  secondary antibodies were then added and incubated for 1h, in the dark, 
at room temperature and then washed again three times in PBS for 5min. PE- or 
FITC-conjugated primary antibodies were incubated for 1h, in the dark, at room 
temperature and washed three times in PBS for 5min. Antibodies were prepared to the 
specified dilution, determined by preliminary testing, using the blocking solution. The 
details of the antibodies used and their dilutions are detailed in Table 4. 4',6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, US) was used 
to label the nuclei and mount the slides. Slides were then wrapped in the aluminium 
foil and kept in the fridge for analysis within a week of staining. 
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2.6.2 Microscopy 
 
Immunofluorescent stained cells were visualised on Zeiss fluorescent microscope and 
analysed using the Metamorph program. At least 250 cells were counted in 5 random 
fields of view to assess the approximate percentage of cells with positive expression 
of the marker of interest. Percentage positivity was calculated as shown below: 
 
 
 
 
 
The cells were counted, at 40x or 20x magnification, in the control, ALDH1hi and 
ALDH1lo cell populations for each marker. All experiments were repeated 3 times for 
both the CaCO-2 and CM1 cell lines. 
 
 
2.7 Colony forming assay 
 
 
ALDH1 sorted cells were diluted so as to obtain 10 cells/mL. They were then plated 
onto 96-well plate, and checked under the microscope so as to pintpoint the wells 
containing 1 cell only. 
For each experiment, 80-100 wells with one unique cell were scored and followed-up 
over 5 weeks for CaCO-2, and 8 weeks for CM1.  
 
After that time, the number of mature colonies was determined, and percentages of 
colony forming potential were determined as follows :  
 
 
2.8 Invasion and migration assays 
 
      Number of Positive Cells                
Percentage Positivity=                              x 100  
       Total Number of Cells 
            
            Number of mature colonies                 
Percentage Positivity =    ----------------------------------------------------   x100             
Total Number of wells containing one cell            
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2.9 Migration assay 
 
 
 
Migration assay was conducted using polycarbonate membrane inserts with 8-µm 
pores (Nunc, Roskilde, Denmark) which were used in standard 24-well cell culture 
plates.  Polycarbonate membrane inserts were placed above the plated cells and 500µl 
of cell suspension (1x105 cells/ml) were added within the insert, in the absence of 
serum. 1mL of 20% FCS medium + 50ng/ml EGF was added in the bottom wells (to 
create a chemo-attractant gradient). No FCS and EGF were added to the control 
bottom wells. The entire chamber system was incubated at 37ºC for 72 hours.  After 
incubation, cells on the membrane were washed and fixed in PFA for 15min at 37°C. 
The filters were then washed twice with PBS and stained with 0.5% crystal violet for 
50min. After several washes with water, the non-migrating cells were removed from 
the upper surface of the membrane by using a cotton tipped swab to scrape the cells 
off the membrane with firm but gentle pressure.  The membrane was cut out using a 
scalpel and placed into a 96-well plate well containing 200µL of 0.1% acetic acid for 
solubilisation of the crystal violet. 
After 20min, OD was directly measured at the wavelength of 470nm using the 
µQuant microplate spectrophotometer. 
 
 
Analysis 
 
To calculate the percent invasion of cells, the following formula was used : 
Migration rate = (mean # OD cells migrating across the pores towards the gradient / 
mean # OD cells migrating across the pores without gradient ). 
 
Three independent (single) experiments were performed. 
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2.10 Oxaliplatin resistance experiment 
 
 
 
ALDH1hi and lo cells (15000 CM1 or 5000 CaCO-2 cells) were plated in 96-well 
plates. They were left overnight to adhere, and were then exposed to oxaliplatin at 
concentrations of 0, 1, 2, 5 and 10 µg/mL. After 96h incubation, 10µL of CCK-8 
were added in each well, and the plates were incubated for 2h and read on the 
spectrophotometer. 
 
 
2.11 Animal study 
 
All animal studies were carried out in accordance with the Animals (Scientific 
Procedures) Act 1986 (A(SP)A 86) and local institutional guidelines. 12 NOD-SCID  
mice (Harlan Ltd., UK) were injected subcutaneously in the right flank with 102, 
5x102, 103, 104 or 105 oxaliplatin chemoresistant CaCO-2 cells, or with 107 CaCO-2 
or LS174T untreated cells. Animals were assessed every 2 days for the presence of 
tumour and were maintained and cared for in accordance with institutional and UK 
guidelines. 
 
 
2.12 Statistical analysis 
 
The Student’s t test was used when experiments were repeated 3 to 5 times. For a 
greater number of experiments, we used the Wilcoxon test. 
Data are presented as the mean±standard deviation (SD). The student t test (2-sided) 
was used for paired samples. Differences of p<0.05 were considered as statistically 
significant. 
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Table 3. Antibodies dilutions and origin for flow cytometry. 
Antibody Supplier Details Dilution 
CD44-FITC Abcam 
Mouse 
monoclonal 
IgG1 
1:20 
CD133-PE 
Miltenyi 
Biotech 
Mouse 
monoclonal 
IgG2b 
Clone 293C2 
1:11 
CD133-PE 
Miltenyi 
Biotech 
Mouse 
monoclonal 
IgG1 
Clone 141 
1:11 
CD133-PE 
Miltenyi 
Biotech 
Mouse 
monoclonal 
IgG1 
Clone AC133 
1:11 
CEA-FITC Abcam 
Mouse 
monoclonal 
IgG1 
1:25 
Villin 
Santa-
Cruz 
Mouse 
monoclonal 
IgG1 
1:25 
CD24 Abcam 
Mouse 
monoclonal 
IgG1 
1:10 
ABCG2 Abcam 
Mouse 
monoclonal 
IgG2a 
1:20 
Mrp1 Abcam 
Mouse 
monoclonal 
IgG2a 
1:20 
Msi-1 
R&D 
Systems 
Goat IgG 1:10 
Lgr-5 
(GRP49) Abcam 
Rabbit 
polyclonal 
1:40 
Nanog Abcam 
Rabbit 
polyclonal 
1:50 
Oct-4 Abcam 
Rabbit 
polyclonal 
1:50 
Isotype  Supplier 
Mouse IgG1-FITC Santa-Cruz 
Mouse Ig1-PE Miltenyi Biotech 
Mouse IgG2b-PE Miltenyi Biotech 
Mouse IgG1 Santa-Cruz 
Mouse IgG2b Santa-Cruz 
Mouse IgG2a Santa-Cruz 
Goat IgG  Santa-Cruz 
Rabbit IgG  Santa-Cruz 
Secondary 
antibodies 
Supplier Dilution 
Rabbit anti- 
mouse FITC 
Dako-
Cytomation, 
Denmark 
1:100 
Mouse anti-goat 
FITC 
Santa-Cruz 1:100 
Swine anti-rabbit 
FITC 
Dako-
Cytomation, 
Denmark 
1:100 
 63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Antibodies dilutions and origin for immunohistochemistry.  
 
 
 
 
Antibody Supplier Details Dilution 
CD44-FITC Abcam 
Mouse 
monoclonal IgG1 
1:100 
CD133-PE 
Miltenyi 
Biotech 
Mouse 
monoclonal IgG1 
Clone 293C2 
1:50 
CD166-PE Abcam 
Mouse 
monoclonal  
IgG1 
1:50 
CD24 Abcam 
Mouse 
monoclonal IgG1 
1:50 
ABCG2 Abcam 
Mouse 
monoclonal 
IgG2a 
1:50 
Msi-1 R&D Systems Goat IgG 1:100 
Lgr-5 
(GRP49) Abcam Rabbit polyclonal 1:25 
Oct-4 Abcam Rabbit polyclonal 1:200 
Isotype  Supplier 
Mouse IgG1-FITC Santa-Cruz 
Mouse Ig1-PE Miltenyi Biotech 
Mouse IgG2b-PE Miltenyi Biotech 
Mouse IgG1 Santa-Cruz 
Mouse IgG2a Santa-Cruz 
Goat IgG  Santa-Cruz 
Rabbit IgG  Santa-Cruz 
Secondary 
antibodies 
Supplier Dilution 
AlexaFluor 488  
anti- mouse  
Invitrogen 1:500 
AlexaFluor 594 
anti-goat  
Invitrogen 1:250 
AlexaFluor 488 
anti-rabbit  
Invitrogen 1:500 
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3 Isolation of putative colorectal CSCs 
according to CD133 expression 
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3.1 Background  
 
 
The use of cell surface markers has been extremely useful in the isolation of various 
types of stem cells from organs such as bone marrow, brain and breast. Since it is 
hypothesised that CSCs are altered stem cells or stem cell-like cells that retain some 
of their original markers, then it is reasonable to attempt to isolate CSCs in the same 
way as normal stem cells.                                                                                                                                                                                                                                      
 
 
 
 
3.1.1 CD133 cell surface marker and stem cells 
 
 
CD133 is a pentaspan membrane protein and part of the prominin family. Its role is 
involved in organising the plasma membrane [207]. Its functional link with stem cell 
biology has not been completely assessed, but several observations have been made 
which associate its presence with a ‘stemness’ state. CD133 is present in the apical 
membrane protrusions of embryonal epithelial structures. It has also been previously 
observed that the differentiation of CaCO-2 cells is associated with the release of 
membrane bound CD133 [208]. Maintaining CD133 expression in the membrane 
may therefore sustain a stem cell phenotype. 
The antibody recognising a glycosylated epitope of the CD133 protein, the AC133 
antigen, detected a subpopulation of CD34+ HSC with long-term repopulating 
capacity in mouse xenografts [123]. AC133 expression is restricted to the CD34+ 
compartment in blood cells and is also a characteristic of endothelial [209] and brain 
stem cells [124]. 
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3.1.2 CD133, a universal cell surface marker for CSCs? 
 
CSCs were initially isolated using CD133 expression. With an antibody that detects 
the glycosylated AC133 epitope, tumour-initiating cells were successfully isolated 
from neural malignancy (in combination or independently of nestin) [93, 94, 105, 
161], prostate cancer (combined with CD44 and α1ß2 integrin) [95], pancreatic 
adenocarcinoma [102], HCC [96, 136], and, importantly for this project, colon 
carcinoma [98, 99].  
 
Focusing on colorectal cancer, CD133 was first chosen by O’Brien et al. (2007) in an 
attempt to identify a tumour-initiating population, using the same approach as in 
previous brain CSC extraction [99]. Out of 17 primary and metastatic colonic tumour 
samples, O’Brien et al. (2007) found that the number of CD133 expressing cells 
comprised between 1.8 and 24.5% of the total cell population. By limiting dilution 
assay, they predicted that when transplanting the total number of colon tumour cells 
in mouse xenografts, one cell out of 5.7×104 was a tumour-initiating cell. When 
CD133+ cells were injected into mice, they established that there was a 200-fold 
enrichment of tumour-initiating cells. Since CD133- cells were never able to induce a 
tumour, it meant that CD133+ cells contained the tumour-initiating population. 
However, not all of them were equally tumourigenic (only one CD133+ cell in 262).  
A study by Ricci-Vitiani et al. (2007) extended the work of O’Brien [98]. They 
isolated CD133+ cells from primary colon cancer (the average CD133 expression was 
2.4%) and also showed that tumourigenicity was restricted to the CD133+ fraction. 
They were able to maintain CD133 expression by culturing CD133+ cells in a serum-
free medium, and the resulting colonies that formed in these culture conditions 
maintained and even increased their tumourigenic potential following in vivo and in 
vitro passages. 
 
These results encouraged us to attempt to isolate a putative CD133+ CSC population 
from metastatic colon carcinoma for their characterisation and potential development 
as a new therapeutic target.  
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3.2 Isolation of putative colorectal CSCs according to 
CD133 expression 
 
 
3.2.1 CD133+ cells isolation 
 
A putative CSC population was isolated from colorectal metastases resected from the 
liver, using a CD133 immuno-affinity assay. The tumour samples that were collected 
from the operating theatre were used to optimise the cell dissociation process with the 
aim of minimising cell death. After optimisation of the protocol (as discussed in 
Material and Methods) five tumour samples were dissociated and incubated with a 
primary biotinylated anti-CD133 antibody (clone AC133, which recognizes epitope 
CD133/1), and then with anti-biotin Microbeads, according to the manufacturer’s 
protocol (Miltenyi Biotech). Labelled cells were isolated by being passed through an 
LS magnetic column twice. Cells eluted by the column were defined as the negative 
fraction while the magnetically labelled cells were retained by the column and 
constituted the positive fraction. The total number of cells before labelling and the 
number in the positive fraction were counted with a haemocytometer. Dead cells 
(trypan blue positive) were excluded. The percentages of cells in the positive fraction 
(7.52±6.36% ; n=5) isolated from the total tumour cell population are listed in Table 
5. 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Percentages of cells in the positive fraction 
1 17.3% 
2 0.9% 
3 2.9% 
4 8.4% 
5 8.1% 
Table 5. Percentages of cells isolated from the total tumour cell population 
and retained by the magnetic column after labelling with anti-CD133 
antibody conjugated to magnetic beads. 
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3.2.2 Assessment of cell purity 
 
To assess the efficiency of the magnetic separation, we stained the positive and 
negative fractions with CD133 antibody-FITC conjugated (clone 293C3, that 
recognizes epitope CD133/2 as recommended by the manufacturer), and analysed 
CD133 expression by flow cytometry.  
 
 
 
 
 
According to the FACS analysis data in Table 6 and Figure 8, the percentages of 
CD133+ cells amongst the total population were only 24.9±31.5% ; n=4. There was 
an enrichment of the positive fraction in CD133+ cells when compared with the 
negative fraction.  
On average, 22% more CD133+ cells were retained in the positive fraction than in the 
negative one. This result indicates that the system did select for CD133, however the 
quality of separation was not optimal. Positive fractions were anticipated to be at least 
90% positive for the CD133 marker after a two-column separation. Only samples 2 
and 3 showed the expected percentage of positivity for CD133+ (87.31% and 94.4%, 
respectively). In samples 1, 4 and 5, percentages of CD133+ cells in positive fractions 
were only between 10 and 68%. The positive fractions were therefore contaminated 
with CD133- cells. The fractions expected to be negative for CD133 expression 
contained a high frequency of CD133+ cells in 4 out of 5 samples tested (up to 81.4% 
in sample 2), indicating that not all CD133+ cells were retained in the column. 
 
Sample 
Percentage of 
CD133+ cells in 
total population 
Percentage of 
 CD133+ cells 
 in negative fraction 
Percentage of  
CD133+ cells 
in positive fraction  
1 NA  43% 65.8% 
2 1.02% 81.4% 87.31% 
3 67.79% 55.17% 94.4% 
4 29.4% 12.78% 46.6% 
5 1.52% 1.6% 10% 
Table 6. FACS analysis for purity check of the total population of samples, the fraction eluted 
by the column (negative fraction), and the fraction retained by the column (positive fraction) 
(use of antibody anti-CD133 clone 293C3). 
 
 69 
                                            
        
    
  
   
Specimen 1   
CD 133- fraction 
Specimen 1  
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Specimen 2  
 Total population 
Specimen 2  
 CD 133+ fraction 
Specimen 2  
 CD 133- fraction 
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 Total population 
Specimen 3  
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Figure 8. Representative flow charts indicating the poor purity of CD133 
magnetic separation by flow cytometry. Blue : IgG. Green : CD133. Total 
population for sample 1 is not available. The charts reveal an enrichment of the 
positive and negative fractions in CD133+ cells, indicating that all CD133+ were 
not retained by the column. Although contaminated with CD133- cells, the 
positive fractions contained more CD133+ cells that the negative fractions. 
43% 
65.8% 
1.02% 81.4% 87.31% 
67.79% 
55.17% 94.4% 
29.4% 
12.78% 
46.6% 
Specimen 5 
 CD 133+ fraction 
Specimen 5  
 CD 133- fraction 
Specimen 5  
 Total population 
1.52% 1.6% 10% 
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3.3 Understanding and overcoming the bad quality of 
separation 
 
To determine why the separation process was not optimal, we considered that the 
problem might occur at different stages : 
 
- the antibody used to check purity is not specific, 
- the microbead labelling is not specific, or 
- the separation process is not efficient. 
 
1) To check the specificity of the antibody (clone 293C3) used to confirm the purity 
of positive and negative fractions, we used the leukemic cell line KG1a as a negative 
control. It has been reported that AC133 does not react to this cell line [123]. KG1a 
cells were labelled with 3 different anti-CD133 antibodies produced by Miltenyi 
Biotech (clones 293C3, AC141 and AC133). The results were indeed negative on the 
flow cytometry, thus eliminating the possibility of non specific staining at this level 
(Figure 9). 
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en
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KG1a 
Clone AC133 
KG1a 
Clone AC141 
KG1a 
Clone 293C3 
0.97% 
1.04% 0.55% 
CD133 
Figure 9. Representative flow charts indicating the expression of CD133 in KG1a cells 
(negative control). The three anti-CD133 antibodies we tested did not react with KG1a 
cells that have been reported to not express CD133. This experiement eliminated the 
possibility of non specific staining when using these antibodies to confirm the purity of 
the separated cells. Blue : IgG. Green : CD133. 
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2) If the problem was at the microbead labelling step, one hypothesis was that adding 
the immunomagnetic beads could trigger a change in the cell membrane, and make 
them more reactive to the anti-CD133 antibody. We decided to compare by flow 
cytometry the percentage of CD133+ positive cells among the total population before 
and after the incubation with the magnetic beads. However, percentages of CD133+ 
cells in sample 3 and the cell line CaCO-2 (known to express CD133) were similar 
before and after the incubation, suggesting that adding the beads to the cells did not 
influence their reactivity to anti-CD133 antibody. 
 
3) As a control for the separation, CD133+ isolation was performed on CaCO-2, and 
on average, 7% of the cells were retained by the column (n=2). Flow cytometry data 
revealed that the unseparated population, as well as the positive and negative 
fractions all contained a very high percentage of positivity (respectively 96.08%, 
98.27% and 95.76% as an average for two experiments) showing poor separation in 
the case of high CD133 expression (cells were separated twice in the column) (Figure 
10). For one of these two experiments, we also used anti-CD133/2 clone 141 and 
anti-CD133 AC133 clone to confirm the FACS results obtained with anti-CD133/2 
clone 293C3. The three antibodies gave similar results. 
 
 
 
 
   
 
 
 
 
 
 
Figure 10. Representative flow charts indicating the strong expression of CD133 in 
CaCO-2 total, positive and negative fractions after magnetic separation. Blue : IgG. 
Green : CD133. After magnetic separation, the negative fraction still contained a high 
percentage of CD133+ cells, indicating that the kit might not be efficient when there 
was high number of CD133+ cells in the total cell population. 
CaCO-2  
Total population 
CaCO-2  
CD133+ fraction 
CaCO-2  
CD133- fraction 
CD133 
94.3 % 
97.62% 
94.7% 
Ev
en
ts
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When Table 7 was analysed relative to Table 6 it appeared that the number of 
CD133+ cells present in the total population was nearly equal to the number of 
CD133+ cells present in both negative and positive fractions after separation, although 
a loss of cells was inevitable during the process. This was consistent for all samples 
except sample 2, in which the positive fraction contained 2 fold more CD133+ cells 
than in the total population. If we consider sample 2 as a technical fault, it appears 
that the problem might be due to a contamination of the negative fraction. All 
CD133+ cells may not be retained in the column as they should be. 
 
 
 
 
 
 
 
 
 
 
The difficulty to obtain pure populations of CD133+ and CD133- cells as well as the 
important number of dead cells contained in both fractions prevented us from 
pursuing further experiments with CD133 labelling.  
 
 
 
 
Sample 
Number of CD133+ cells 
in total population 
Number of 
CD133+ cells 
in negative fraction 
Number of 
CD133+ cells 
in positive fraction 
Total number of 
CD133+ cells after 
separation 
1 
 NA   1.02 107 3.29 106 1.35 107 
2 0.09 107 7.26 107 0.07 107 7.33 107 
3 2.3 107 1.82 107 0.09 107 1.91 107 
4 5.6 107 2.22 107 0.74 107 2.96 107 
5 1.67 106 1.62 106 0.9 106 2.57 106  
Table 7. FACS analysis of purity of cells in the total population of samples, in the fraction 
eluted by the column (negative fraction), and in the fraction retained by the column (positive 
fraction) (use of antibody anti-CD133 clone 293C3). 
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3.4 Discussion 
 
 
CSC research is still a newly emerging field, thus isolating CSCs still remains a major 
challenge. Since promising results have been reported throughout the literature, we 
decided to isolate CSCs from colorectal liver metastases based on their cell surface 
expression of CD133. However, after dissociation of the clinical specimen, our study 
was hindered. We have attempted to separate CD133+ and CD133- fractions by 
immuno-affinity on a magnetic column, however both positive and negative fractions 
contained a high percentage of CD133+ cells in the majority of the samples. In one 
sample only, the negative fraction contained fewer than 2% of CD133+ cells, but in 
this case, only 10% of the corresponding positive fraction were CD133+. 
 
The commercially available kit from Miltenyi Biotec for CD133+ cell isolation has 
been designed to isolate stem cells from haematopoietic tissues and not from solid 
tissues. After mechanical dissociation and enzymatic degradation of solid tissues, cell 
damage and debris might have resulted in a lack of specificity for the antibodies at the 
time of cell labelling.  
It is important to add that, at the time we started CD133 isolation, Miltenyi Biotec 
had redesigned their labelling kit where the new protocol involved an indirect 
labelling step. Miltenyi Biotec refused to provide an explanation for this change. The 
indirect method involved a primary incubation with a biotinylated antibody against 
CD133, followed by a secondary incubation with anti-biotin microbeads. In the 
original kit, the anti-CD133 antibody was conjugated to the beads and only required 
one incubation. The use of a two-step process may therefore have increased the risk 
of unspecific staining. Although the direct kit is now available again, we did not have 
the opportunity to compare it with the indirect method. 
 
 
To help interpret our results, we questioned the specificity of the antibody that was 
provided with the kit. The CD133 cell surface marker has two potential epitopes 
which are currently targeted by monoclonal antibodies. These epitopes are AC133 
(epitope 1 = CD133/1)) and AC141 (epitope 2 = CD133/2)). Miltenyi Biotec provides 
four monoclonal antibodies : clones AC133 (mouse IgG1) and W6B3C1 (mouse 
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IgG2b) recognize epitope 1. Clones 293C3 (mouse IgG2b) and AC141 (mouse IgG1) 
recognize epitope 2. The clone used for magnetic separation is AC133, and the 
manufacturer advises the use of clone 293C3 (epitope 2) for checking the purity of 
the separated fractions. The location of these epitopes has not been described yet, but 
it is known they are spatially distinct [123]. A key point is that both of these epitopes 
are glycosylated, and the monoclonal antibodies we used are designed to recognize 
the glycosylated form of the CD133 molecule. Glycosylation is a post-translational 
process in which the neo-synthesized proteins are modified by being linked to a 
glucid. This process is site-specific, enzymatic (i.e. tightly regulated), and mainly 
involves cell surface and secreted proteins. Glycosylation confers stability to the 
proteins by protecting them from proteolysis, and has been shown to be highly 
involved in cell signalling and cell-cell adhesion [210]. Importantly, glycosylation 
can also affect the tertiary structure of proteins since some proteins cannot fold 
properly until they have been glycosylated. Any variation in the glycosylation 
regulation can easily alter the protein folding. In our case, the access of the antibody 
to the epitopes may therefore be impossible due to steric hindrance. Moreover, 
changes in the glycosylation pattern can alter specific sites on the protein, and 
therefore the antibodies might not be able to recognize their antigen [211].  
 
According to our data, however, the system did select for CD133+ cells, as there was 
an enrichment of CD133+ cells in the fraction retained by the column, compared with 
the fraction eluted by the column. Moreover, the positive and negative controls 
(CaCo-2 and KG1a cells, respectively) confirmed the specific recognition of the 
CD133 marker by the antibodies used in the kit. Therefore the glycosylation issue 
may not be the key element to explain our data. We have also demonstrated with the 
CaCO-2 cell line, which expresses high levels of CD133, that the use of the Miltenyi 
Biotec kit for large amounts of CD133+ cells was not appropriate since CaCO-2 
positive and negative fractions both contained more than 94% of CD133+ cells. We 
believe that an excess of labelled cells in the column might not be retained once all 
the binding sites have been occupied. The manufacturer indicates that a maximum of 
107 labelled cells can be retained in the small (MS) columns, and 108 cells in the large 
ones (LS). We used an LS column to process 3×107 CaCO-2 cells, but were still not 
able to produce an optimal isolation as the negative fraction contained 97% of 
CD133+ cells (Figure 10). As the kit was designed for haematopoietic cells, the 
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maximum number of cells retained by the column may be different with colorectal 
cancer cells. It would be important to determine in future experiments whether the 
saturation of the column is responsible for the bad quality of separation. This 
experiment could be conducted using firstly a mixed population of KG1a and CaCO-
2 cells, with an increasing percentage of CaCO-2 cells, to detect the threshold number 
of colorectal CD133+ cells the column is able to retain.  Similar experiments should 
be conducted with cancer cells extracted from fresh tumour samples, starting with a 
low number of total cells to prevent saturation in the column. 
 
At the time we were facing technical difficulties with isolating CSCs according to 
their expression of CD133, the literature reported problems caused by using 
glycosylation-dependent CD133 antigens. 
Shmelkov et al. (2008) demonstrated that CD133 expression extended to a wide 
range of differentiated colonic cells, and not only to a low percentage of stem 
cells/CSCs as had previously been assumed using the CD133 antibodies [212]. In 
their study, Shmelkov et al. (2008) created a knock-in tumour mouse model, where 
CD133 expression could be detected by histochemistry using a LacZ reporter 
associated with the CD133 gene. To detect CD133 molecule, they chose an 
alternative method, avoiding the use of the anti-CD133 antibodies. Their method 
revealed a broad expression of CD133 in a large number of differentiated colonic 
cells, suggesting that the technique of using antibodies (anti-CD133) may not be 
sufficiently sensitive to detect all the CD133 expressing cells. The discordance 
between the results obtained by these different methods seems to be limited by the 
state of glycosylation in these samples. In the CaCO-2 cell line, it has been observed 
that there is a decrease of immunoreactivity of the AC133 antigen upon 
differentiation, while the levels of mRNA (ribo-nucleic acid) were still elevated 
[213]. This observation therefore suggests that the antibodies directed to AC133 were 
not able to bind to their antigen while the CD133 protein was expressed. A loss of 
glycosylation could be the main reason for this lack of recognition, and would be 
consistent with the fact that in HT-29 colorectal cancer cell line (a model for 
enterocytic differentiation) the glycosylation pattern is variable and correlates with 
the stage of differentiation [214]. Therefore, if the CD133 pattern of glycosylation is 
dependent on the cell status of differentiation then variations in the antigen affinity 
 76 
will be expected. These data therefore directly question the specific targeting of 
CD133 with the current antibodies that are commercially available. 
In addition to the limiting factors caused by the state of glycosylation, doubt still 
remains as to whether CD133 is as essential as initially expected in brain tumour and 
colorectal cancer initiation, and ipso facto in CSC isolation. In brain cancer, CD133 
was thought to be a CSC marker [93]. A recent study has shown that CD133- cells 
also presented CSC characteristics as they were able to form neurospheres and were 
tumourigenic in nude rats [186, 187]. Moreover, CD133- cells were capable of 
generating CD133+ cells after their re-implantation in rat brains, suggesting that the 
CD133- fraction contained precursors of CD133+ cells [187]. Another study showed 
that GBM tumours negative for the CD133 marker still contained CSCs and were still 
able to form tumour spheres in vitro, as well as maintaining tumourigenicity in vivo 
[186]. Shmelkov et al. (2008) also reported that, in their hands, CD133- cells from 
metastatic colon cancer were as tumourigenic as CD133+ cells. Like the two studies 
quoted above  for colorectal CSC isolation [98, 99], they used the Miltenyi Biotec kit 
with the anti-CD133 antibodies to isolate CD133+ cells, but obtained opposite results.  
Other compromising results obtained by Horst et al. (2008) indicate that although 
CD133 maybe an important prognostic factor in colorectal cancer, it is not essential 
for cancer initiation or metastasis [145]. 
 
These studies question the use of CD133 itself as a marker of choice for CSC 
isolation as it does not seem to be essential for CSC characteristics. Its expression still 
continues in differentiated colonic cells.It is possible that these controversial data may 
be the result of a lack in specificity from the glycosylated epitopes used for CD133 
isolation. Perhaps if a new epitope was chosen it may change the results. Indeed, 
other anti CD133-antibodies are commercially available from other companies (Santa 
Cruz Biotechnology, Abcam and Cell signalling Technology) and recognise non 
glycosylated extracellular epitopes. Their use has not been reported yet throughout 
the literature and it would be interesting to compare the results obtained with these 
antibodies. 
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The role of CD133 has to be reconsidered in the light of these observations. CD133 
might be an appropriate marker to isolate CSCs, but only when it is in its 
glycosylated form. In this case, the fact that only a glycosylated variant of CD133 is 
required for positive CSC recognition brings in numerous technical hurdles 
specifically for antibody recognition. However, this still does not explain how 
tumours that do not express CD133 at all [100, 215], still contain a subpopulation of 
tumour-initiating cells [186]. It does however confirm that CD133 is not an absolute 
marker of CSCs.  
 
It is important to consider the origin of cancer cells in order to define the best strategy 
to isolate them. The stage of differentiation at which the mutations leading to 
malignant transformations happen is not known yet, and it is quite possible that early 
or even late progenitor cells as well as stem cells can function as CSCs, and express a 
different panel of markers. The evidence that in the same organ two sets of CSC 
populations can exist, such as CD133+ and CD44+/CD166+ in colorectal cancer [98, 
100], and are similarly able to initiate tumours, proves that none of these markers is 
exclusively expressed by CSCs. Moreover, the proposed CSC markers are not 
expressed in 100% of the primary tumours examined, which seems to indicate that the 
search for one single marker or even a combination of markers might be the wrong 
strategy. It is therefore necessary to use other complementary techniques to isolate a 
true CSC population.  
 
 
Based on all these considerations, and as we were limited on the technical front, we 
made the decision not to pursue on further experiments with the CD133 cell surface 
marker. 
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4 Establishment of primary culture from 
colorectal cancer metastases 
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4.1 Background 
 
 
 
Several experimental models are commonly used to understand cancer biology. 
Pathological specimens freshly isolated from patients represent the best available 
sources for isolation and characterisation of CSCs. Indeed, if CSCs are truly present 
in tumours, it is more relevant to analyse them immediately after their isolation to 
prevent any potential alterations in their state following in vitro culturing (division 
and differentiation, number, mutations, etc.). However, these models are not ideal to 
investigate the origin of tumours since they reflect the real state of tumours in vivo 
only at the time of resection which is already at a late stage of tumour growth. 
Additionally, the direct isolation of stem cells from solid tumours raises technical 
hurdles. During the process of mechanical and/or enzymatic dissociation, tissues are 
severely damaged, and large numbers of cells are destroyed. It is extremely difficult 
to limit the number of dead cells, and to separate them from the viable ones. Lastly, 
initiating cancer cell growth in vitro after a dissociation process is another limiting 
step as less than 10% of the viable cells in a primary colorectal culture preparation are 
able to attach and to grow [216]. 
In order to circumvent these difficulties and the problem of specimen availability, 
other models have been explored. 
 
Cancer cell lines have been widely used, even though their validity is debatable. They 
are easily available and propagate to many passage numbers. However, they may not 
necessarily represent the original cancer cells in a reliable way. There are several 
reasons for this uncertainty. 
Cell lines represent a clonal selection of a heterogeneous population of cells [217]. 
For instance, different metastases from the same patient have been shown to give rise 
to cell lines that are genetically different [218]. Each particular lineage constitutes a 
distinct model of the same disease and does not necessarily reflect the initial 
heterogeneity of the neoplasm [218]. The lineage selected for may simply represent a 
subtype of cell that grew more favourably in the in vitro culture environment.  
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Culture conditions are critical since infections, genome instability and even cross 
contamination can alter the cell lines. A high number of passages considerably 
increases those risks [219].  
A change in the genome as a result of selective pressure from a growth condition is an 
important issue as many studies have shown that the pattern of gene expression 
changes in cell lines grown in different culture conditions. The longer the cells are 
kept in vitro, the greater is the likelihood that they will undergo epigenetic or genetic 
changes. When comparing individual cancers from various organs and the 
corresponding cell lines from different origins, the genetic evolution is such that cell 
lines surprisingly tend to genetically group together and to display more similarities 
between each other than with the original tumours [220-222]. Moreover, in many 
cases, genetic profile has been shown to be less distinct between the normal tissues 
and their corresponding tumours than between the tumours and the derived cell lines 
[221, 223, 224]. This indicates that the processes of genetic alterations that would 
have started in vivo continue and are even amplified in vitro as cells are passaged.  
 
Some cell lines clearly segregate from the tumour from which they derive whereas 
some of them still evolve slowly and can retain several properties of the original 
tissue [225]. Analysing cell lines newly isolated from primary tissues therefore seems 
to be the best option for representing a particular cancer cell lineage, as suggested by 
a recent study [226]. Colorectal cancer cells cultured in vitro are an encouraging 
example. In a recent paper, it has been shown that, out of 389 mutations analysed in 
the cell lines derived from colorectal cancers in vitro and passaged for six months to 
one year maximum, 99.3% were present in the primary tissue of colorectal cancers 
[227].           
 
Collecting and isolating CSCs from fresh patient specimens was technically 
challenging in our hands. Based on all the above considerations, we sought to grow 
cancer cells prior to analysis and CSC isolation. We herein describe the method we 
used to establish a cancer cell line, in order to analyse it for the presence of CSCs. 
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4.2 Results 
 
 
4.2.1 Culturing and developing CM1 primary cell line 
 
 
Fresh samples of colorectal cancer liver metastases were processed as detailed in 
Materials and Methods. In total, 15 samples were processed. Cells from 33% of the 
samples did not reach confluence in culture and did not survive to the first passage. In 
these cases, the cells did not adhere on to the plastic culture dishes and subsequently 
died. In 66% of the samples, cells were able to adhere and to survive. After 1 to 2 
weeks, adherent fibroblasts were observed, followed by adherent epithelial cells 
which started to spread as dense islands, typical of colorectal cancer cells (Figure 11). 
Once confluent (usually after a month), cells were passaged in T25 flasks. However, 
fibroblasts predominantly overtook the culture space since epithelial cells failed to 
develop after passage (P)1. After P3, cells were grown in DMEM supplemented with 
2% FBS to favour epithelial cell growth. We also used 1% T/E to help remove the 
fibroblasts. Cells started to grow faster after P4. 
A primary cell line (CM1) was developed from one colorectal metastasis. Thus, the 
efficacy of obtaining cell lines from colorectal cancer metastases was 6%.  
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A. Sample 6 – 2 weeks in culture B. Sample 6 – 2 weeks in culture 
C. Sample 6 – 3 weeks in culture. Epithelial  cells D. Sample 6 – 3 weeks in culture. Fibroblasts 
E. CM1 – After passage 2 F. CM1 – After passage 2 
Figure 11. Representative pictures of colorectal liver metastases in culture. After 2 
weeks in Petri dishes, epithelial outgrowth appeared and spread from the tissue explants 
(A, B, C, D). CM1 : epithelial cells started to grow after passage 2 (E,F) and the 
fibroblast population appeared to diminish as epithelial cells spread.  
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4.2.2 Patient history 
 
 
The CM1 cell line was established from the liver metastasis of a patient, aged 65, 
with colorectal cancer. This patient first underwent a right hemicolectomy, and 
received adjuvant FOLFOX (FOLinic acid, Fluorouracil and OXaliplatin [228]) 
postoperatively for 5 months. Nevertheless, 18 months later, the disease had 
metastasised to the liver thus requiring liver resection and cholecystectomy. 
 
4.2.3 Brief characterisation of the CM1 cell line 
 
To confirm the nature of our CM1 cells, we analysed them for the expression of two 
markers : carcino-embryonic antigen CEA and villin (Figure 12).  
 CEA is a tumour-associated antigen, specifically expressed by colorectal cancer cells 
[229]. FACS analysis revealed that 69% of the cells were positive.  
CM1 cells were also positive (>70%) for villin, a gastrointestinal-associated 
cytoskeletal protein expressed specifically in the microvilli of epithelial cells. This 
confirmed the epithelial nature of these cancer cells. 
 
 
 
                                           
 
 
 
 
 
 
A B 
CEA Villin 
Ev
en
ts
 
Figure 12. Representative flow charts indicating the strong expression of CEA (A) and villin 
(B) by CM1 cells. Blue : isotype. Green : CEA or villin. This FACS analysis was conducted to 
check the CM1 cells express markers associated with epithelial and carcinogenic 
characteristics. 
79% 88% 
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This experiment was performed using cells at passages 14 and 15. 
 
 
 
4.2.4 Growth behaviour of the CM1 cell line  
 
 
 
In all the experiments, we decided to use the CM1 primary cell line at low number of 
passages, up to a maximum of 15 passages. We observed a change in the cell 
behaviour. In particular, cells increased their proliferation rate after passage 3-4 (data 
not available, and based only on observation), with a doubling time of 1 to 2 days. As 
passages increased, the cells seemed to become more resilient as we also noticed a 
better recovery after freezing-thawing when cells were frozen at later passages.  
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4.3 Discussion 
 
 
Specimens collected from the patients were metastases of colorectal cancer in the 
liver. Out of 15 samples, we were able to establish only one primary cell line, CM1, 
which represents a 6% success rate.  
The difficulty of growing and expanding such colorectal carcinoma tissues in vitro 
has previously been reported [216, 230]. The use of collagen-coated flasks is also 
recommended as it might be beneficial to facilitate the adherence of the cells to the 
dishes. We tried this method but did not obtain much success, and therefore kept our 
initial protocol, i.e. with uncoated dishes. 
 
In all our cultures, the rapid expansion of fibroblasts constituted a limiting step. It 
was necessary to constantly control their growth, essentially by reducing the 
percentages of FBS from 10% (ideal for fibroblastic cultures) to 2% in the culture 
medium, or by proceeding to differential trypsinisation (cf. Materials and Methods). 
Fibroblasts are major constituents of the tumour stroma and play a very important 
role in cancer initiation and expansion. Malignant cells cannot expand without the 
help of the surrounding stroma as their growth also depends on angiogenesis, 
inflammatory cells and fibroblasts [231]. In healthy tissues, fibroblasts are 
responsible for the deposition of the extracellular matrix (ECM), they regulate 
inflammation and epithelial differentiation by secreting cytokines and growth factors, 
and are involved in wound healing [232]. Fibroblasts are recruited and activated by 
cancer cell secreted factors (transforming growth factor ß (TGF ß), platelet-derived 
growth factor (PDGF) and fibroblast growth factor-2 (FGF-2)) into an activated 
phenotype. Once activated, they are referred to as cancer associated fibroblasts (CAF) 
and are able to secrete indispensable cancer growth factors (TGFß and stromal 
derived factor-1 (SDF1) and enzymes such as the matrix-metalloproteinases (MMP) 
to help cancer progression [233]. Some of the CAF might have a malignant origin as 
it has been shown in some cases that cancer cells have a potential to turn into 
fibroblasts, through a process referred to as epithelial-to-mesenchymal transition 
(EMT). Epithelial and cancer cells can acquire through EMT a mesenchymal 
phenotype, and this phenomenon seems to be involved in metastasis and in the 
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production of additional CAF [234]. We are not sure whether EMT is the reason why 
so many fibroblasts developed in our culture dishes as fibroblasts were present for a 
limited number of passages only. In the CM1 culture dishes, the fibroblasts started to 
disappear as the epithelial islets expanded. After P6, we no longer observed any 
fibroblasts in our culture flasks. Therefore it seems that the fibroblasts were not of 
tumourigenic origin, but died progressively as happens in the case of non-
immortalized healthy tissue cultures. Whatever the origin of the fibroblasts in our 
cultures was, it is important to keep in mind that in vitro culture conditions determine 
the behaviour of the cultured cells. 
 
For CM1 cell line, the epithelial cells began to increasingly expand amongst the 
fibroblasts and formed several growth islands after 2 passages. This clearly indicates 
that only a low number of cancer cells was able to survive and proliferate and 
provides evidence that only the most resistant clones are able to adapt to in vitro 
culture conditions. Additionally, the prolonged duration required by these cells to 
initiate their expansion may be due to adaptative epigenetic/genetic changes. These 
changes seem to have persisted and even amplified since the cell growth behaviour 
progressively improved over time. 
 
Obtaining a cancer cell line from colorectal primary culture is a tedious and time 
consuming process, and therefore we did not establish any other short-term cell line 
after CM1. Rather, we decided to extract CSCs from CM1 cells. These cells are 
derived from a colorectal cancer metastasis in the liver that appeared after a FOLFOX 
chemotherapeutic regimen, and it would have been interesting to compare the 
presence of CSCs in the primary tumour to the corresponding metastasis. Indeed, the 
CSC theory predicts that CSCs should be present in metastases as they have the 
potential 1) to escape chemotherapy, 2) to migrate and initiate a tumour at distant 
sites and 3) to sustain tumour growth. Moreover, the presence of CSCs has been 
reported in colorectal cancer metastases [99, 100, 215]. Unfortunately, we were 
unable to obtain both primary and metastatic tumour specimens together.  
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In the following chapters, we have tested various methods to isolate CSCs from the 
CM1 cell line and from a long-term cancer cell line, CaCO-2, derived 40 years ago 
from a moderately differentiated primary colon adenocarcinoma [235]. The CaCO-2 
cell line has been shown to differentiate spontaneously upon culture into mature 
enterocyte-like cells  [236]. Cell lines are not the most appropriate model of cancer as 
they are not the exact representation of the in vivo tumour cell population. They only 
represent a late stage of cancer. They do not reproduce the whole tumour 
heterogeneity, and they undergo genetic/epigenetic changes depending on the in vitro 
culture conditions. That is why, in addition to CaCO-2, we used a cell line as close as 
possible to its corresponding original tumour, by limiting the number of passages (up 
to passage 15 maximum) and keeping the in vitro procedures as simple as possible.  
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5 Isolation and characterisation of putative 
CSCs from CaCO-2 and CM1 cell lines 
using a chemoresistance assay 
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5.1 Background 
 
 
As mentioned in the introduction, the choice of an appropriate method is a critical 
point for isolating CSCs. The methodological and theoretical concerns raised by the 
isolation of stem cells using cell surface antigens have been discussed in the first 
chapter. To bypass the problem caused by CD133 targeting, we decided to tackle 
CSC isolation differently, independently of cell surface markers and on the basis of a 
putative functional characteristic of CSCs, in particular chemoresistance. 
  
 
5.1.1 Cancer and chemoresistance 
 
From a clinical perspective, understanding the basis of drug resistance is a principal 
goal. Besides surgical intervention, other regimens such as chemo- or radiotherapy 
have been developed to treat cancer. However, the efficacy of such methods is limited 
since cancer cells sometimes display or are able to acquire a resistant phenotype, 
usually following long term chemotherapy.  
Molecular mechanisms of resistance have been at the centre of extensive work [237].  
They reveal that cancer cells can undergo alterations in various signalling elements, 
culminating in the elevated expression or activity of ABC multidrug efflux pumps or 
DNA-repair enzymes [238, 239]. Genetic alterations can affect growth factor 
signalling elements such as EGF receptor (EGFR), hedgehog and Wnt/ß-catenin 
expression [240-242]. Resistance to drugs or radiation may also be the consequence 
of deregulation within the apoptotic cascade [243], in particular through the ceramide 
signalling pathway [244]. 
  
Additionally, when cancer cells are exposed to a single drug, they are prone into 
acquiring a multidrug resistance (MDR) phenotype. As its name implies, MDR 
confers resistance to other functionally and structurally unrelated anticancer drugs  
via the overexpression of genes of the ABC super family [245]. ABCB1 (Adenosine 
triphosphate-binding cassette B1, also called MDR1 and encoding for P-glycoprotein 
(P-gp)), ABCG2 (or breast cancer resistance protein1 (BCRP1) and ABCC1 (also 
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known as MDR associated protein 1 (Mrp1)) are the best defined representatives of 
this super family. These genes encode membrane bound ATP-transporters, which 
play a key role in the efflux of cytotoxic compounds from the cells. They are 
expressed in the placenta and other physiological barriers such as the intestinal 
barrier. For instance, on the apical membrane of enterocytes, the expression of P-gp 
and BCRP1 determines the absorption, distribution and excretion of drugs, 
xenobiotics and their metabolites, and prevents their entry into the circulation [246]. 
 
 
5.1.2 Innate versus  acquired resistance 
 
The distinction between innate and acquired resistance is an essential concept to 
understand the CSC model of chemoresistance. Essentially, cancer cells can be 
inherently (or intrinsically) resistant to a drug, or they can develop (acquire) 
resistance after exposure to the drug.  
 
In the traditional model of cancer, resistance in tumour cells is thought to arise from 
the clonal selection of genetically transformed cells within a heterogeneous 
population of cells. Intrinsic resistance is therefore the result of random genetic 
alterations. Several cells are able to obtain a transformed growth advantage and 
maintain this even in the presence of chemotherapeutic compounds to ultimately 
repopulate the tumour mass with drug resistant cells.  
If cancer cells are initially responsive to chemotherapy, they may acquire resistance 
through genetic mutations and clonal selection of the transformed cells, subsequently 
leading to an MDR phenotype. 
 
Alternatively, in the CSC model, resistance is considered to be the monopoly of the 
small subset of CSCs. It is hypothesised that CSCs are intrinsically resistant as a 
result of their inherent stem cell characteristics. Since the CSC status is an epigenetic 
phenomenon, CSCs lose this resistant phenotype upon differentiation [85] . 
Therefore, the majority of non-CSC cancer cells would be more sensitive to 
chemotherapeutics. Intrinsic (or innate) resistance allows CSCs to circumvent 
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treatment, and subsequently, these CSCs repopulate the tumour since they also 
possess the tumourigenic ability, thus establishing a resistant lineage [247]. The CSC 
model does not exclude the possibility that, under treatment pressure, genetic 
alterations may occur and confer an MDR phenotype on cancer cells, but this is not 
the main reason why cancer can recur following therapy. 
 
 
5.1.3 Factors responsible for CSC intrinsic resistance 
 
It is necessary for stem cells to be preserved for the entire life of the organism as they 
ensure the long-term maintenance of tissues throughout life. To ensure their 
longevity, several mechanisms protect them from death and toxin-induced damage. 
 
In stem cells, innate resistance is associated with the upregulation of the ABC 
transporters. ABCG2 expression, for instance, has been shown to be upregulated in 
HSC, whilst it is downregulated in progenitor and fully differentiated cells [248]. 
With regard to CSCs, many studies in blood and diverse solid tumours report that the 
SP, characterised by cells with high capacity for pumping out Hoechst dye through 
ABC transporters possess stem cell properties [103, 104, 120, 121]. In several solid 
tumours CSCs have also displayed a resistant phenotype with high expression of 
MDR genes (MDR1, Mrp1, BCRP1) [105, 249, 250] and apoptosis inhibition [251].  
 
 
Stem cells and by extension CSCs have also been described as having slow cell cycle 
rates [252]. For instance, whilst the expression of cell cycle initiating factors such as 
cdk4 is barely detected in long term HSC, these factors are highly expressed in 
progenitor cells [252]. Similar to stem cells, quiescence may be a characteristic of 
CSCs that protects them from drugs inhibiting cell cycle-initiating factors. Although 
the quiescent nature of CSCs has been extensively cited in the literature as a possible 
feature, it has not yet been confirmed. 
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Several clues for CSC chemoresistance have been reported by in vitro studies 
showing that putative CSCs display a higher resistance to chemotherapeutic drugs 
compared with somatic cancer cells. Liu et al. (2006) demonstrated that glioma 
CD133+ cells were significantly more resistant to 4 chemotherapeutic reagents, 
possibly through an upregulation of anti-apoptotic proteins [251]. Similarly, CD133+ 
cells freshly isolated from GBM clinical specimens were also less sensitive to 
radiation-induced apoptosis than the rest of the population, and identical results were 
obtained in medulloblastoma cell lines [253]. Other cancer cells with CSC markers 
from pancreas, liver, breast and colorectal cancer might also display resistant 
properties against chemo/radiotherapeutic regimens [191, 254-257]. In colorectal 
cancer, higher resistance to oxaliplatin and 5-FU treatments was shown in putative 
CSCs such as CD133+ cells and spheres grown in serum-free medium [258]. 
An interesting in vivo study seems to confirm the chemoresistant nature of CSCs. 
Breast cancer cells isolated from chemotherapy-naïve patients were compared with 
cancer cells isolated from patients who received chemotherapy [190]. Cells were 
analysed for their potential to form mammospheres and to express the putative breast 
CSCs CD44+/CD24- phenotype. Results showed that a higher percentage of cells 
obtained from chemotherapy-patients were able to self-renew and to display the CSC 
phenotype. Thus in an in vivo setting, chemotherapy appears to be adding a selective 
pressure for the enrichment of tumour-initiating cells.  
 
 
5.1.4 Isolation of CSCs using a chemotherapeutic assay 
 
Developing an assay in which putative CSCs are isolated by virtue of their 
chemoresistant phenotype has been previously attempted. For instance, resistant 
cancer cells have been isolated in vitro from L3.6pl and AsPC-1 pancreatic cancer 
cell lines following long-term gemcitabine exposure. Interestingly, the long term 
resistant cells displayed more invasive and migratory properties than their non 
resistant counterpart  and CSC markers CD44, CD24 and ESA were also expressed in 
higher proportion in these resistant cells (about 10-15% more) [204].  
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Other studies have isolated intrinsically resistant cancer cells after short but lethal 
exposure to a chemotherapeutic drug. GBM cells resistant to a lethal dose of 1,3-
bis(2-chloroethyl)-1-nitrosourea (BCNU) showed cancer stem-like cell properties 
[203]. They were enriched in CD133+ cells, were multipotent and able to generate 
neuron- and glial-like cells, and formed tumours when transplanted in brain of 
NOD/SCID mice. 
 
Isolating resistant cells should therefore be a means of obtaining CSCs. Little work 
has been done yet to confirm this hypothesis. To our knowledge, only two studies on 
brain glioma (as mentioned above) and on leukaemia have explored intrinsically 
resistant cells [203, 205] and shown they possessed CSC-like properties.  
 
To explore a method of CSC isolation independent from cell surface marker 
expression, we chose to isolate and characterise a population of cells intrinsically 
resistant to oxaliplatin, a chemotherapeutic drug commonly used to treat colorectal 
cancer. Oxaliplatin is a third generation platinum compound. This drug has shown 
efficacy in colorectal metastatic cancer as it potentiates the effects of 5-FU, and it is 
generally used in combination with 5-FU and folinic acid (FOLFOX) [259]. 
Mechanisms of action of the drug are still hypothetical, but it is known that like other 
platinum agents such as cisplatin, oxaliplatin triggers direct damage to DNA leading 
to cell death [260]. 
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5.2 Isolation of oxaliplatin-resistant CaCO-2 cells 
 
 
 
We first set out to establish the ideal dose of oxaliplatin that would select for a 
resistant population of CSCs. We found that the optimal condition for selection of the 
putative population of CSCs was at a concentration of 5µg/ml for 48h. We chose the 
shortest incubation time, as surviving cells should possess an intrinsic resistance to 
chemotherapy rather than acquiring a resistant phenotype upon long term exposure 
with the drug. The concentration of oxaliplatin used was chosen to eliminate about 
90% of cells since we wanted to attain the reported percentage of CSCs (2-3% of the 
total cancer cell population). Our other criterion was that surviving cells should be 
able to regrow after drug exposure. 
 
 
 
5.2.1 Establishment of an oxaliplatin dose  
 
 
 
An initial experiment was set to establish the concentration of oxaliplatin necessary to 
have an effect on cell viability (Figure 13). In this experiment, cells were incubated 
with oxaliplatin for 24, 48, 72 or 144h.  
Although oxaliplatin half-life has been reported to be short (10-25 mn in human 
blood in vitro [261]), the effect of oxaliplatin increased with the length of incubation 
in our setting. There was more cell death with longer incubations. 
We found that the growth of cells was slower at low drug concentrations (0.2 to 
1µg/ml) as compared to cells not treated with the drug (0µg/ml). Cell growth was 
inhibited at 2µg/ml, and the number of live cells was lower for doses higher than 
2µg/ml, after 48h of incubation.  
 
 95 
 
Number of CaCO-2 surviving cells after 
incubation with oxaliplatin for 24 to 144 h 
0
10000
20000
30000
40000
50000
60000
0 0.2 0.5 1 2 10 50 100
Oxaliplatin (µg/ml)
N
u
m
be
r 
o
f s
u
rv
iv
in
g 
c
e
lls
24h
48h
72h
144h
 
 
 
 
 
 
 
 
 
Based on this preliminary evaluation, the optimal dose was then defined more 
accurately (Figure 14). Cells were plated in Petri dishes and incubated with 
oxaliplatin for 48h at 3, 4 and 5µg/ml. The number of surviving cells was counted 
according to trypan blue exclusion. We counted the number of live cells over three 
weeks and, for each dose, cell kinetics followed a similar pattern.  The number of 
cells decreased, to plateau at around day 12 after incubation, and cells started to re-
grow after day 17. A dose of 5µg/ml was chosen as the percentage of surviving cells 
fell below the 10% mark after day 9, after which cells displayed resistance to 
treatment by recovering growth. 
 
Oxaliplatin resistant CaCO-2 cells (CaCO-2-OR cells) were harvested at day 12 or 13 
after incubation for further characterisation. 
 
Figure 13. Incubation of CaCO-2 cells with oxaliplatin. Cells were incubated 
with oxaliplatin at different concentrations and for different time periods. Up to 
dose 1µg/ml, cell growth rate was slower, whereas it was inhibited at 2µg/ml. 
For doses higher than 2µg/ml, the number of live cells started to decrease after 
24-48h. 
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5.2.2 Characterisation of CaCO-2-OR cells 
 
 
 
 
5.2.2.1 Morphology of the drug resistant cells 
 
 
CaCO-2 cells are morphologically heterogeneous. As represented in Figure 15 (A), 
the majority of the cells have a similar diameter, whereas a certain percentage of cells 
have a much larger diameter.  
Under the microscope, CaCO-2-OR cells appeared rounded and “spindle-shaped” as 
illustrated in Figure 15 (B).  
 
 
 
 
Figure 14. After 48h exposure to oxaliplatin, CaCO-2 cells died progressively, until their 
population formed a plateau about 12 days after incubation. Cells started to re-grow at 
about day 17. Oxaliplatin at 5µg/ml was chosen, and the cells were harvested between 12 
and 13 after incubation. Day 0 on the graph represents the end of 48h incubation with the 
drug. Percentages are relative to the number of cells at the time of drug induction. n=3. 
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We found that CaCO-2-OR had on average a larger diameter than untreated CaCO-2 
cells.  
 
We hypothesised that cells with a significantly larger diameter might be more 
resistant and we therefore established an indicative dose response curve to assess the 
Figure 15.  Morphology of CaCO-2 and CaCO-2-OR cells. (A-B) : CaCO-2 cells. The arrow 
indicates cells with a larger diameter. (C-D) : CaCO-2-OR cancer cells, 12 days after exposure 
to the drug. (×20). Arrows indicate the spindle-shaped cells of CaCO-2-OR cells. 
A B 
 C D 
CaCO-2 cancer cells (no treatment) 
CaCO-2-OR cancer cells (post treatment) 
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percentages of surviving cells with a large diameter in comparison to the rest of the 
cells (Figure 16). 
Cells were seeded at a density of 270,000 cells/Petri dish. Oxaliplatin was then added 
at various concentrations (0-10µg/ml) and cells were incubated for 12 days.  
At day 0, the percentage of cells with a large diameter was 5%. 
At day 12, live cells were counted using a haemocytometer. Results are shown in 
Figure 10. The percentages of larger cells were established as follows (based on 
observation)  =  
 
        % of larger cells =                Number of larger cells at day 12      ×   100 
 
Number total of  surviving cells at day 12 
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Figure 16 clearly shows that the proportion of cells with a large diameter increases 
when cells are exposed to oxaliplatin, suggesting that they might be more resistant to 
oxaliplatin. Although this experiment was based only on visual assessment of the cell 
diameter, and was conducted only once, this phenomenon was observed for each dose 
of oxaliplatin tested. 
Figure 16.  CaCO-2 cells were seeded and exposed to various concentrations of drugs. The 
percentages of surviving cells were established 12 days after incubation. n=1. The error bars 
represent the standard deviation of triplicates in the same experiment. For each drug 
concentration, the percentages of CaCO-2 cells with a larger diameter were higher than in 
the non treated population.  
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5.2.2.2 Cell marker analysis 
 
 
To assess an eventual enrichment of CSCs among CaCO-2-OR cells, we analysed by 
flow cytometry the expression of markers related to MDR (ABCG2, Mrp1), putative 
stem cell  and CSC markers (CD44, CD24, Msi-1, Lgr-5) and genes that functionally 
contribute to a ‘stemness’ state by regulating self-renewal and pluripotency (Oct-4, 
Nanog).  
 
CaCO-2-OR cells did not show upregulation in markers of drug resistance. On the 
contrary, expression of Mrp1 and ABCG2 was lower in resistant cells (p = 0.023 and 
p = 0.001, respectively). Expression of stem cell markers Msi-1 and CD24 was below 
10% in both population and Lgr-5 was highly expressed but without any significant 
difference between the two populations. There was however a significant difference 
in CD44 expression between both populations. Whilst it reached a level of 
46.8±14.5% in CaCO-2 cells, there was almost no expression of CD44 in CaCO-2-
OR cells (p = 0.005). 
 
CaCO-2-OR cells expressed significantly less ‘stemness’ genes Oct-4 and Nanog (p = 
0.011 and p = 0.019, respectively) compared with the parent cell line. For all markers, 
results are displayed in Figure 17. 
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Figure 17. Flow cytometry analysis of CaCO-2-OR cells as 
compared to the untreated CaCO-2 cells. Markers analysed were 
(A) Abcg2 and Mrp1 (drug resistance related), (B) CD44, CD24, 
Lgr-5 and Msi-1 (stem cell markers) and (C) Nanog and Oct-4 
(‘stemness’ state). * = p <0.05 ; ** = p <0.005 (t test).  
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5.2.2.3 Cell cycle analysis 
 
 
 
Since stem cells are described as slowly cycling cells, the cycling status of CaCO-2 
and CaCO-2-OR cells was assessed. Cells were incubated with PI, a reagent able to 
intercalate with DNA (Figure 18). Proportions of cells in the G0/G1 and S/G2/M 
phases are reported in Figure 19 for both populations. No significant difference in cell 
cycle distribution was noted between CaCO-2 and CaCO-2-OR cells.  
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Figure 18 . Representative charts of PI integration for cell cycle analysis of CaCO-2 cells 
(A) and CaCO-2-OR (B) cells. Results show no significant difference between the two 
populations. 
G0/G1 
 
G0/G1 
 
S/G2/M 
 
S/G2/M 
 
Figure 19. Distribution of CaCO-2 and CaCO-2-OR cells in the cell cycle. A) represents 
number of cells in GO/G1 phase, B) represents number of cells in S/G2/M phase. Number 
of quiescent cells was not significantly different in the two populations (n=6, Wilcoxon 
test). 
 
B A 
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5.2.2.4 Measurement of ALDH1 activity  
 
 
In order to further characterise the CaCO-2-OR cell population, we measured its 
ALDH1 activity relative to non treated CaCO-2 cells. ALDH1 is responsible for the 
oxidation of intracellular aldehydes. Cells with high ALDH1 activity are believed to 
represent a CSC enriched population in blood and also solid tumours, particularly in 
the brain and colon [100, 171]. As described in Chapter 2,  an Aldefluor® kit was 
used and flow cytometry analysis showed that 18.2±6.6% of CaCO-2 cells had a 
positive ALDH1 activity versus 7.7±2.7% cells in CaCO-2-OR group (p = 0,04) 
(Figure 20).  
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Figure 20. ALDH1 activity was measured using Aldefluor® kit 
and cells were analysed by flow cytometry. Fewer CaCO-2-OR 
cells than CaCO-2 cells were positive for ALDH1 activity.  
* = p value<0.05, n= 5 (Wilcoxon test). 
 
       * 
 103 
5.2.2.5 In vivo experiment 
 
 
Since CSCs are believed to harbour an innate tumourigenic potential, which implies 
that injection of a small population of isolated CSCs in immunocompromised mice 
should develop tumour growth. CaCO-2 and CaCO-2-OR cells were injected 
subcutaneously in the right flank of NOD/SCID mice (Table 8). LS174T colorectal 
cancer cells (107 cells) were used as a positive control and formed a detectable tumour 
after 3 weeks. 107 CaCO-2 cells were also tumourigenic and the tumour was 
detectable 12 weeks after injection (Figure 21).   
100 to 100 000 CaCO-2-OR cells did not trigger a tumour after 12 weeks and the 
animals were sacrificed. 
 
 
 
 
 
 
Cell type Number of 
cells injected Tumour incidence 
Detection of tumour 
(weeks after inoculation) 
LS174T 10 000 000 1/1 3 weeks 
CaCO-2 10 000 000 1/1 12 weeks 
CaCO-2-OR 100 000 0/2 - 
CaCO-2-OR 10000 0/2 - 
CaCO-2-OR 1000 0/2 - 
CaCO-2-OR 500 0/2 - 
CaCO-2-OR 100 0/2 - 
Figure 21. In vivo tumourigenicity of CaCO-2 and CaCO-2-OR 
cells. 12 weeks after injection, 107 CaCO-2 cells were able to grow 
a tumour nodule in NOD/SCID mouse. A low number of CaCO-2-
OR cells (up to 105) was not tumourigenic in vivo. 
 
Table 8. Summary of the in vivo tumour development experiments.  
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5.2.2.6 Markers of differentiation 
 
 
 
According to the in vivo and in vitro analysis, CaCO-2-OR cells did not appear to 
exhibit CSC characteristics. It may be that, instead of oxaliplatin selecting a CSC 
population, drug treatment might rather be inducing a more differentiated phenotype 
in the majority of the resistant cells. This has recently been shown in HT-29 
colorectal cancer cell line after exposure to oxaliplatin [262]. 
CaCO-2 cells naturally differentiate to an enterocytic phenotype upon confluence in 
culture. Morphologically, CaCO-2 cells develop microvilli on the apical side and 
tight junctions between adjacent cells. Functionally, an enterocytic differentiation is 
characterised by a higher activity of enzymes normally present on the brush border of 
the intestine including small hydrolase enzymes such as SI, lactase and 
aminopeptidase [263], with a peak of secretion 9 days after confluence [264]. In 
parallel, the activity of AP enzyme has been shown to be elevated upon 
differentiation and confluence in CaCO-2 cells [265]. AP activity reached a peak 18 
days after confluence [264]. 
 
 
We chose two relevant markers of the enterocytic differentiation pathway : the 
intestinal AP and SI. We compared their expression in resistant CaCO-2-OR and non-
resistant CaCO-2 cells (Figure 22). 
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On average, none of these enzymes were significantly upregulated in the resistant 
CaCO-2-OR population. AP expression was more elevated in the CaCO-2-OR cells 
(34.85±12.30% vs. 32.0±15.5% in the CaCO-2 cells), but with no significant 
difference. SI was expressed at 8.33±2.18% in CaCO-2 cells and 5.35±4.62% in 
CaCO-2-OR cells. 
CaCO-2-OR cells did not exhibit a more differentiated phenotype than CaCO-2 cells 
after oxaliplatin exposure, although more differentiation markers should be analysed 
to confirm our result. 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Flow cytometry analysis of CaCO-2-OR cells as compared to the 
untreated CaCO-2 cells. Markers analysed were alkaline phosphatase (AP) and 
Sucrase isomaltase (SI). n=5. As these two markers were equally expressed in 
both populations, exposure to oxaliplatin does not seem to stimulate the 
enterocytic differentiation of CaCO-2 cells. 
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5.3 Isolation and characterisation of oxaliplatin-resistant 
CM1 cells 
 
 
 
To validate the results obtained with the CaCO-2 cell line, we repeated the same 
isolation and characterisation of oxaliplatin resistance on CM1 cells to see whether 
cells cultivated at low passage numbers behaved in the same way as the established 
cell lines. 
 
 
5.3.1 Choice of a therapeutic dose 
 
 
 
Although we had previously established that 5µg/ml was the appropriate dose for 
CaCO-2 cells, we did not know whether the same applied to CM1 cells. We therefore 
performed a dose response assay to determine viability of CM1 cells to oxaliplatin 
(Figure 23).  
 
CM1 cells responded similarly to CaCO-2 cells with 5µg/ml of oxaliplatin after 48h. 
However, CM1 cells appeared more resistant, since more than 20 days were 
necessary to reach a 10% viability of the original number of seeded cells, vs. 12 days 
for CaCO-2 cells. 
 
The number of surviving oxaliplatin resistant CM1 (CM1-OR) cells slowly started to 
grow after day 30. 
 
CM1-OR cells were therefore harvested at days 22 or 23 after incubation with 
oxaliplatin, and consecutively characterised. 
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Figure 23. Dose response of CM1 cells to oxaliplatin treatment. Cell viability reached a 
minimum 22 days following treatment but recovered thereafter. A dose of 5µg/ml of 
oxaliplatin was chosen, and cells were harvested at days 22-23. Percentages are relative 
to the number of cells present at day 0. 
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5.3.2 Analysis of CM1 oxaliplatin resistant cells 
 
 
 
5.3.2.1 Morphologic observation 
 
 
Similar to our observations with CaCO-2-OR cells, CM1-OR cells also exhibited 
cells with a spindle shape and a larger diameter. This was observed under the 
microscope (Figure 24). 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
Figure 24.  Morphology of CM1 and CM1-OR cells. (A-B) CM1 cells. (C-D).  CM1-
OR cells, 22 days after exposure to the drug. (×20). The arrows indicate the spindle-
shaped cells, similar to those observed in CaCO-2-OR cells. Like in CaCO-2 cell line, 
CM1-OR cells showed a larger diameter than CM1 untreated cells. 
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5.3.2.2 Cell markers analysis 
 
We performed FACS analysis with CM1 and CM1-OR cells to determine the 
expression of Oct-4, msi-1 and Lgr-5 stem cell markers, of the putative CSC markers 
CD44, CD166, CD24 and CD133, and of the marker of chemoresistance ABCG2 
(Figure 25). 
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Figure 25. Flow cytometry analysis of CM1-OR cells as compared to the untreated 
CM1 cells. Markers analysed were (A)ABCG2 (drug resistance related), (B) CD44, 
CD133, CD166, CD24 and (C) Msi-1 (stem cell markers) and Oct-4 (stemness 
state). * = p <0.05 (t test). The error bars represent the standard deviations for n=3 
independent experiments. For markers without error bars, n=2. None of the markers 
was upregulated in the resistant CM1-OR cells. 
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5.3.2.3 Cell cycle analysis 
 
 
 
 
 
 
When analysing the cell cycle status of CM1 and CM1-OR cells, a similar 
distribution was observed between the two populations, with on average 85.4% and 
83.8% of quiescent cells respectively (Figure 26). This experiment has been 
conducted twice only, and more repeats are needed to confirm our observations. 
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Figure 26. Distribution of CM1 and CM1-OR cells in the cell cycle. (A) represents 
number of cells in GO/G1 phase, (B) represents number of cells in S/G2/M phase. The 
proportion of quiescent cells was similar in the two populations (n=2). 
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5.4 Discussion 
 
 
In our study, cancer cells that potentially possess an intrinsic resistance to 
chemotherapy were isolated and characterised for the presence of CSCs. We chose 
oxaliplatin as the treatment compound since it is commonly used in chemotherapeutic 
regimens to target colorectal cancer. CaCO-2 and CM1 cells were exposed to 5µg/ml 
oxaliplatin only for a short period of time (48h). Resistance to oxaliplatin has 
previously been reported, and in patients with metastatic colorectal cancer, the 
median time of progression to resistance is about 8 months [266]. To avoid the events 
leading to acquired resistance, we chose to apply a lethal dose of oxaliplatin for 48h. 
This allowed us to isolate cells with an intrinsic resistance. The dose of oxaliplatin at 
5µg/ml eliminated more than 90% of the CaCO-2 and CM1 cells. We have shown 
that under the conditions we defined, resistant cells were later able to re-grow. This 
was an important parameter as our aim was to mimic the events in patients where 
recurrence occurs after apparent remission. Comparative characterisation of treated 
and untreated cells was performed with CaCO-2-OR cells harvested 12 to 13 days 
after exposure to the drug (Figure 14), and CM1-OR cells 22-23 days after exposure 
to the drug (Figure 23), as those were the points where cells with intrinsic resistance 
would be selected for. CM1 cells are derived from the tumour of a patient that 
followed a chemotherapy regimen including oxaliplatin, which might be an 
explanation as to why CM1 cells were more resistant to the drug than CaCO-2 cells. 
 
In vivo characterisation of xenotransplanted CaCO-2-OR cells did not show potential 
for high tumour growth in animals. CaCO-2-OR population apparently did not 
contain an increased number of cancer-initiating cells since 12 weeks after injection 
in NOD/SCID mice, 107 untreated CaCO-2 cells were able to form a tumour whilst a 
comparatively reduced number of CaCO-2-OR injected cells (102 to 105) were not 
tumourigenic.  
In vitro analysis of the resistant population confirmed the in vivo experiment, where 
there were no detectable signs of CSC characteristics.  
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We first looked at expression of the markers ABCG2 and Mrp1 as they are described 
as being associated with a resistant phenotype. These proteins are part of the super 
family of ABC transporters involved in the exclusion of drugs out of cells. ABCG2 is 
an important determinant in the SP phenotype of  haematopoietic, muscle, neural and 
testicular stem cells [267] and has also been identified in populations of cancer-
initiating cells [102]. Neither of these proteins were upregulated in the resistant 
population. This suggests that the intrinsic resistance of CaCO-2 cells to oxaliplatin is 
not linked to the expression/activity of these transporters. Indeed, resistance to 
oxaliplatin seems to be mainly associated with defects in apoptosis, impaired DNA 
adduct formation and increased expression of copper efflux transporters ATP7A and 
ATP7B [260, 268]. In contrast, expression of ABCG2 and Mrp1 was down-regulated 
in CaCO-2-OR cells according to the FACS analysis data. ABCG2 expression was 
also lower in CM1-OR cells when compared to CM1 cells. Another important 
transporter involved in MDR is the MDR1 (ABCB1) protein, and it would be 
interesting to analyse its expression in further studies, as well as ATP7A and ATP7B, 
as little is known yet on the role of these transporters in colorectal resistance to 
oxaliplatin [268] . 
 
We also studied the expression of markers previously used to isolate CSC populations 
from several types of cancer (breast, colorectum, prostate) : CD44, Msi-1 and CD24, 
none of them was strongly expressed in CaCO-2-OR cells or CM1-OR cells. 
Unexpectedly, CD44 was significantly down-regulated in CaCO-2-OR cells and 
CM1-OR cells, as well as CD166 in CM1-OR cells. CD44 is known to associate with 
CD166 and has previously been used as a marker for colorectal CSCs [100].  
 
Interestingly, Lgr-5, a marker of stem cells in small intestine and colon [66] was 
equally expressed in more than 50% of CaCO-2 cells and CaCO-2-OR cells. In 
normal intestine, this marker is expressed only in the basal columnar cells of the 
crypts. It has recently been shown that Lgr-5 positive cells in the intestine may be the 
cells from which colorectal tumours originate [269]. Although Lgr-5 was not 
overexpressed in the resistant population compared to the non treated cells, its 
upregulation in the CaCO-2 cell line may indicate the importance of this marker in 
the development of cancer. 
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Beside cell surface markers, we also investigated the cell cycle status of treated and 
untreated cells. We performed a test with PI integration, which can discriminate the 
number of cells in G0/G1 phases from the number of cells in the other phases 
S/G2/M. We did not find any difference in the cell cycle status of both CaCO-2/CM1 
cells and their corresponding resistant cells. Although CSCs are often described as 
potentially quiescent [83, 106], i.e. maintained in G0 phase, the literature does not 
report any convincing evidence of this characteristic. In pancreas, for instance, 
CD44+/CD24+/ESA+ cells have been identified as the putative pancreatic CSCs 
population, but no difference in the PI incorporation was observed when compared 
with CD44-/CD24-/ESA- cells. Similarly, in breast cancer the CD44+/CD24-/ESA+ 
CSCs, and in nasopharyngeal cancer the CSC population defined as SP, were not 
enriched for cells at a particular stage of cell cycle when compared to the rest of the 
cancer population [92, 121]. The putative CSCs isolated thus far do not appear to 
exhibit the characteristics of quiescence.  
In another functional test to investigate the potential CSC-like state of CaCO-2-OR 
cells, we wanted to see whether the enzyme ALDH1 was differentially regulated 
relative to the CaCO-2 untreated cells. We found high levels of ALDH1 activity in 
CaCO-2 cells, and negligible amount in treated CaCO-2-OR cells.  
Intrinsically resistant CaCO-2 and CM1 cells did not exhibit the expected CSC 
characteristics. This suggests that the attempt to isolate CSCs based on an ‘intrinsic’ 
resistant phenotype is not a sufficiently characterised attribute. 
 
As an explanation of our results, we propose the following conclusions : 
 
1)  Several studies have reported that exposing cancer cells to chemotherapeutic 
agents could trigger numerous effects on them. This includes their transformation into 
a more aggressive and alternative phenotype, by rendering them either more invasive, 
or more differentiated.  
It has been shown in colorectal cancer cells that treatment with oxaliplatin initiates a 
process similar to what usually happens in embryos to facilitate cell motility. This is 
referred to as epithelial-to-mesenchymal transition (EMT) [262]. As briefly 
mentioned in Chapter 4, EMT is a developmental process through which cells lose 
their epithelial characteristics such as adherence, and acquire mesenchymal properties 
in order to facilitate motility and invasion. EMT could therefore be involved in 
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metastasis [41, 42], although this theory is still largely controversial [270]. Both 
KML24 and HT29 colorectal cancer cells that have acquired resistance to long term 
oxaliplatin treatment begin to show transformation to mesenchymal-like features. 
This includes phenotypic changes (intercellular separation, pseudopod formation and 
loss of polarity) and functional changes (enhancement of migrating and invading 
capabilities) [262]. These observations have also been reported following treatment 
with 5-FU and methotrexate [271]. Further studies on our CaCO-2 and CM1 
oxaliplatin resistant cells should take into account those observations, specifically as 
we noted morphologic changes in the cells after incubation with oxaliplatin 
(appearance of spindle-shaped cells). 
Chemoresistance could be somehow linked to differentiation treatments involving 
differentiating therapy. This therapy is based on the concept that cancer cells are 
immature cells, unable to regulate their own proliferation. Such agents are able to 
induce differentiation and therefore to resume the normal processes that have not 
been engaged naturally. For instance, sodium butyrate, a differentiating agent, tested 
on colorectal cancer cell line LS174T selects for cancer cells with enterocytic 
differentiation [272]. Cancer cell growth is thus restrained, although these agents do 
not induce cell death. The interesting point is that in some cases, differentiating 
treatments also induce the expression of ABCB1. In the LS174T study, it was 
demonstrated that butyrate generated an increase cell resistance towards the agents 
cisplatin, 5-FU and methotrexate. Therefore, these studies could explain why the 
resistant cells we have isolated seem to have been directed to a more differentiated 
phenotype, rather than exhibit the CSC characteristics.  
In our case, the two markers of differentiation we studied, AP and SI were not 
upregulated in CaCO-2-OR cells. Further experiments to analyse a potential 
differentiation process should be led, with for instance the assessment of the AP 
activity rather than its expression, and the analysis of other markers of enterocytic 
differentiation. 
 
2) The model of intrinsic resistance of  CSCs could be more complex than previously 
expected. Firstly, the current literature does not yet include conclusive evidence that 
CSCs possess an innate chemoresistance. If in brain tumour cells, expression of 
CD133 seems more and more convincingly linked to a more resistant phenotype (be it 
chemo- or radioresistance), in some other organs the differences in drug sensitivity 
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might be significant but not always marked enough to explain the escape of CSCs 
from chemotherapeutic treatments [258]. It is also important to consider carefully the 
results regarding chemoresistance. For instance, in a study on lung cancer, it was 
demonstrated that putative CSCs (lung cancer spheres) were resistant to drug 
concentrations conventionally used in chemotherapy. However, no comparison has 
been done with the rest of the non-CSC population [140] ; therefore there is no 
evidence showing that chemoresistance is higher in the putative CSCs than in the rest 
of the population. Further work is needed to prove the innate chemoresistance of 
CSCs.  
The CSC model of chemoresistance does not explain how sometimes chemotherapy 
in patients has no effect on somatic cancer cells or CSCs [247]. In those cases, all the 
cells in the tumour bulk possess the same degree of innate resistance, which 
contradicts the notion that CSCs are the only resistant cells.  
It is important to add that intrinsic resistance of CSCs might not be the only 
explanation for the presence of cells able to survive drugs and able to repopulate the 
tumour. Cells might be less responsive for other reasons than a hierarchical 
organisation. Genetically determined differences or a protective environment could be 
some of these reasons. For instance, we observed that resistant cells looked 
morphologically larger in both cell lines. Our observations were preliminary and 
deserve further attention in order to prove whether the resistant cells are significantly 
larger, and to study whether, in that case, larger cells are simply more resistant due to 
their size or whether this phenotype is induced following exposure to the drug. In a 
non-CSC model of chemoresistance, in which all cancer cells have the same 
probability to be tumourigenic, it is conceivable that any cell, having survived 
chemotherapy for reasons independent of intrinsic resistance, might be responsible 
for recurrence without any interference of so-called CSCs. The traditional model of 
cancer predicts the existence of genetic and epigenetic changes that could be 
sufficient to account for the unequal degrees of chemoresistance among cancer cells 
[72]. 
 
3) Our model to isolate innate chemoresistant cells may not be appropriate. In the 
hierarchical model of cancer, CSCs are predicted to be intrinsically resistant. For this 
reason, we chose to analyse the cells surviving a short dose of oxaliplatin, assuming 
that they may contain intrinsically resistant cells. This strategy has proven efficient to 
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isolate cells with CSC characteristics in brain tumour and leukemic cells [203, 205]. 
It is conceivable that, in our setting, the resistant populations we isolated did contain 
the target CSCs, however their number was too low for detection. ABCG2 and Mrp1 
were less expressed in the CaCO-2-OR and CM1-OR populations than in their 
respective counterpart. These drug resistant genes may be downregulated following 
an overexpression at the time we added the drug. This may also be an indication that 
the majority of the isolated cells have not survived due to an intrinsically resistant 
phenotype, as mentioned above. Comparative studies on the resistance capacity of 
CaCO-2 and CaCO-2-OR cells (and CM1/CM1-OR cells) following isolation will be 
a means to ascertain the resistance degree in both populations and the validity of our 
initial hypothesis. Besides ABCG2 and Mrp1, CD44 and ALDH1 were also strongly 
downregulated in CaCO-2-OR and CM1-OR cells. Cross-experiments involving the 
isolation of cells with the phenotype expressed by CaCO-2-OR cells (ABCG2lo, 
Mrp1lo, CD44lo or/and ALDH1lo) and CaCO-2 cells (ABCG2hi, Mrp1hi, CD44hi 
or/and ALDH1hi) and the comparison of their resistance capacity will allow us to test 
our initial hypothesis and to determine whether cells surviving a short dose of 
oxaliplatin truly are resistant.  
 
The idea of culturing cells over a long period of time in the presence of oxaliplatin 
maybe another strategy to select for resistant clones and obtain a good number of 
resistant cells. A recent paper on colorectal cancer cells has studied the effects of long 
term exposure to the drug [273].  They used the human colorectal HT29 cancer cell 
line, and exposed it to increased concentrations of oxaliplatin, starting from 
0.5µmol/L up to the clinically relevant plasma concentrations (2µmol/L). Their 
results are very interesting since they show that their resistant cells are 22 times more 
enriched in CD44+/CD133+ compared to the original cell line. The potential of those 
resistant cells to form colonies in anchorage-dependant conditions and to form 
spheres was also enhanced. Oxaliplatin resistant cells were as expected more resistant 
to oxaliplatin but were additionally cross-resistant to 5-FU, compared to the non 
resistant cells. Therefore, studying these long term rather than intrinsically resistant 
cells may be more promising to isolate cells with CSC-like attributes.   
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6 Isolation and characterisation of putative 
CSCs according to their ALDH1 activity 
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6.1 Background 
 
 
Since the full compendium of CSC specific surface markers has yet to be fully 
characterised, their use as a target for isolating specific subtypes of CSCs is still open 
to criticism. Whilst numerous groups are still involved in this area of research, others 
are attempting to characterise CSCs independently of stem cell surface markers. The 
use of ALDH is one such example. 
  
ALDH and ‘stemness’ state 
 
 
ALDH enzymes are part of the ALDH superfamily ; in the human genome, 19 genes 
and 3 pseudogenes have been described [274, 275]. In mammals, they are divided in 
3 sub-classes. Enzymes of class 1 and 3 are cytosolic, whereas class 2 is 
mitochondrial. In all cases, their main activity is the oxidation of various substrates, 
be they endogenous (substances derived from endogenous metabolism, essentially 
aliphatic and aromatic aldehydes) or exogenous (related to the xenobiotic 
metabolism) [276].  
Among all the isotypes of ALDH, ALDH1 seems to be predominantly involved in 
stem cell biology as it is expressed at elevated levels in haematopoietic, neuronal and 
breast stem cells, and also in intestinal crypts [170, 171, 277].  
Additionally, ALDH1 is mainly responsible for the oxidation of cytosolic aldehydes 
into carboxylic acids [278]. Aldehydes have important roles in eye development 
where they are linked in retinoid metabolism where ALDH1 biosynthesizes retinol 
(vitamin A) into retinoic acid [167, 278]. The retinoids influence the balance of self-
renewal/differentiation either way depending on the stage of cell differentiation. In 
murine HSC, they are responsible for the terminal differentiation of late progenitors 
whereas they maintain the self-renewing function of the early precursor cells [168, 
169]. Therefore, ALDH1 is involved in SC self-renewal through regulation of 
retinoid metabolism. 
Aldehydes can also mediate deleterious effects on cells (essentially cytotoxicity and 
mutagenicity). The oxidation of these aldehydes is therefore a strategy to preserve the 
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cell integrity. Hence, elevated levels of ALDH1 in stem cells reflect its function in 
mediating the long term survival of stem cells and CSCs.  
 
ALDH and tumourigenesis 
 
It is noteworthy that ALDH also plays a role in carcinogenesis. It has been observed 
that the ALDH activity changes during tumourigenesis, in rodents and human colon 
and liver primary neoplasms, leukemic cells, and in human mammary 
adenocarcinoma cell lines [71]. The activity of classes 1 and 3 ALDH is enhanced, 
where this increase has been related to resistance against the anti-cancer agents 
oxazaphosphorines (cyclophoshamide (CPA) is the best known [279, 280]). Sladek et 
al. (2002) demonstrated that exposing primary and metastatic breast cancer cells to 
CPA increases ALDH1 activity [257]. Additionally, ALDH3A1 modulates the 
response of cells under oxidative stress, and is involved in mediating resistance to 
other chemotherapeutic drugs including etoposide [281]. 
In vitro studies revealed that inhibiting ALDH in a panel of cancer cells induced 
apoptosis, reduced tumour growth and invasiveness [282]. 
The biological properties of ALDH enzymes therefore makes them an important 
factor that maintains resistance of cancer cells (and possibly CSCs) to chemotherapy 
by preventing apoptosis and oxidative stress, thus facilitating tumour growth and 
development. 
 
 
 
ALDH1 and CSCs 
 
To isolate a population of cells with high ALDH1 activity, Storms et al. (1999) 
developed an Aldefluor® kit in which ALDH1 activity can be quantified through the 
degradation of a fluorescent substrate in murine and human species [206]. ALDH1 is 
the main enzyme detected by this kit, and human HSC enriched for CD34+/CD38- 
could thus be isolated by FACS sorting. The emergence of this kit permitted the 
expansion of ALDH1hi cell detection in various malignant and non malignant tissues.  
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Among solid tumours, breast tumour ALDH1hi positive cells are the first to have been 
described as a functional marker of cancer stem and progenitor cells [277, 283]. At 
present, ALDH1 shows increasing potential as a CSC marker since various studies 
have also isolated putative CSCs from ALDH1hi populations in leukaemia [173], 
colorectal [100], liver [175], pancreatic  and lung cancers [176]. 
 
 In colorectal cancer, the role of ALDH1 in the CSC population is still being studied. 
Preliminary data showed that putative colorectal CSCs ESA+/CD44+ cells were 
characterised by a higher activity of ALDH1, but in their hands, 
ESA+/CD44+/ALDH1hi cells were not significantly more tumourigenic than 
ESA+/CD44+/ALDH1lo cells [100].  
In another study, Dylla et al. (2008) confirmed an increase of ALDH1 activity in 
ESA+/CD44+ cells, and showed a possible role of ALDH1 in tumourigenicity in 
combination with CD44 marker. Indeed, CD44+/ALDH1hi cells were tumourigenic 
whereas CD44+/ALDH1lo cells  and CD44-/ALDH1+ cells were not [131]. The 
combined role of ALDH1 and CD44 in tumourigenicity was recently confirmed by 
Chu et al. (2009) who reported that, for two patients, xenografted CD44+/ALDH1hi 
tumour cells produced a 10-fold increase of  the tumourigenic potential of CD44+ 
cells [132]. 
Recently, ALDH1 was shown to be expressed specifically in the intestinal crypts of 
malignant and non malignant colonic epithelia [284]. Using ALDH1 as a single 
marker for CSC isolation, they confirmed the exclusive tumourigenicity of ALDH1hi 
cells and their functional capacity for self-renewal compared to ALDH1lo cells. 
CD44+/ALDH1hi cells were not consistently more tumourigenic than ALDH1hi cells, 
indicating that ALDH1hi could be used as a single marker. 
 
The use of ALDH1 as a CSC marker therefore needs to be further elucidated in 
colorectal cancer. Hence, the aim of this study was to characterise putative colorectal 
CSCs via ALDH1 staining of a colorectal cancer cell line (CaCO-2) and primary cell 
culture of colorectal metastasis in the liver (CM1). 
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6.2 Isolation and characterisation of CaCO-2 and CM1 
ALDH1hi cells 
 
 
6.2.1 ALDH1hi cells labelling and FACS sorting 
 
 
 
6.2.1.1 Percentages of ALDH1hi cells in both cell lines 
 
 
CaCO-2 and CM1 cell populations were labelled with the Aldefluor® kit and sorted 
using FACS. Doublets of cells were excluded. 
Results showed that compared to controls, on average 15% of CaCO-2 cells were 
ALDH1hi, whereas 26% showed ALDH1hi in the CM1 cell population (Figure 27).  
 
 
 
 
6.2.1.2 Viability of CaCO-2 cells and CM1 cells after FACS sorting 
 
Cell viability was evaluated by trypan blue exclusion after ALDH1 sorting. In the 
first trials, the viability of ALDH1hi cells was generally higher than that of ALDH1lo 
cells, specifically in the CM1 primary cell line where the ALDH1hi cells (70±12% 
viability) were more viable than the ALDH1lo cell population (51±8% viability). 
However, we could later increase the viability with more than 90% for CaCO-2 and 
80% for CM1 each time in each fraction, by making sure the cells were in optimal 
conditions through the addition of fresh medium 24h prior to harvesting and by 
supplementing the buffer with 1% BSA during the sorting process. 
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Figure 27. Flow cytometric isolation of putative colon CSC on the basis of ALDH1 activity. 
CaCO-2  (A, B) and CM1 (C, D) cells were labelled with the Aldefluor reagent in the 
presence (A, C) or absence (B, D) of DEAB, an ALDH1 activity inhibitor. ALDH1lo cells 
were gated in P3, and ALDH1hi cells in P4 with an indication of their respective percentages. 
On average, ALDH1hi cells represented 15% of the CaCO-2 cells and 26% of the CM1 cells. 
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6.2.1.3 Assessment of the  purity of ALDHhi and lo fractions obtained after 
FACS sorting 
 
 
 
 
 
Cells that were sorted and collected were gated so as to avoid any contamination 
between the negative and positive fractions. 
 
The purity of each fraction was checked after FACS sorting. Purity was usually good, 
considering that no method achieves perfect separation, as illustrated in Figure 28. 
 
 If negative fractions were ≥98 % pure, the positive fractions for both CM1 and 
CaCO-2 were less pure (around 90 and 84%, respectively), which, besides the sorting 
which is never 100% efficient, might certainly be due to the dye leaking out of the 
cells. Indeed, we observed a slight decrease of the dye intensity over the time, 
sometimes even during the sorting process.  
ABC transporters are responsible for the extrusion of fluorescent substrates out of 
cells, and this process can be extremely rapid if they are not inhibited as indicated in 
the manufacturer’s instructions from the Aldefluor® kit. The buffer in which cells are 
incubated contains the inhibitors specific to the human haematopoietic cells for which 
it has been designed, but these inhibitors may not necessarily prevent active efflux in 
other cell types. 
In order to prevent efflux, the manufacturer recommends storing cells in the buffer 
and on ice after incubation (to prevent the transporters enzymatic activity), and 
proceeding to FACS sorting shortly after incubation. Although we always proceeded 
to FACS sorting immediately the incubation, the cells were not kept at 4°C during 
and after the procedure. This may account to why some leakage must have occurred. 
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Figure 28. Purity sort check of the ALDH1 high and low fractions after FACS sorting. (A, 
B) = CaCO-2 cells, ALDH1hi and ALDH1lo cells respectively. (C, D) = CM1 cells, 
ALDH1hi and ALDH1lo cells respectively. ALDH1lo cells were gated in P3, and ALDH1hi  
cells in P4, with an indication on their respective percentage. In CaCO-2 and CM1 cells, 
the ALDH hi cells did not show 100% purity (84.5 and 91%, respectively), which might be 
due to the dye leaking out of the cells.  
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6.2.2 Decrease of Aldefluor® intensity over the time 
 
 
As mentioned above, Aldefluor® fluorescent substrates leaks out of the cells rapidly 
if cells are not kept on ice in the buffer containing inhibitors of the ABC transporters. 
As we wanted to use the cells derived from FACS sorting for other staining 
experiments involving fluorescence, we thought it necessary to check first whether 
the dye was fading rapidly enough so as not to interfere with other dyes. Cells were 
cultured in fresh medium at 37°C and the fluorescence measured 3h and 24h after 
sorting. Results are shown in Figure 29.  
 
 
 
 
 
 
 
 
 
 
 
 
  B 
 
 
 
 
 
 
 
 
 
 
 
Percentage of fluorescently labelled cells 
 0 H 3 H 24 H 
CaCO-2 100 % 32.6 ± 9.9% 2.8 ± 2.4% 
CM1 100 % 25.1 ± 4.4% 0.5 ± 0.4% 
CaCO-2
0
20
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80
100
0 3 24
Hours after sorting
Figure 29. Measurement of Aldefluor® fluorescence in ALDH1hi cells 3 and 24h after FACS 
sorting. Data are summarized in (A). Representatives charts (B) indicate clearly the rapid drop of 
fluorescence of the Aldefluor® dye. The values at t=0h were considered to be 100%, although we 
did not check the exact value each time. n=3. 
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After 24h, the fluorescence of ALDH1hi cells for both cell lines were almost 0 % (2.8 
% for CaCO-2 ALDH1hi cells, and 0.5 % for CM1 ALDH1hi cells). Prior to 
fluorescent labelling for immunofluorescence of ALDH1hi and lo populations, we 
therefore cultured the cells for 24h, so as to avoid interference with the dyes.  
 
We also did not want to leave the cells any longer in culture in order to preserve as 
much as possible the putative ‘stemness’ characteristics of the ALDH1hi fractions. 
There is no well-defined cut-off point for this state of ‘stemness’. However, since 
differentiation is a process coupled to proliferation, it was preferable to analyse cells 
shortly after their isolation, i.e. before any potential CSCs have had time to commit to 
a differentiation pathway, thus loosing their CSC characteristics. 
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6.3 Characterisation of Aldefluor® positive cells 
 
 
6.3.1 Cell marker analysis 
 
 
ALDH1hi and ALDH1lo cells isolated from CaCO-2 and CM1 cell lines were 
analysed for the expression of putative CSC markers by immunocytochemistry : cell 
surface markers conventionally chosen to proceed to CSC extraction, CD44, CD133, 
CD24 and ABCG2, and also markers highly expressed in embryonic stem cells such 
as Oct-4, and specific markers of colonic stem cells lgr-5 and msi-1 were 
investigated. 
Due to a very low number of cells resulting from the FACS sorting, we chose 
immunocytochemistry as the optimal method to proceed with this study.  
 
 
Caco-2  
 
In the CaCO-2 cell line, the expression of two markers was significantly different in 
the ALDH1hi cell population when compared with the ALDH1lo cell population, 
CD44 and Lgr-5. Lgr-5 was expressed by 46±8% of the ALDH1hi cells which is 2.5 
times more than the 19±10% expression by the ALDH1lo cells (p<0.05). CD44 
marker expression was almost 3 times more in the ALDH1hi cells in comparison with 
the ALDH1lo cell population (59±19% and 20±4%, respectively, n=3, p<0.05). All 
other putative CSC markers tested showed no statistically significant differences 
between ALDH1hi and ALDH1lo cells from the CaCO-2 cell line. These results are 
displayed in Figures 30, 31 and 31bis.  
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Expression of putative CSC markers in the CaCO-2 cell 
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Percentage of expression of putative CSC markers 
in ALDH1hi and lo CaC0-2 cells 
CSC Marker  
(Mean percentage positivity ±  
standard deviation, n=3) 
ALDH1lo ALDH1hi 
CD24   24±3% 20±6% 
CD44    20±4% 59±19% 
CD133   69±30% 81±9% 
CD166  51±31% 76±25% 
Abcg-2  78±19% 86±14% 
Oct-4  18±8% 21±8% 
Msi-1  40±10% 52±5% 
Lgr-5   19±10% 46±8% 
Figure 30. Mean expression of the putative CSC markers tested in ALDH1hi and ALDHlo cell 
fractions of CaCO-2 cell line (A) and corresponding representative chart (B). Immediately after 
FACS sorting, cells were plated onto 96-well plates and immuno-stained for the different markers. 
Fluorescent cells were detected by fluorescent microscopy, and the percentages represent the 
number of fluorescent cells out of 250 counted cells. n=3. * = p <0.05 (t test). CD44 and Lgr-5 
markers were significantly more expressed in ALDH1hi cells than in ALDH1lo cells. 
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ALDH1hi ALDH1lo Isotype 
ABCG2 
CD133 
CD166 
CD24 
CD44 
Figure 31. Immunohistochemistry analysis for ABCG2, CD133, CD166, CD24 and CD44 
CSC markers expression. Immediately after FACS sorting, ALDH1hi and lo CaCO-2 cells were 
plated onto 96-well plates for 24h, fixed in 4% PFA, and incubated with the primary and 
secondary antibodies when required. Nuclei were stained with DAPI. The fluorescent cells 
were detected under fluorescent microscopy. The experiment was repeated 3 times and 250 
cells per field were counted. CD44 marker was significantly more expressed in ALDH1hi cells, 
whereas there was no difference in the expression of the other markers. 
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Lgr-5 
Msi-1 
Oct-4 
Figure 31bis. Immunohistochemistry analysis for Lgr-5, Msi-1 and Oct-4 CSC/stem cell 
marker expression. Immediately after FACS sorting, ALDH1hi and lo CaCO-2 cells were 
plated onto 96-well plates for 24h, fixed in 4% PFA, and incubated with primary and 
secondary (when required) antibodies. Nuclei were stained with DAPI. The fluorescent cells 
were detected under fluorescent microscopy. The experiment was repeated 3× and 250 cells 
per field were counted. Lgr-5 marker was significantly upregulated in ALDH1hi cells, whereas 
there was no difference in the expression of the other markers. 
 
Isotype ALDH1hi ALDH1lo 
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CM1 
 
CM1 ALDH1hi cells showed a significant difference in the expression of three 
markers when comparing ALDH1hi and ALDH1lo CM1 cells (See Figures 32, 33 and 
33bis). A significant difference was observed for the CD44 marker which showed 
almost twice the expression in ALDH1hi cells when compared to ALDH1lo cells 
(78±17% and 40±9%, respectively, n=3, p<0.05). ALDH1hi CM1 cells also expressed 
more CD166 and ABCG2 markers than ALDH1lo CM1 cells with a 50% increase 
(CD166=88±8% and 59±1%, ABCG2 =74±6% and 48±3%, respectively, n=3, 
p<0.005 for both). All other putative CSC markers tested demonstrated no 
statistically significant differences between the ALDH1hi and ALDH1lo cell 
populations in the CM1 primary cell line.  
 
The combination CD44/CD166 has been reported to be expressed by colorectal CSCs 
[100]. In the samples that contained a higher number of CM1 ALDH1hi cells, we 
analysed the combined expression of CD44 and CD166 by FACS analysis in 
ALDH1hi cells (Figure 33ter). Out of 3 independent experiments, an average of 
35.6±14.8% ALDH1hi cells was CD44+/CD166+. Nearly all CD44 positive cells 
(89.7±7.5%, n=3) were also positive for CD166 marker. 
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in the CM1 cell line
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
CD24 CD44 CD133 CD166 Abcg-2 Oct-4 Msi-1 Lgr-5
Putative CSC Marker
M
a
rk
e
r 
Ex
pr
e
s
s
io
n
 
(P
e
rc
e
n
ta
ge
)
ALDH1 lo
ALDH1 hi
**
 
 
**
 
 
*
 
 
 
 
Percentage of expression of putative CSC markers 
 in ALDH1hi and lo CM1 cells 
CSC Marker Expression 
(Mean percentage positivity ± 1 
standard deviation) 
ALDH1lo ALDH1hi 
CD24   25±10% 25±11% 
CD44    40±9% 78±17% 
CD133   45±15% 61±17% 
CD166  59±1% 88±8% 
ABCG2  48±3% 74±6% 
Oct-4  16±9% 22±13% 
Msi-1  36±16% 42±30% 
Lgr-5   34±11% 48±17% 
B 
Figure 32. Mean expression of the putative CSC markers tested in ALDH1hi and 
ALDH1lo cell fractions of CM1 cell line (A) and corresponding representative chart (B). 
Immediately after FACS sorting, cells were plated onto 96-well plates and immuno-
stained for the different markers. Fluorescent cells were detected by fluorescent 
microscopy, and the percentages represent the number of fluorescent cells out of 250 
counted cells. n=3. * = p <0.05 (t test). CD44, CD166 and ABCG2 markers were 
significantly more expressed in ALDH1hi cells than in ALDH1lo cells 
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ALDH1hi ALDH1lo Isotype 
ABCG2 
CD133 
CD166 
CD24 
CD44 
Figure 33. Immunohistochemistry analysis for ABCG2, CD133, CD166, CD24 and CD44 
CSC markers expression. Immediately after FACS sorting, ALDH1hi and lo CM1 cells were 
plated onto 96-well plates for 24h, fixed in 4% PFA, and incubated with the primary and 
secondary antibodies when required. Nuclei were stained with DAPI. The fluorescent cells 
were detected under fluorescent microscopy. The experiment was repeated 3× and 250 cells 
per field were counted. CD44, CD166 and ABCG2 markers were significantly more expressed 
in ALDH1hi cells, whereas there was no difference in the expression of the other markers. 
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Lgr-5 
Msi-1 
Oct-4 
Figure 33bis. Immunohistochemistry analysis for Lgr-5, Msi-1 and Oct-4 CSC/stem cell 
markers expression. Immediately after FACS sorting, ALDH1hi and lo CM1 cells were 
plated onto 96-well plates for 24h, fixed in 4% PFA, and incubated with primary and 
secondary antibodies when required. Nuclei were stained with DAPI. The fluorescent cells 
were detected under fluorescent microscopy. The experiment was repeated 3 times and 
250 cells per field were counted. None of these markers was significantly more expressed 
in ALDH1hi cells. 
 
ALDH1hi ALDH1lo Isotype 
Figure 33ter. Facs analysis evaluating the co-expression of CD166 and CD44 CSC 
markers in ALDH1hi CM1 cells. Cells were incubated with directly conjugated antibodies. 
The fluorescent cells were detected by flow cytometry. Out of three independent 
experiments, 65.7±22.7% ALDH1hi CM1 cells were CD166+, 38.38±13.7% were CD44+ 
and 35.6±14.8% co-expressed CD166 and CD44. 
 
35.8%
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In summary, immunofluorescence analysis revealed that a high ALDH1 activity was 
related to a significant increase in several CSC markers in both cell lines. 
Interestingly, CD44, which has been used in several studies to isolate colorectal CSCs 
was over-expressed in both CaCO-2 and CM1 ALDH1hi cells. CD166, which was 
overexpressed in CM1 ALDH1hi cells was co-expressed with CD44. As the literature 
reports that CD44+/CD166+ phenotype is expressed by cells with CSC characteristics 
[100], the overexpression of both these markers suggest an enrichment of CSCs in the 
ALDH1hi cell population.  The Lgr-5 colorectal stem cell marker has recently been 
defined as a stem cell marker in the intestine, and is under investigation as a possible 
CSC marker. Interestingly, it was highly expressed in CaCO-2 ALDH1hi cells. In 
CM1 ALDH1hi cell populations, the levels of ABCG2 were higher than in the 
negative population. The fact that ALDH1hi cells express more CSC/SC markers 
suggested that isolating cancer cells with a high ALDH1 activity might select cells 
with a CSC phenotype. Further in vitro experiments were needed to observe whether 
ALDH1hi cells possessed other CSC characteristics. 
 
6.3.2 Colony forming assay 
 
CSCs essentially are cancer cells possessing stem cell characteristics. As mentioned 
in the introduction, a hallmark of stem cells is their capacity to self-renew and to 
differentiate. They have the capacity to regenerate themselves and to give rise to a 
fully differentiated progeny. Two assays are commonly used to explore this capacity. 
The most popular is the in vivo xenograft assay, where cancer cells are injected into 
mice. If these cells are able to reproduce a whole tumour containing cells 
hierarchically organised in the same manner as in the original tumour, then there is 
evidence for their self-renewing potential. There exists another assay designed for in 
vitro use, also called the colony forming assay. If one cell is able to self-renew and to 
differentiate, then it should be able to regenerate the whole cell line. The clonogenic 
cells are defined as those cells capable of forming a large family of descendants in an 
artificial in vitro environment. 
To achieve this experiment and compare the colony forming efficiency of ALDH1hi 
to ALDH1lo cells, we plated one cell per well in 96-well plate (cf. Materials and 
Methods) and tracked its regenerative potential. 
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CaCO-2  
 
The difficulty of this assay is based on the fact that it is rather subjective to determine 
what a mature colony with extensive growth capacity is. We proceeded with 
preliminary trials, and observed after 6 weeks 4 types of development : 
 
1. the cell in the well had died without any division, 
2. the cell had divided only a few times, but all died thereafter, 
3. the cell had divided but was not able to repopulate the whole well, so it 
seemed that its capacity for repopulation was restrained, or 
4. the well was confluent or nearly confluent. 
 
We therefore decided to set up a cut-off point at week 6 after plating, with a well at 
75% confluency. In these cases, we assumed that the original cell was able to 
regenerate the whole cell population. Results showed that no significant difference in 
colony forming potential existed between total population, ALDH1hi and ALDH1lo 
cells (4±2.82%, 6.6±1.52% and 8.6±%3.78, respectively) (Figure 34).  
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Figure 34. CaCO-2 ALDH1hi and lo cells were plated in 96-well plate, at a rate 
of one cell per well. Each well was visualised and validated when it contained 
one cell only. Six weeks later, wells with 75% confluency were scored. The 
experiment was repeated three times, and percentages established out of 75-100 
cells per category for each experiment. There was no difference in the colony-
forming potential of ALDH1hi and lo CaCO-2 cells. 
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    CM1 
 
 
 
The same experiment was repeated with CM1 cells after FACS sorting. However, 
these cells did not grow in the same way as CaCO-2 cells as they grew in multilayers 
rather than spread as a monolayer, thus forming a piling-up structure. In preliminary 
trials we observed that some CM1 single cells lost viability without dividing or after a 
few divisions. Some of them formed small colonies, or large colonies by piling-up as 
multi-layers. We scored the colonies displaying the piling-up structure 8 weeks after 
plating (see Figure 35). 
 
 
 
 
 
   
           
 
 
Figure 35. Morphology of CM1 cells colonies in 96-well plates, after 8 weeks in 
culture. (A) A single cell divided several times before dying. (B) The single cell 
divided and formed a colony but with a limited size and stopped growing. (C) Mature 
colony with obvious piling-up structure. (D) Detail of the piling-up structure. Mature 
colonies only were scored. 
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Similarly to CaCO-2 cells, the percentages obtained in Figure 36 do not reveal any 
significant difference in the colony forming potential of our ALDH1hi and lo CM1 
cells (4.4±3.2% and 2.1±0.7% respectively, no significance). The total population 
reached 13.2±2.7%, which was significantly more than the negative ALDH1 
population (p=0.01), but not the ALDH1hi cells. 
 
 
 
 
ALDH1hi cells in this setting did not reflect a higher colony forming potential. 
 
 
Figure 36. CM1 ALDH1hi and lo cells were plated in 96-well plates, at a rate of one cell 
per well. Each well was visualised and validated when it contained one cell only. 8 
weeks later, one-cell wells with confluent colony (i.e. starting to pile up) were scored. 
The experiment was repeated 3 times, and percentages established out of 75-100 cells 
per category for each experiment. Like in the CaCO-2 cell line, ALDH1hi cells were not 
enriched in colony forming cells. 
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6.3.3 Cell cycle analysis 
 
 
A resting phenotype has been attributed to stem cells, and possibly to CSCs. 
ALDH1hi and lo populations were stained with PI, and the DNA content of cells 
measured by FACS analysis. 
 
 
 
 
Results in Figure 37 indicate that a higher number of CM1 cells is quiescent (i.e. in 
G0/G1 phase) than in CaCO-2 cells (74.3±4.3% and 80.4±6.4% for ALDH1hi and lo 
CM1 cells, respectively, vs. 56.9±6.7% and 66.4±7.9% in ALDH1hi and lo CaCO-2 
cells). 
 
When comparing G0-G1 phases of ALDH1hi and lo cells in the same cell line, there 
was no significant difference, attesting that the ALDH1 high activity does not 
correlate with a higher quiescent state, although studies have shown that ALDH1hi 
phenotype correlated with a dormant phenotype, as revealed by slow growing 
colonies and a low proliferative rate of growth [285]. However, it has also been 
shown that tumour growth and development are impeded when using ALDH 
inhibitors [282]. Therefore, if ALDH1 facilitates expansion, ALDH1hi cells may 
therefore not be expected to be in a quiescent stage. 
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Figure 37. Distribution of ALDH1hi and lo CaCO-2 and CM1 cells in the cell cycle. 
Number of quiescent cells (G0/G1) was not significantly different between ALDH1hi and 
lo
 cells for both cell lines. n =5 for CaCO-2 cells and n=4 for CM1 cells. 
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6.3.4 Differentiation of ALDH1hi and ALDH1lo cells over the time 
 
 
 
An important parameter that might help in recognising a cell population as a CSC 
population is its capacity to differentiate, and to regenerate the whole tumour 
population. CSCs are theoretically expected to give rise to more differentiated 
progeny.  
One way of verifying the differentiation capability of putative CSCs is the analysis of 
markers of differentiation. An alternative idea is that a putative CSC phenotype 
should be able, after a certain time, to generate a progeny comprising of the original 
CSC phenotype, and also of the more differentiated non-CSC phenotype. On the 
other hand, a non-CSC phenotype should not be able to have a progeny with a more 
primitive phenotype. 
We therefore attained short term cultures of ALDH1hi and lo populations, and 
analysed their progeny 2 weeks after isolation. 
 
CaCO-2 
In CaCO-2 cells, we analysed the activity of ALDH1 2 and 4 weeks after the isolation 
of ALDH1 hi and lo cells (Figure 38). 
Results interestingly showed a decrease of ALDH1 activity in the ALDH1hi fraction, 
but becoming more stable after 2 and 4 weeks to a value of 25% (26.9±7.9% and 
26.55 ±2.9%, respectively). This suggested that after a month, some of ALDH1hi cells 
had differentiated into ALDH1lo cells, but the activity of ALDH1 remained beyond 
the initial value of 15%. 
  
In the ALDH1lo fraction, we were even more surprised to see that after 2 weeks, cells 
had recovered to the initial amount of ALDH1hi cells (14.0±2.9% and 14.64±2.1%, 
respectively).This suggested that either the contaminating ALDH1hi cells developed 
quickly enough to readjust their number up to the initial percentage, or ALDH1lo cells 
could also regenerate ALDH1hi cells, thus recapitulating the heterogeneity seen in the 
original population. 
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CM1 
In CM1, ALDH1 activity was assessed 2 weeks after FACS sorting, and in both 
ALDH1hi and lo cells, the initial percentage (26%) of ALDH1 activity had almost 
been recovered (32.9±11.5% and 36.1±15.9%, respectively) as shown in Figure 39. 
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Figure 39. CM1 ALDH1hi and lo cells were left in culture after FACS sorting 
isolation. Error bars represent the standard deviations for n=3 experiments. The 
green line indicates the ALDH1 percentages of cells with a high ALDH1 activity 
in the total cell population (26%). 
 
 
Figure 38.  CaCO-2 ALDH1hi and lo cells were left in culture immediately after FACS 
sorting isolation. 2 and 4 weeks later, each fraction was reanalysed for ALDH1 activity. 
Error bars represent the standard deviations for n=4 experiments at  week 2 and n=2 at week 
4. The values at week 0 were considered to be 100% in ALDH1hi cells and 0% in ALDH1lo 
cells, although we did not check the exact value each time. The green line indicates the 
ALDH1 percentages of cells with a high ALDH1 activity in the total cell population = 15%. 
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6.3.5 Resistance to oxaliplatin 
 
 
 
An intrinsic property of CSCs is their resistance to chemotherapeutic drugs. ALDH 
has been implicated in resistance to the common chemotherapeutic agent CPA in 
colorectal cancer [131].  
 
 It was interesting to establish whether cells expressing ALDH1 would possess a 
higher capacity of resistance to other chemotherapeutic drugs, more commonly used 
in regimens directed against colorectal cancer. In our study, we chose oxaliplatin. The 
patient from whom the CM1 cells had been derived underwent chemotherapy with 
oxaliplatin. The metastatic cells were therefore cells that showed resistance to this 
drug. Since the putative CSC marker ALDH1 maybe involved in generating a 
chemoresistant phenotype, we established if this was the case by incubating both 
ALDH1hi and lo cells of both cell lines for 96h with various concentrations of 
oxaliplatin. The percentages of viable cells were then analysed by a colorimetric 
assay. 
 
According to Figure 40, the response to oxaliplatin was similar for the ALDH1hi and 
lo
 cells in both cell lines. Thus resistance to oxaliplatin does not seem to be mediated 
through ALDH. 
At 96 h, the percentage of resistant cells was higher in CM1 cells, which is consistent 
with the fact that CM1 cells are derived from an oxaliplatin resistant clone. 
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Figure 40. Oxaliplatin resistance of ALDH1hi and lo cells. CaCO-2 and CM1 cells 
were exposed to various concentrations of oxaliplatin over 96h. The number of 
surviving cells was normalised to the number of cells with no oxaliplatin exposure 
(0µg/ml). Error bars represent standard deviations of 3 experiments in triplicates. 
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6.3.6 Migration assay 
 
 
 
A transwell migration assay was carried out to determine if there was any difference 
in the migration potential of ALDH1hi vs. lo cells.  
As CSCs are defined as being responsible for metastatic growth, we expected the 
CSCs to have increased capacities for migration and invasion. Indeed, in breast 
cancer, migrating and invading capabilities are enhanced in CD44+/CD24+ CSCs 
compared to the rest of the cancer population. In breast cancer cell lines, a high 
ALDH1 activity has also been correlated with higher invasive properties in vitro as 
well as in vivo [174]. 
 
It has also been reviewed that the CD44 marker was specifically associated with a 
highly invasive/migrating phenotype in cancer [151, 153, 154]. In both cell lines, we 
detected a high expression of CD44 in ALDH1hi cells in comparison to the ALDH1lo 
cells, and therefore expected them to be able to migrate more than their counterpart. 
 
 
 
Preliminary experiments 
 
 
Before begining any assay with our sorted cells, we carried out a preliminary 
migration assay with the total cell populations. We chose PC3wtAR prostate cancer 
cell line as a positive control, since these cells are known to be invasive and 
migratory. Although the literature reports on CaCO-2 cell invasiveness, the same has 
not yet been assessed with CM1 cells. 
 
Cells were seeded in medium without serum on 8µm pore transwells (5×104 
cells/transwell). A 20% FCS gradient was established in the lower wells (except in 
the control wells). After 48h incubation, PC3wtAR cells had migrated. However, 
CaCO-2 and CM1 did not, even after 72h. 
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We then checked whether the number of cells we had seeded was adequate and did 
not provoke contact inhibition to prevent the cells from growing. Migration and 
invasion events can only happen if they are conjugated to cell growth. If cells are 
sensitive to the gradient, then they should expand towards the gradient rather than 
parallel to it. 
When plating 5×104 cells in a 96-well plate, the number of cells had doubled for each 
cell line after 72h (Table 9), thus showing at this seeding density there was no contact 
inhibition, and the number of cells obtained after 72h was still reasonable to allow 
analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Once we optimised the seeding density of the cells, we then decided to increase the 
gradient by adding 50ng/ml EGF to 20% FBS in the lower wells. Under these 
conditions, CaCO-2 cells were able to migrate across the pores after 72h (Figure 41). 
However, CM1 cells, although their diameter was smaller than CaCO-2’s,  were not 
able to migrate across the pores, even when we added 50ng/ml EGF and 50ng/ml 
hepatocyte growth factor (HGF), as suggested in the literature for colorectal cancer 
cells. PC3wtAR prostate cancer cells were used as a positive control and were able to 
migrate across the pores after 48h under a 20% FBS gradient.    
                   
Fold-expansion after 24h 48h 72h 
PC3wtAR 1.3 1.4 2 
CaCO-2 1.2 2.5 4.4 
CM1 1.0 1.6 2.7 
Table 9. Proliferation rate of PC3wtAR, CaCO-2 and CM1 cell lines. 5×104, 
2.5×104 and 7.5×104 cells of each cell line were plated in a 96-well plate, 
respectively. Cells were trypsinised and counted in a haemocytometer 
chamber after 24, 48 and 72h. 
 
B 
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Migration of ALDH1hi and lo CaCO-2 cells 
 
ALDH1hi and lo CaCO-2 cells were isolated, and immediately after FACS sorting 
were seeded in the upper chamber of the transwell system with or with a gradient and 
incubated for 72h. After fixation and incubation with crystal violet, the membranes 
were removed from the insert housing using a scalpel, mounted on a microscope 
slide, and observed under light microscopy. 
The membranes were then incubated in 0.1% acetic acid to dissolve the crystal violet. 
OD was read on a spectrophotometer.  
 
 
 
 
        
 
 
 
         
 
 
 
 
Figure 41. Migration of ALDH1hi and lo CaCO-2 cells. CaCO-2 cells were able to 
migrate through an 8µm pore membrane after 72h under a gradient of 20% FBS and 
50ng/ml EGF. (A) ALDH1lo CaCO-2 cells with and without gradient. (B) ALDH1hi cells 
with and without gradient.For each condition, 2.5×104 cells were seeded in the upper 
well of a transwell system. After 72h, transwells were washed in PBS, fixed in 4% PFA 
and stained with 0.5% methyl blue for 50mn. Membranes were washed, cut out with a 
scalpel and placed onto glass slides. Images were captured under light microscopy 
(×20). 
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Results in Figure 42 indicate that a high ALDH1 activity did not correlate with an 
increased migratory phenotype in CaCO-2 cells. 
Although we expected that ALDH1hi cells migrate more across the pores towards the 
gradient, there was no statistical difference in the migration rates of ALDH1hi and lo 
cell populations. In our case, a high expression of CD44 and ALDH1 activity did not 
increase the migrating capacities of the cancer cells. 
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Unfortunately, we could not conduct that experiment on CM1 cells, as we were not 
able to determine the right conditions for their migration across the pores. Analysing 
the invading properties of the cells through a matrigel membrane, to reproduce the in 
vivo degradation of a basal membrane by the cancer cells would be another 
interesting experiment to conduct. 
Figure 42. Migration rate of ALDH1hi and lo CaCO-2 cells. Cells migrated 
through an 8µm pore membrane, under a 20%FBS+50ng/ml EGF gradient, 
after 72h. The OD of ALDHhi and lo cells in the gradient inserts was 
normalised to the OD of cells in the control inserts (with no gradient). Error 
bars represent the standard deviations for 3 independent experiments. The 
migration rate of cells was similar in both populations. 
 
 
 149 
6.4 Discussion 
 
In solid tumours, ALDH1 appears to be a successful method to select a breast cancer 
cell population with CSC characteristics. This target for isolation has rapidly 
expanded and an increasing number of studies are now being conducted using this 
enzyme as a potential CSC marker. The simplicity of the Aldefluor® kit and, 
importantly, the high rate of cell viability after staining are two key parameters 
explaining the emerging use of thistechnique.  
 
As mentioned in this chapter, the importance of ALDH1 has not been fully 
established yet in colorectal cancer and its role in tumourigenicity is still to be 
confirmed. 
Two preliminary studies mention the high expression of ALDH1 in pre-selected 
CD44+/ESA+ cell populations, and the possible enhancement of tumourigenicity 
when ALDH1 is co-expressed with CD44 cell surface marker [100, 131]. 
In our study, we analysed the role of ALDH1 as a single marker, and assessed its 
impact on various cell processes relevant to a potential CSC state. 
When comparing the phenotype of ALDH1hi and ALDH1lo populations, two markers 
were significantly overexpressed in CaCO-2 cancer cell line, Lgr-5 and CD44. 
In the CM1 primary cell line, an increase of CD44 in ALDH1hi cells was noticed and, 
interestingly, as were CD166 and ABCG2. 
 
Therefore, in both CaCO-2 cell line and CM1 primary cell line, CD44 was 
upregulated in the ALDH1hi fraction. This is consistent with reports which have 
revealed an increase of ALDH1 expression among CD44+ population [100, 131]. In 
the CM1 cell line, FACS analysis of ALDH1hi cells showed that more than 90% of 
CD44 cells were comprised in the CD166 fraction. The phenotype CD44hi/CD166hi of 
our ALDH1hi CM1 cells is also consistent with the CD44+/CD166+/ESA+ phenotype 
proposed by Dalerba et al. (2007) as a colorectal CSC phenotype [100].  
 
Looking further down into the functionality of ALDH1hi cells, a clonogenic assay was 
conducted in order to define the self-renewing capacity of ALDH1hi cells in 
comparison to ALDH1lo cells. Our data do not show any significant difference in the 
colony forming potential of positive and negative cell lines. To define a population as 
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self-renewing, more than one passage are ideally necessary in order to establish an 
obvious evidence of that potential. In our case, the technical difficulty of the method 
and the time required to conduct it did not allow us to achieve several passages. None 
of the studies on colorectal CSCs using ALDH1 as a possible marker has reported a 
test on in vitro clonogenicity. Further work is therefore needed to confirm our results 
and to be able to compare them. 
 
Chemoresistance linked to ALDH1 expression has been reported in various organs, as 
for example in breast cancer. In a study conducted on patients undergoing 
chemotherapy (paclitaxel and epirubicin), the number of ALDH1hi breast cancer cells 
in the tumours significantly increased after neoadjuvant therapy [286]. Similarly, 
more ALDH1 cells were present in metastatic tumours insensitive to paclitaxel than 
in those that did respond to the drug [257]. In colorectal cancer,  an enrichment in 
ALDH1hi cells has also been reported when xenogeneic tumours were submitted to a 
treatment with CPA [131]. 
Based on these studies, we analysed the chemoresistance of ALDH1hi and ALDH1lo 
cells. When comparing the percentages of surviving ALDH1hi and ALDH1lo cells 
after exposure to oxaliplatin, no difference could be established between the two 
populations, indicating that ALDH1hi cells are not more resistant to this drug. 
However, according to immunohistochemistry, data revealed an increase in ABCG2 
expression in CM1 ALDH1hi cells (not in CaCO-2 cell line), suggesting a possible 
resistant phenotype of these cells to other chemodrugs, but obviously not to 
oxaliplatin. Therefore, it seems that an upregulation of ABCG2 is not involved in the 
mechanisms of resistance to oxaliplatin, which is consistent with the results on 
chemoresistance obtained in Chapter 5.  
 
An argument in favour of the self-renewing/differentiating capabilities of ALDH1hi 
cells is that short term in vitro cultures of ALDH1hi cells were capable of generating 
ALDH1lo cells in a time-dependent manner. After two weeks of culture growth, the 
ALDH1 expression had already reached a steady state and returned to the ALDH1 
expression level of the cell line from which it was originally sorted ((15% for CaCO-
2, 26% for CM1), demonstrating that at least some cells were able to keep a self-
renewing ability whilst others perhaps progressed along a differentiation pathway.  
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Such an observation had previously been made in a study on HCC CD133+ cells 
[137]. In this study, the expression of CD133 in CD133+ cells was followed-up over 6 
weeks and it was observed that a steady state was reached after that period of time. 
The authors concluded that among CD133+ cells, which they assumed to be 
stem/progenitor cells due to their in vivo tumourigenic potential, part of them did not 
possess the self-renewal capacity and therefore shortly developed into CD133- cells. 
However, the fact that not all CD133+ cells developed into CD133- cells, and that 
some persisted in culture, suggested to them that some CD133+ cells would therefore 
be more primitive progenitor/CSCs. Another explanation maybe that there is a 
regulation of the differentiation process of progenitor/CSCs, tending to maintain the 
proportions of putative CSCs at their initial level. This was also observed in SP cells 
extracted from human lung cancer, in which the hierarchy was re-established after a 
period of two weeks [122]. 
 
Similarly to our data, the two studies mentioned above report that non-putative CSCs 
also regenerate putative CSCs, and the authors attribute this phenomenon to the 
contamination of the negative population by the positive one. 
Contamination might be one issue, but another reason could be that ALDH1lo cells 
are not less primitive and also contain progenitor/CSC with self-renewal capacity. 
This would be consistent with the negative results obtained in the clonogenic assay, 
however, the only way to determine this would be through in vivo transplantation of 
our cells into xenogeneic model for a tumourigenicity test.  
 
In summary, a high ALDH1 activity in CaCO-2 and CM1 colorectal cancer cell lines 
correlated with a high expression of CD44, CD166, Lgr-5 and ABCG2 colorectal 
stem cells and CSC markers. To confirm these results, experiments involving the 
isolation of cells expressing these markers (in combination preferentially) should be 
conducted in order to verify their high ALDH1 activity.  
The biological functions attributed to CSCs, such as clonogenicity, chemoresistance 
and migration, were not enhanced in cells with a highly active ALDH1 enzyme. The 
fact that the percentages of cells with high ALDH1 activity returned to the normal 
value after a couple of weeks suggests that ALDH1 activity may not be an 
appropriate marker for CSC isolation, as ALDH1lo cells could regenerate ALDH1hi 
cells.  
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An in vivo experiment would be highly recommended to confirm the in vitro work, 
but we did not have the opportunity to conduct this and therefore doubt remains on 
the use of ALDH1 for colorectal CSC isolation. 
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7 Discussion 
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This work was aimed at isolating and characterising putative cancer stem cells 
(CSCs) in the liver metastases of colorectal cancer. Over the past three years, the 
landscape on concepts around CSCs has considerably developed. Different 
approaches have been explored in order to achieve efficient isolation of these cells. 
Whilst several promising results have arisen, controversy exists as to the exact 
definition of the term CSC, the validity of the hierarchical model of cancer 
progression, and its putative implications in other concepts related to cancer, 
including chemoresistance and metastasis. Essentially the theory of CSCs still has to 
overcome two challenges. The first one is to confirm the existence of true CSCs. This 
can only be achieved through their specific isolation and characterisation. The second 
challenge would then be to provide evidence on whether targeting CSCs would be of 
any therapeutic benefit.  
 
The primary challenge within the field of CSC research is efficacy of CSC isolation.  
Since the hierarchical model of cancer posits that CSCs are the only cells to possess 
tumourigenicity, then it is crucial that optimal isolation and eradication of these cells 
are achieved.  
Although we were not successful in obtaining a pure isolation of CSC population 
from CaCO-2 and CM1 cell lines in our study, we have highlighted here that the 
accuracy of isolating tumour-initiating cells is not only dependent on the choice of 
techniques and the type of cells, but also that the specificity of each method is 
undoubtedly related to each system. In addition to the technical hurdles faced in 
isolating CSCs in our system, we also had to contend with the issue that the cells we 
used may have followed a traditional (stochastic) model of cancer progression rather 
than a hierarchical model. The traditional model of cancer predicts that the isolation 
of tumour-initiating cells is quasi impossible as the property of tumourigenicity can 
be randomly acquired by all cancer cells, under the influence of extrinsic or intrinsic 
factors. The lack of particular characteristics to discriminate the tumour-initiating 
cells therefore should prevent their isolation. On the contrary, according to the CSC 
model, tumourigenicity is the exclusive property of a distinct population of cells with 
specific characteristics (capacity of self-renewal, undifferentiated state, pluripotency). 
CSCs can differentiate into non-tumourigenic cells through irreversible epigenetic 
changes, and thus constitute a distinct population that can be isolated on the basis of 
their phenotypic and functional attributes. 
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7.1 Techniques 
 
 
To date, several techniques have been used to isolate cells that are classed as 
possessing tumour-initiating potential. 
 
7.1.1 Isolation of CSCs according to the expression of the cell surface 
marker CD133  
 
For this project, we initially set out to use cell surface markers that have previously 
been described as the ‘gold standard’ for CSC isolation. In opposition to a traditional 
model of cancer, in which cancer cell properties vary randomly according to genetic 
or epigenetic transformations [72], the hierarchical model follows that cells with a 
tumourigenic potential differ from the rest of the cells on the basis of epigenetic 
differences only. According to this model, it has been proposed that tumourigenicity 
is exclusive of only a few cells expressing a specific marker or combination of 
markers that are progressively down-regulated during differentiation at a non-genetic 
level [85]. Using this principle, therefore CSCs may be feasibly isolated on the basis 
of particular cell surface markers that are expressed at a particular time point during 
CSC differentiation. 
 
 
We initially chose to isolate putative colorectal CSCs through the expression of 
CD133, since its expression is reported to be associated with high tumourigenicity in 
cells from many organs, specifically brain and colon cancers [93, 99].  
Unexpectedly, technical hurdles prevented us from obtaining a pure CD133 CSC 
population out of freshly isolated tumour samples. We therefore were not able to 
continue studying their characteristics. To improve the isolation, optimising the 
conditions of separation would have been necessary. However, further experiments 
should also take into account that, since the epitopes targeted by the commercially 
available CD133 isolation kit are directed against glycosylated domains of CD133, 
the success of the isolation may be dependent on the level of glycosylation present 
within these cells. Although this problem may not be directly involved to explain the 
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purity of our isolated fractions, it is extremely rate limiting for CSC research, as the 
state of glycosylation is dependent on the state of differentiation of the cells, as 
explained in Chapter 3. Recent investigations into CD133 biology report 
controversial results about its relevance to be a CSC marker, and glycosylation of the 
CD133 epitopes may be the key to inconsistent data. Indeed, latest studies have 
shown that CD133 expression profile was too broad to be used as a tool for CSC 
isolation. Shmelkov et al. (2008) have demonstrated that the expression of CD133 
continues in differentiated colonic cells [212]. Moreover, CD133- cells from primary 
and metastatic colon cancer have been demonstrated to be as tumourigenic as CD133+ 
cells [212]. This observation has also been reported in a study on brain cancer [187].  
In our setting, therefore, as well as in other recent publications, glycosylation of 
CD133 is a rate limiting step and questions the reliability of CD133 as a bona fide 
colorectal CSC marker [187, 212].  
Future work needs to focus on antibodies that target non-glycosylated epitopes of a 
putative marker which demonstrates a narrower pattern of expression specific to 
undifferentiated CSCs. 
 
Besides the practical and technical aspects involved when relying on cell surface 
markers to target CSCs, one of the caveats of the CSC hypothesis is the question of 
the cellular origin of cancer. Both the clonal and hierarchical models of cancer are 
based on the concept that the origin of cancer stems from a single cell [72], the nature 
of that cell however has yet to be determined. The American Association for Cancer 
Research (AACR) reports (2006) clearly state that stem cells do not have to be the 
cells from which a malignant progeny is derived [287]. There is indeed evidence that 
cancer may preferentially emerge from the stem cell compartment, as it was shown 
for instance with experiments in the intestine. A constitutive activation of the Wnt 
self-renewal pathway in Lgr-5+ intestinal stem cells initiates their transformation and 
consequently generates an adenoma [67]. Activating the same Wnt pathway in a stem 
cell progeny (transit-amplifying cells) does not have the same effect and only 
generates an adenoma in very rare cases. This therefore suggests that hyperactivation 
of the Wnt pathway triggers a tumour within the stem cell compartment rather than in 
their progeny. Despite this, however, there is evidence to show that cancer can arise 
from a population of differentiated cells. Transducing neural stem cells and/or mature 
astrocytes to express constitutively active EGFR induced a glioblastoma (GBM) in 
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both cell types, indicating that the deregulation of a specific pathway is able to induce 
GBM regardless of the cell origin [288].  
If a cell with a cancerous phenotype can originate from any given cell population, and 
the expression of cell surface protein is specific for the stage of differentiation and 
cancer type, then the attempt to identify a CSC population based solely on cell 
surface marker is almost unachievable. It may be more accurate to extract CSCs 
based on the expression or activity of markers that are associated with maintaining a 
state of pluripotency. None of the currently targeted cell surface markers has an 
apparent functional role in the regulation of self-renewal and ‘stemness’ function. 
They may be associated with low survival in cancer patients (CD133 and 
CD166[145] [146] [147]), or migration, invasion, and metastasis of cancer cells 
(CD24 and CD44 [152]). CD44 has also been reported to be involved in invasion and 
migration. Even CD133 has not clearly proven to have a functional role in 
maintaining a stem cell function, although it has been reported to be expressed by 
CSCs from various types of cancer [93, 94, 105, 161] [95] [102] [96, 136] [98, 99].  
 
7.1.2 Isolation of CSCs according to the activity of ALDH1 
The literature reports on ALDH1 enzyme as a non-immunological approach for stem 
cell isolation. ALDH1 is known to be directly linked to the regulation of stem cell 
phenotype and by extension possibly that of CSCs [168, 278]. Although this 
enzymatic marker has proven efficient in the isolation of a primitive cell population 
from breast, colorectal, lung and liver cancer tissue [92, 172, 174, 175, 289], it is still 
too early to confirm whether or not ALDH1 can be used as a specific marker of CSCs 
[100]. To address this gap in data, we tested how specific ALDH1 would be in 
isolating CSCs from colorectal cancer cells. 
Since ALDH1hi cells expressed more CD44, CD166 and Lgr-5 intestine CSC markers 
than ALDH1lo cells, we confirmed that ALDH1 cells may be enriched in putative 
CSC. ABCG2 was upregulated in our ALDH1hi cells but its expression did not appear 
to bear influence on resistance to oxaliplatin. ABCG2 is responsible for an MDR 
phenotype, and we expected ALDH1hi cells to be resistant to oxaliplatin. Our data in 
Chapter 6 showed that ALDH1hi cells were not significantly more resistant to 
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oxaliplatin than ALDH1lo cells. This result was also consistent with data from 
Chapter 5 that shows that ALDH1 activity was higher in CaCO-2 cells than in CaCO-
2-OR cells. Little is know on the therapeutic compound oxaliplatin, and we showed 
here that ABCG2 does not mediate cell resistance to oxaliplatin. 
 We did not find ALDH1hi cells to bear additional in vitro stem cell characteristics 
such as an enhanced clonogenicity and capacity to migrate. Since numerous factors 
could affect the biochemistry of cells in an in vitro environment, a more accurate 
method to compare the biological behaviour of ALDH1hi and ALDH1lo cells would 
involve in vivo models. This will undoubtedly form a future plan for the continuation 
of this project. 
7.1.3 Isolation of CSCs according to their innate resistance 
 
It is believed that CSCs possess an innate resistance to drugs due to the key features 
of stem cells which allow them to escape chemotherapy. Studies in brain tumours and 
leukaemia have explored the characteristics of intrinsically resistant cells and shown 
they possess CSC-like properties [26, 27]. Since chemoresistance of cancer cells has 
been attributed to CSCs and may be more relevant from a clinical point of view, we 
decided to focus our research on an assay based on the chemoresistance of cancer 
cells. We hypothesized that chemoresistance could therefore be used as a tool to 
select for a CSC-like population from the tumour bulk.  
In our study, a subpopulation of putative CSC-like cells possessing an intrinsic 
resistance to the chemotherapeutic agent oxaliplatin was isolated from an established 
CaCO-2 colorectal cancer cell line, and from the shorter passage cell line CM1. We 
have shown that intrinsically resistant cells (CaCO-2-OR and CM1-OR cells) isolated 
after short term exposure to oxaliplatin (5µg/ml for 48h) did not exhibit enhanced 
CSCs characteristics when compared to  the non-resistant CaCO-2 and CM1 cells. 
We analysed expression of CSC/stem cell markers, cell cycle status and in vivo 
tumourigenicity, however all tests were consistent to show that there was no sign of a 
CSC phenotype in the resistant cells. It must be noted that the in vivo experiments 
with the CaCO-2 cell line was inconclusive as time constraints meant that we were 
unable to meet the required number and also to proceed to the CM1 cell line in vivo 
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experiments. We also noted that resistance to oxaliplatin was not associated with an 
upregulation of the ABCG2 or Mrp1 transporters. 
 
Isolating CSCs through exploitation of their intrinsic resistant phenotype is not a 
priori a good way to achieve it. Further studies must be conducted for a better 
understanding of the role that CSCs have in chemoresistance as currently our 
knowledge of CSCs is only limited to a number of observations : 
 
1) when comparing putative CSCs with the rest of the cancer cell population, 
published data support the observation that CSCs are more resistant to 
chemotherapeutic agents. [251] [191, 253-258]. If chemoresistance is the attribute of 
CSCs, then it is worth targeting them but as discussed in Chapter 5, further data 
comparing the capacity of chemoresistance in CSC and in non-CSC are necessary.  
2) In order to prove that CSCs possess an intrinsic resistance to therapeutic 
compounds, these cells must be able to display their phenotype following short term 
exposure with the relevant drugs.  Since our isolated cell populations did not show 
evidence of a primitive phenotype, we postulated in Chapter 5 that the ability of cells 
to survive short term exposure with the drug may involve factors other than a stem 
cell phenotype, such as a protective environment or the capacity to undergo EMT. 
There is therefore a need to test the initial hypothesis and to verify whether the 
isolated cells truly are resistant with a second exposure to the drug. 
3) The literature reports of an experiment in which cancer cells were exposed to 
increasing concentrations of drugs over 8 months [273]. In this setting, 
chemoresistant clones were selected and propagated until they were able to survive 
the clinically relevant dose. Those cells with acquired resistance were shown to 
possess several CSCs characteristics in vitro. The setting of this type of experiment, 
however, does not address the question whether CSCs are inherently more resistant 
than non-CSCs. 
 
Further data are needed to establish a clinically relevant link between CSCs and 
chemoresistance, and to prove whether or not their primitive phenotype provides on 
them an advantage to escape chemotherapeutic treatment. This issue has to be 
addressed in order to confirm the relevance of targeting CSCs from a clinical point of 
view. 
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7.2 Choice of cells 
 
 
In Chapter 4 the use of cancer cell lines to study the origin and development of cancer 
was discussed.  Since there is a selection pressure on cancer cell lines to survive in an 
artificial in vitro environment, they are not always the best choice to study a 
particular cancer model. Progressive passages of these cell lines ultimately result in 
accumulated genetic changes which sometimes take them further away from their 
parental phenotype. In order to address these issues, we studied an established CaCO-
2 cell line alongside a newly created cell line CM1 where we kept the passage 
numbers as low as possible. 
In the CM1 cell line, we found a high proportion of the intestine stem cell marker 
Lgr-5 (up to 46%) and of CSC markers CD166, CD24 (more than 80% for both 
markers). CaCO-2 cells also expressed high levels of CD133 (98%), Lgr-5 (60%), 
CD166 (47%) and Nanog (40%) CSC/stem cell markers. It is important to bear in 
mind that, when using cell lines to study the CSC model, the CSC markers expressed 
in the primary tumours may not be similarly expressed in the cancer cell lines. In 
normal organs, and even in tumours, the CSC/stem cell markers have been shown to 
be expressed at a low level. It seems that the proportion of cells with CSC markers is 
increased in our cell lines, suggesting that in vitro culture conditions either artificially 
upregulate these markers, or maintain CSCs proliferation, thus increasing their 
proportions in vitro. This may account as to why we could not discriminate a putative 
CSC population from a non-CSC one.  
A clue supporting the hypothesis that cancer cell lines are in fact a culture of CSCs, is 
that cancer cell lines not only retain their tumourigenic potential over decades, but 
also some of them have been shown to maintain their aptitude to differentiate, when 
cultured under certain conditions. As we have previously mentioned, the CaCO-2 cell 
line is known to be able to differentiate into enterocytic cells upon confluence [263]. 
HRA-19, another colorectal cancer cell line, is capable of differentiating into the three 
intestinal cell lineages (absorptive enterocytes, mucus-producing goblet cells and 
entero-endocrine cells) when cells are cultured in serum-free medium supplemented 
with insulin, transferrine and ascorbic acid [290]. When cultured in DMEM 
supplemented with 10% FBS, HRA-19 cells maintained an undifferentiated state. 
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When grown as xenografts, these cells formed tumours containing absorptive, 
mucous and endocrine cells [291], which is a reflection of their pluripotency. 
However, as an objection to the hypothesis that the majority of cells in a cancer cell 
line are CSCs, we found that in vitro clonogenicity was restricted to only 13.6% of 
the CM1 cells. We would expect a higher percentage if the majority of cells in a cell 
line was to be CSCs. It would be extremely interesting to test in vivo and in vitro the 
clonogenicity and tumour-initiating potential of these cells. 
 
 
It is therefore not known yet whether cells in cancer lines should all be considered as 
CSCs, if they keep the initial hierarchy, or if they simply follow a traditional (non-
CSC) model of development as it was recently suggested for the HCT116 colonic 
cancer cell line [292]. Since we were not able to extract CSCs from CaCO-2 and 
CM1 colorectal cancer cells, an alternative reason simply may be that our cell lines 
do not follow a CSC model, and rather develop according to a traditional model of 
cancer in which all cells progress through clonal evolution.  
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7.3 Cancer model 
 
Our results suggest that the current techniques for isolating CSCs are not entirely 
satisfactory. There are indeed limitations to our study as discussed in this report, and 
it is possible that a single technique alone is not sufficient to attain isolation of a CSC 
population.  
Despite the emergence of an established model that accounts for cancer 
initiation/progression through CSCs, there are still gaps in our understanding. The 
quiescence of CSCs for instance, as well as the mechanism of chemoresistance, have 
yet to be better characterised.  
The gold standard in vivo xenogeneic transplant of CSCs designed to prove their 
tumourigenic potential is itself subject to limitations. Firstly, it seems that the growth 
of xenotransplanted cells is extremely variable depending on the conditions in which 
this assay is realised. The site of transplantation and the medium in which cells are 
injected (e.g. with or without matrigel) have shown to influence the results and to be 
partly responsible for the heterogeneity of the observed results [199, 293]. Secondly, 
the degree of immunodeficiency of the animal models may also influence the survival 
of the xenografted cells. A recent study has shown that a large proportion (25%) of 
unselected melanoma single-cells is capable of tumourigenic potential in vivo when 
using NOD/SCID mice strongly immunocompromised (with an additional 
interleukin-2 receptor gamma chain null (Il2rg-/-) [199]. When using a standard 
NOD/SCID mouse model, the average number of melanoma cells capable of forming 
a tumour was only one cell in a million.  
This observation is reinforced by the fact that, when transplanting 10 cells to several 
thousands murine lymphoid and myeloid tumour cells into histocompatible mice, i.e. 
generating no immuno-reactivity at all,  the number of cells being able to initiate a 
tumour has also been shown to be relatively large (>10%) [200]. Previous reports 
indicated that the average number of tumour-initiating cells was only one in one 
million when xenografting human AML cells into NOD/SCID mice [294]. Therefore, 
it is very likely that the number of tumourigenic cells detected depends on the cell 
capacity to survive the host environment. 
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If further studies reveal a number of tumour-initiating cells broader than expected, it 
may severely questions the concept of hierarchy. Heterogeneity may thus be simply 
due to random genetic/epigenetic differences as it is predicted in the traditional model 
of cancer. Although the number of tumour-initiating cells within cancers has been 
claimed not to be an important parameter in the CSC theory [295], the existence of 
CSCs may nevertheless become irrelevant from a clinical point of view. Indeed, 
cancers in which a majority of cells are CSCs will be treated as any cancer that 
follows a traditional model of development [85].  
 
If the numerous studies described in Chapter 1 indicate that some cancers must truly 
follow a hierarchical model, as demonstrated by a minority of cells able to sustain the 
tumour growth in several solid tumours, there are nevertheless other studies tending 
not to confirm this hypothesis. It seems that both models of cancer are not exclusive, 
and vary according to the type of cancer. For instance, a hierarchical model is not 
exclusive of the traditional model. It is important to keep in mind that CSCs can 
themselves undergo genetic alterations, following the traditional model of selective 
mutations, and transmit these alterations to their clones/progeny, thus creating 
heterogeneity in the same patient. Indeed, a study on colorectal cancer has reported 
chromosomal instability in the CSCs themselves [215]. One of the key study that will 
support the authenticity of the CSC model will be the investigation of the nature of 
the differences between tumour-initiating cells compared with the rest of the cells, as 
proposed by Shackleton et al. (2009) [85]. 
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7.4 Future work 
 
Based on the data we have obtained in this study, isolating colorectal CSCs in our 
hands would involve the improvement of some of the techniques we have been using 
here, and would also require the establishment of innovative assays. 
 
1. Developing the isolation and culture of fresh tumour samples 
 
Since in vitro cultured cancer cells are not entirely representative of the tumour they 
are derived from, then isolating CSCs from freshly resected tumours will be a more 
accurate approach. The major hurdle associated with the use of primary tissues is the 
presence of large amount of dead cells and debris obtained during mechanical 
dissociation of the samples. To eliminate this, several methods are conceivable. For 
instance a ficoll gradient traditionally used for mononucleocyte isolation could be 
adapted for our purpose. Ficoll is a medium widely used for density centrifugation 
and it exploits gradient centrifugation and cell size/density to enrich or fractionate cell 
populations. Using this principle, we may be able to separate live cells from the 
debris according to their density. Alternatively, a more expensive approach would be 
from commercially available kits which are designed to remove cell debris.  
It is important to bear in mind that the choice of any method that reduces the amount 
of cell debris will also result in the potential loss of viable CSCs – thus limiting the 
number of downstream experiments. 
 
 
2. Developing and confirming our results – need for cross-experiments 
 
- The isolation of putative CSCs based on ALDH1 activity is a technique currently 
being investigated within the field of CSCs. Our observations that markers of CSCs 
were upregulated in isolated ALDH1hi population compared with ALDH1lo suggests a 
possible enrichment of CSCs. This technique, however, was subject to limitations as 
demonstrated from our inconclusive in vitro data.  A more accurate characterisation 
of our ALDH1hi and lo cells would involve their xenotransplantation into an animal 
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model to further determine their status as CSCs. The direct isolation of cells with a 
CD44/CD166/Lgr-5 phenotype and the analysis of their ALDH1 activity would 
constitute a proof to confirm the results we obtained in immunofluorescence. 
 
 
- Since we identified certain limitations when relying on cell surface markers as an 
isolating technique, other biological characteristics were approached as a possible 
target. We attempted to isolate CSCs based on their chemoresistant phenotype, but in 
vitro results were inconclusive. It will be necessary to test our initial hypothesis, i.e. 
to verify that cells surviving a lethal dose of oxaliplatin possess true oxaliplatin 
resistance. The cells we isolated (CaCO-2-OR and CM1-OR) may contain CSCs, but 
they may be so rare that a majority of these surviving cells may not show enhanced 
chemoresistance when exposed to a second adjuvant treatment with oxaliplatin.  
In preliminary experiments, we redesigned our existing protocol whereby CaCO-2-
OR cells were now exposed to a second exposure to oxaliplatin. Our preliminary data 
showed that expression of the enterocytic marker AP was upregulated in CaCO-2-OR 
cells after two exposures to the drug (data not shown). To confirm whether these 
resistant cells were directed towards a more differentiated or undifferentiated state 
under the influence of oxaliplatin, other pluripotent genes and markers of CSC should 
be analysed. If the number of isolated cells allows it, it would also be ideal to 
investigate the biological behaviour of the resistant CaCO-2 cells when xenografted 
in vivo.  
The validation of this approach also requires further in vivo characterisation. 
Essentially, the same numbers of CaCO-2 and CaCO-2-OR cells should be injected in 
mice for a comparative analysis of their tumourigenic potential. 
 
 
3. Exploration of other approaches 
 
- A non immunological assay that has previously proven successful in isolating CSCs 
from brain, breast and colon relies on the growth of spheres in serum-free medium. 
This technique is believed to maintain the self-renewal capacity of stem cells and to 
preserve their pluripotency. However, despite its usefulness, this assay is not exempt 
from limitations (as discussed in the Introduction). In particular, the capacity to self-
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renew is not strictly restricted to stem cells as progenitor cells are also able to do so, 
albeit for a shorter period of time. Reynolds et al. (2005) reported the existence of 
cells able to form spheres for up to two or three passages maximum [182]. It is 
therefore never possible to assume that all spheres in a culture are derived from stem 
cells, and it is of major importance to define the number of passages necessary to 
isolate true stem cells.  
Regardless of the fact that the neurosphere assay is so far one of the best in vitro tests 
to account for the existence of stem cells, it does not allow the isolation of a pure 
population of stem cells since spheres also comprise of differentiated cells. In brain 
cancer, the number of cells isolated from neurospheres necessary to reproduce 
tumours in vivo was generally not lower than 5000 cells, which is still far from the 
theoretical value of one cell being able to reconstitute the whole tumour [157-161]. 
Therefore, trying to characterise CSCs from a population of cells derived from a 
sphere will always be approximate as each sphere contains self-renewing and non 
self-renewing cells.  
 
- The data from Chapter 3 led us to question the reliability on the use of surface 
markers to isolate CSCs. Further experiments using a wider range of CSC markers 
will have to take into account that the nature of the initial cancer cell has not been 
defined yet. Cancer cells emerging from a cell at the basis of the hierarchy may not 
possess the same surface marker pattern as cancer cells emerging from a cell at the 
top of the hierarchy, due to the epigenetic changes that occur as cells differentiate. 
For that reason, CSC markers are not only tissue-specific, but they may also be 
patient-specific. However, with regard to colorectal cancer, recent studies have shown 
that activation of the Wnt pathway triggers a tumour only from the Lgr-5+ cells [67]. 
If a majority of colorectal cancers are initiated from Lgr5+ cells, then the use of Lgr-5 
as a putative CSC marker may prove relevant for CSC isolation. 
 
- Since epigenetic changes have been suggested to occur when CSCs progress into a 
differentiation pathway responsible for the loss of their tumour-initiating capacity, it 
may be possible to screen for the validity of isolated CSCs based on their epigenetic 
profile [85]. Epigenetics involve all the mechanisms responsible for the modification 
of the gene activation status. These mechanisms predominantly include DNA 
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methylation and histone modification. Designing a technique allowing this analysis 
based on our small numbers of isolated CSCs will however make this challenging. 
 
In conclusion, more work is needed to develop and confirm the validity of the 
techniques we have used for the isolation of CSCs. In the meantime, the current 
literature on CSCs keeps proving the difficulty of attaining this population. New 
methods of isolation need to be developed in order to improve on the specificity of 
CSC isolation. Although different techniques have proven efficient for isolating 
putative tumour-initiating cells in certain cancers, the issue of disease specificity 
comes into play as these techniques are not always transferable. There is an obvious 
need to redefine the studies in order to be able to unify the results and better 
understand the biology of cancer stem cells. 
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